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ABSTRACT  
  
One of the most consistent biochemical changes associated with colon cancer 
progression is the altered expression of cell-associated carbohydrates. For example, the 
elevated expression of β1-6 branched N-linked oligosaccharides correlates with the 
presence of metastatic disease in colon cancer patients. Thus, it has become desirable to 
identify glycoproteins that are modified by these cancer-associated carbohydrates.  
Previous work in our laboratory identified the tumor-associated antigen 90 kDa 
(TAA90K) as a carrier of these cancer-associated carbohydrates. Since TAA90K has 
been previously implicated in cancer progression and metastasis, we examined its 
expression and function in human colon tumors. Immunohistochemical analysis 
revealed elevated expression of TAA90K in all tumor samples analyzed compared to 
normal colon. To examine the function of TAA90K in colon cancer, we performed 
protein binding and cellular assays with TAA90K purified from HT-29 human colon 
cancer cells infected with recombinant vaccinia virus expressing TAA90K.  Purified 
TAA90K bound to ECM proteins including fibronectin, collagen IV, laminins-1, -5 and 
-10 and galectin-3. Unlike TAA90K isolated from other cell types, TAA90K isolated 
from HT-29 cells failed to mediate adhesion of colon cancer and normal cell lines, due 
in part to cell-specific glycosylation differences.  Although TAA90K did not directly 
mediate cellular adhesion, it did modulate galectin-3-dependent adhesion of HT-29 
cells. In addition, TAA90K bound to and was a substrate for MMP-7, a matrix 
metalloproteinase previously implicated in colon cancer progression. MMP-7-cleavage 
of TAA90K had little effect on its binding to pro- and active MMP-7, laminin-1 and 
galectin-3, but reduced significantly its binding to fibronectin and laminin-10. In 
addition, treatment of cells with MMP-7-cleaved TAA90K resulted in lower levels of 
proMMP-7 in the conditioned medium than cells treated with intact TAA90K. This may 
be mediated by the reduced binding of MMP-7-cleaved TAA90K to IL-6 and IL-1β, 
cytokines previously implicated in enhanced proMMP-7 expression in prostate cancer 
cells. Thus, a possible mechanism by which TAA90K may contribute to colon cancer 
progression is by modulating tumor cell adhesion to extracellular proteins and 
extracellular matrix remodeling through interactions with MMP-7 and galectin-3.  
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1.0 INTRODUCTION 
 Cancer is a widespread disease accounting for millions of deaths each year.  
Cancer is a complex disease due to its ability to arise in a number of different tissues 
and organs.  Treatment and diagnosis of cancer can be difficult due to the large number 
of mutations or alterations that can arise during initiation, progression and invasion.  
Cancer research focuses on identifying cancer-associated alterations in cells that may 
contribute to cancer progression.   
 The research presented in this thesis focuses on the tumor-associated antigen         
90 kDa (TAA90K), a glycoprotein which bears cancer-associated carbohydrates and has 
been associated with the progression of a number of cancers.  
 
2.0 LITERATURE SURVEY 
2.1 CANCER 
 Cancer represents a major global health problem accounting for 7 million deaths 
worldwide in 2001 (Danaei et al., 2005).  Analysis of trends in cancer statistics led to a 
prediction for 2005 that almost 1.4 million new cancer cases would result in over half a 
million deaths in the United States alone.  These findings indicate that almost 1 in 4 
deaths in the United States is cancer-related.  As a result, cancer is ranked as the second 
leading cause of all deaths, behind heart disease. The most commonly diagnosed types 
of cancer among men include prostate, lung and colorectal cancer whereas cancers of 
the breast, lung and colorectum predominate in women (Jemal et al., 2005).  Cancer 
results in the development of a tumor at a primary site, however it is the metastatic 
spread of cancer cells to secondary sites that is usually resistant to conventional 
therapies and accounts for over 90% of human cancer deaths (Weigelt et al., 2005).  
These statistics emphasize the need for improved methods of prevention, detection and 
treatment. 
The development of cancer or carcinogenesis is initiated with mutations that 
confer upon a cell an altered phenotype. The aberrant cell has the potential to develop 
into a mass of altered cells or a tumor.  Mutations can be present in germline cells and 
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passed on from one generation to the next as is observed in hereditary types of cancer 
such as xeroderma pigmentosum and adenomatous polyposis coli. Alternatively, 
exposure of somatic cells to carcinogens, transforming viruses and other mutagens can 
induce mutations resulting in sporadic types of cancer. For example, it has been 
proposed that 35% of the 7 million worldwide cancer deaths in 2001 are attributable to 
a set of behavioural risk factors or exposure to environmental risk factors (Danaei et al., 
2005). For example, overweight or obese individuals have an elevated body mass index 
which is a risk factor for colorectal cancers and post-menopausal breast cancer.  
Similarly a lifestyle consisting of physical inactivity and a diet reduced in fruits and 
vegetables were also risk factors for colorectal cancer.  On the other hand, cigarette 
smoke contains known carcinogens, which are risk factors for cancers of the lung, 
mouth, stomach and liver. Exposure to environmental factors such as urban air pollution 
was also attributable to lung cancer. Elevated consumption of alcohol was shown to be 
a behavioural risk factor for liver, mouth, and breast cancer.  Other behavioural risk 
factors include exposure to viruses such as certain strains of human papilloma virus 
spread by sexual contact or to hepatitis viruses B or C, which can be acquired by using 
contaminated needles. Transforming viral proteins expressed by human papilloma virus 
or hepatitis viruses have been linked to cervical cancer and liver cancer, respectively 
(Danaei et al., 2005). 
 
2.1.1 Initiation  
The development of a tumor or tumorigenesis is initiated when genetic or 
epigenetic modifications affect the activity of one of three types of genes, namely 
oncogenes, tumor suppressor genes or stability genes (reviewed in Vogelstein and 
Kinzler, 2004). Genetic mutations in proto-oncogenes result in enhanced activity of the 
oncogene product compared to the wild-type gene product.  For example, chromosomal 
translocations, gene amplification or intragenic mutations that affect the activity of the 
gene product are all mechanisms by which oncogenes become activated (reviewed in 
Vogelstein and Kinzler, 2004).  Oncogene products that are involved in cellular 
signaling events result in the enhanced transcription of gene products responsible for 
cellular proliferation.  For example, a constitutively active ras oncogene product 
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enhances signaling of the Ras-Raf-MAP (mitogen activated protein) kinase pathway 
which results in activation of transcription factors such as Myc, Fos or Jun, all of which 
transcribe gene products necessary for enhancing the rate of cellular proliferation 
(Medema and Bos, 1993).  Mutations in the ras oncogene have been observed in 50% 
of human colon tumors (Kinzler and Vogelstein, 1996). 
 Tumor suppressor genes normally play a role in the regulation of cellular 
homeostasis by monitoring cell cycle regulation and DNA damage. For example, the 
retinoblastoma protein (pRb) has the ability to block cellular proliferation by preventing 
aberrant cells from entering the S phase of the cell cycle (Weinberg, 1995). Another 
tumor suppressor, p53, becomes activated in response to DNA damage and plays a role 
in cell cycle arrest and the induction of apoptosis (Prives and Hall, 1999). Mutations in 
tumor suppressor genes induced by missense mutations, truncations or deletions can 
result in a gene product that is inactive or has reduced activity. Reduced activity of 
tumor suppressors allows aberrant cells to continue through the cell cycle, resulting in 
synthesis of mutated DNA and the accumulation of a mass of abnormal cells.  For 
example, the functional inactivation of p53 is observed in 50% of all cancers (Harris, 
1996). 
 The final class of genes frequently mutated in cancer consists of the stability 
genes.  Stability genes include mismatch repair genes, nucleotide-excision repair genes 
and base-excision repair genes. Collectively, these genes are responsible for repairing 
DNA damage incurred by normal DNA replication or by exposure to DNA damaging 
agents. In addition, they play a role in homologous recombination and chromosomal 
segregation (reviewed in Vogelstein and Kinzler 2004). Analysis of the number of 
spontaneous mutations observed in normal cells does not account for the large numbers 
of mutations observed in human cancers.  Therefore, cancer cells are hypothesized to 
display a mutator phenotype (reviewed in Loeb, 2001).  This mutator phenotype results 
when stability genes are lost and genomic instability arises. This phenotype is 
characterized by chromosomal instability and microsatellite instability. Microsatellite 
instability occurs when mutations arise in highly repetitive regions of DNA, resulting in 
the inactivation or mutation of mismatch repair genes.  Chromosomal instability refers 
to mutations that affect chromosomal segregation resulting in a change in the number of 
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chromosomes, known as aneuploidy (reviewed in Loeb, 2001). The inactivation of 
stability genes results in the accumulation of mutations at an elevated rate compared to 
the mutation frequency observed in normal cells (reviewed in Vogelstein and Kinzler, 
2004). 
 Although genetic mutations play an important role in the development of cancer, 
epigenetic changes can also result in altered expression of gene products (reviewed in 
Kondo and Issa, 2004). Epigenetic changes include alterations to DNA or chromatin 
such as DNA methylation or histone modification that affect the accessibility of 
transcription factors and accessory proteins to the promoter regions of certain genes 
(Bird and Wolffe, 1999).  The DNA in normal cells is frequently methylated, resulting 
in the addition of a methyl group to the 5’ cytosine of CpG dinucleotides.  DNA 
hypermethylation has been observed in a number of cancers and is characterized by 
elevated levels of DNA methylation compared to normal cells (reviewed in Kondo and 
Issa, 2004).  This aberrant DNA methylation results in the silencing of tumor suppressor 
genes such as pRb resulting in reduced gene expression and the perpetuation of a cancer 
phenotype (Santini et al., 2001). Other examples of epigenetic changes common to 
cancer cells are histone modifications.  Histones play a role in the condensation of DNA 
by packaging it into nucleosomes.  Histone proteins can be modified by 
phosphorylation, acetylation and methylation, all of which can affect the packaging of 
DNA into nucleosomes, which in turn affects the accessibility of transcription factors 
and accessory proteins to promoter regions (Jenuwein and Allis, 2001).  Thus, histone 
modifications and DNA methylation have the ability to affect the expression of genes 
without altering the DNA sequence. 
 
2.1.2 Characteristics of Cancer Cells 
 The accumulation of both genetic mutations and epigenetic changes results in 
transformed cells, which are characteristically distinct from their normal progenitor 
cells, allowing for progression of tumorigenesis (reviewed in Hanahan and Weinberg, 
2000). For example, normal cells respond to external stimuli in a paracrine manner 
through cell surface receptors that bind growth factors secreted by other types of cells. 
In contrast, cancer cells acquire the ability to act in an autocrine manner by secreting 
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growth factors and effectively regulating their own growth and proliferation (Fedi et al., 
1997). In addition, cancer cells can also enhance their rate of proliferation by increasing 
the expression of cell surface receptors that bind to growth factors, resulting in 
enhanced sensitivity to external stimuli. Alternatively, cancer cells may produce 
mutated growth factor receptors that are constitutively active and stimulate intracellular 
signals even in the absence of growth factor binding to the receptor (Fedi et al., 1997). 
 Another difference between cancer cells and normal cells is their response to 
antigrowth signals (reviewed in Hanahan and Weinberg, 2000).  Normally, cellular 
proliferation can be halted and cells forced into a quiescent state by the binding of 
external antigrowth factors to their cell surface receptors.  For example, transforming 
growth factor β (TGFβ) binds to its cell surface receptor (TGFβR) and signaling events 
result in the activation of pRb, effectively blocking cellular proliferation.  In some types 
of cancer, decreased expression of the TGFβR, expression of a mutant receptor lacking 
a ligand binding domain or expression of a mutant pRb can allow the cell to elude this 
checkpoint and continue to proliferate at an elevated rate (Fynan and Reiss, 1993), thus 
contributing to the progression of tumorigenesis. 
 Apoptosis is a process that normally functions as a protective mechanism to 
eliminate potentially aberrant cells from further proliferation (Kerr et al., 1972).  
Signaling events are initiated in response to DNA damage, hypoxia or loss of cell-cell 
or cell-extracellular matrix (ECM) contacts (Evan and Littlewood, 1998; Giancotti and 
Ruoslahti, 1999). One pathway leading to the initiation of apoptosis is mediated by the 
tumor suppressor protein p53, which becomes activated in response to cellular stress 
and functions to increase the expression of the pro-apoptotic protein Bax (Green and 
Reed, 1998). Elevated levels of Bax result in the release of cytochrome c from the 
mitochondria, which is necessary for the activation of a class of proteases known as 
caspases. These enzymes are responsible for the proteolysis of cellular organelles and 
the genome (Thornberry and Lazebnik, 1998).   In contrast to normal cells, cancer cells 
have acquired mechanisms to evade apoptosis, thus enabling them to continue to 
proliferate even in the presence of aberrant genetic mutations thus enhancing tumor 
progression (reviewed in Hanahan and Weinberg, 2000). One mechanism that cancer 
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cells employ to achieve this is by expressing a p53 protein with reduced activity 
(Symonds et al., 1994). 
 Another characteristic cancer cells acquire that is important for the progression 
of tumorigenesis is their ability to undergo an unlimited number of cellular divisions 
(reviewed in Hanahan and Weinberg, 2000).  Normal cells have a pre-determined 
number of cellular divisions before they stop dividing and enter senescence (reviewed 
in Hayflick, 1997).  This limited replicative potential has been shown to be the result of 
shortening of the ends of chromosomes, or telomeres, following multiple rounds of 
DNA replication.  Cancer cells overcome this limited replicative potential by 
upregulating the activity of telomerase, an enzyme that replicates the telomeres on the 
ends of chromosomes, effectively preventing telomere shortening (Bryan and Cech, 
1999). This enhanced telomerase activity and subsequent telomere maintenance has 
been observed in virtually all types of malignant cells (Shay and Bacchetti, 1997). 
 The aforementioned characteristics of cancer cells confer upon cells the ability 
to replicate at an elevated rate.  Although enhanced proliferation is necessary for 
tumorigenesis, the development of a tumor that is larger than 1 mm in diameter requires 
the development of new blood vessels to supply the tumor cells with adequate oxygen 
and nutrients. If a tumor exceeds 1 mm in diameter, cancer cells must acquire the ability 
to initiate angiogenesis (Bouck et al., 1996; Hanahan and Folkman, 1996).  
Angiogenesis is a process of neovascularization involving the development of new 
blood vessels.  It is a necessary event during normal processes such as menstruation or 
embryogenesis and is regulated by both stimulatory and inhibitory signals (Hanahan 
and Folkman 1996).  For example, vascular endothelial growth factor (VEGF) is a 
soluble factor that binds to its receptor, VEGFR, on the surface of endothelial cells, thus 
stimulating the development of new blood vessels (Fedi et al., 1997).  Angiogenesis by 
cancer cells involves invasion of the surrounding tissue by the secretion of proteases in 
addition to enhanced secretion of angiogenesis-stimulating factors that induce the 
migration of endothelial cells towards the tumor (Stetler-Stevenson, 1999). 
 The final characteristic of cancer cells is the ability to invade surrounding tissue 
and establish metastases at distant organs. Metastasis is characterized by the spread of 
cancer from a primary tumor to secondary sites and organs, representing the last step of 
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tumor progession (reviewed in Hanahan and Weinberg, 2000).  There are two main 
hypotheses that attempt to explain how metastatic cells arise from the primary tumor.  
The first theory, known as the clonal progression model, hypothesizes that genetic 
alterations which would enhance the ability of cells within the primary tumor to 
metastasize may arise at any time during tumorigenesis. Cells with this metastatic 
phenotype would predominate in the cell population of the primary tumor (Nowell, 
1976).  An alternate theory, known as the rare variant model, hypothesizes that 
metastatic cells represent a minor population of the primary tumor arising from rare 
variants. This model is supported by experiments that isolated variants with distinct 
differences in metastatic potential from the cells making up the primary tumor (Fidler 
and Kripke, 1977; Fidler and Hart 1982). The primary tumor is thought to be 
heterogeneous in nature resulting from genetic instability that results during the process 
of tumorigenesis (Loeb, 2001). Thus, as tumorigenesis progresses, resulting tumors are 
heterogeneous, consisting of cells with varying ability to invade and metastasize (Fidler, 
2002).  Analysis performed by Kerbel (1990) revealed that rare metastatic variants 
preexist within the primary tumor, but may replicate to become the dominant cell type 
composing the tumor mass.  This is referred to as the clonal dominance theory of cancer 
progression (Kerbel, 1990).  
The process of tumorigenesis is not sufficient for metastasis.  Further genetic 
mutations are required in order for cells to acquire metastatic potential.  Cells with 
metastatic potential share some genomic similarities to the less metastatic cells 
comprising the primary tumor. However, examination of differences in gene expression 
between these two types of cells led to the discovery of a class of genes known as 
metastasis suppressor genes (van’t Veer et al., 2002).  The expression of these genes, 
including NM23 has been observed to be down-regulated in highly metastatic variants 
as compared to their less metastatic counterparts (reviewed in Steeg, 2003).    
The process of metastasis is often referred to as the metastatic cascade. One of 
the first barriers for metastasis is for cells with metastatic potential to disengage from 
the primary tumor.  This is accomplished by loss of cell-cell and cell-ECM contacts 
(reviewed in Hanahan and Weinberg, 2000).  For example, tumor cells maintain cell-
cell contacts with each other through interaction of cell surface receptors known as E-
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cadherin receptors. Tumor cells with enhanced metastatic potential have been shown to 
express reduced or mutated E-cadherin receptors on their cell surfaces allowing them to 
separate from the primary tumor (Bracke et al., 1996). In addition, integrins are cell 
surface receptors that play a role in mediating cell-ECM interactions.  Integrins bind to 
ECM components such as laminins, collagens and fibronectin.  The interaction between 
integrin receptors and their ligands can initiate the transmission of signals to the inside 
of the cells.  This integrin activation can also result in the lateral clustering of integrin 
receptors and their ECM ligands to form complexes that are linked to the cytoskeleton.  
These complexes are called focal adhesions and they are linked to actin filaments, 
which propel the cell during migration.  Loss or altered expression of integrin receptors 
by tumor cells can result in reduced binding to ECM components in addition to altered 
intracellular signaling (reviewed in Giancotti and Ruoslahti, 1999). 
 Once cells have separated from the primary tumor they must invade through the 
surrounding stromal tissue, another barrier to metastasis. This process is mediated by 
enhanced secretion of proteases by invading cells and the surrounding stroma. Matrix 
metalloproteinases (MMPs) are a class of proteases that play an important role in 
invasion of metastatic cells. MMPs are represented by a family of approximately 26 
members, all of which contain a prodomain and a catalytic domain (Figure 2.1).  The 
catalytic domain consists of a conserved binding site for the catalytic zinc ion.  Five 
family members reside on the cell surface as they have transmembrane domains and are 
referred to as membrane-type (MT)-MMPs.  The other family members function 
extracellularly as they are secreted in zymogen form as proMMPs.  MMPs are activated 
upon cleavage by other active MMPs or by other proteases such as plasmin or 
urokinase-type plasminogen activator. MMPs are important in normal processes such as 
wound repair, inflammation and embryogenesis (reviewed in Egeblad and Werb, 2002). 
However, the secretion of MMPs by both tumor cells and stromal tissues has been 
observed at the leading edge of invasive tumors.  In fact, proMMPs and their activating  
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Figure 2.1: Matrix metalloproteinases and their putative domains.  PRE, pre-
domain; PRO, pro-domain; CAT, catalytic domain; H, hinge; HEM, hemopexin 
domain; F, furin-cleavage consensus domain; FN, fibronectin-like domain; GPI, 
glycophosphatidyl inositol anchor; TM, transmembrane domain; Ig, immunoglobulin-
like domain; CA, cysteine array; CL, collagen-like domain.  Adapted from Wagenaar-
Miller et al. (2004). 
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factors are secreted by both the tumor and stromal cells, thus indicating that both cell 
types likely play a role in invasion (reviewed in Deryugina and Quigley, 2006). 
 In addition to playing a role in invasion of the ECM and stromal tissue, MMPs 
have been shown to play a role in a number of stages during metastasis (reviewed in 
Deryugina and Quigley, 2006). For example, remodeling of the ECM as well as cell 
surface receptors by MMP cleavage can alter cell-ECM as well as cell-cell contacts.  
MMP-3 has been shown to degrade E-cadherin on the surface of tumor cells, resulting 
in loss of tumor cell-tumor cell contacts (Veerle et al., 2000).  MMPs have also been 
shown to cleave cell surface receptor CD44, which binds to hyaluronic acid in the 
ECM.  This cleavage results in loss of tumor cell-ECM contacts, allowing tumor cells to 
escape from the primary tumor (Nakamura et al., 2004).  Normally, the loss of cell-cell 
and cell-ECM contacts induces a type of apoptosis referred to as anoikis.  There is some 
evidence to suggest that the expression and secretion of MMPs may protect liberated 
tumor cells from undergoing anoikis (reviewed Deryugina and Quigley, 2006).    
MMPs have also been implicated in the process of intravasion and enhanced 
survival of tumor cells upon entry into the circulation.  Intravasion is characterized by 
the entry of metastatic tumor cells into the blood or lymphatic vessels.  Upon entry into 
the vasculature, tumor cells must survive attack by the immune system if they are to 
establish tumor foci at a secondary organ (reviewed in Deryungina and Quigley, 2006). 
MMPs secreted by tumor cells have been implicated in immunosuppression.  
Specifically, MMP-9 has been shown to mediate the cleavage of IL-2Rα, which results 
in the reduced infiltration of lymphocytes to the tumor cells (Sheu et al., 2001).   MMPs 
may also protect circulating tumor cells by enhancing embolization, which involves the 
establishment of tumor cell clusters with aggregated platelets (Alonso-Escolano et al., 
2004). For example, the activation of MMP-2 by membrane type-1 (MT1)-MMP 
present on the tumor cell surface results in the enhanced activation and subsequent 
aggregation of platelets with the tumor cells. Embolization of tumor cells with platelets 
may allow the tumor cells to survive for longer periods of time in the circulation 
compared to individual tumor cells (reviewed in Deryugina and Quigley, 2006).   
 Upon embolization, tumor cells move through the circulation until they arrest at 
the capillary bed of secondary organs.  This process is mediated by cell adhesion and 
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involves the expression of cell surface receptors known as selectins, which mediate 
tumor cell-endothelial cell interactions.  Adherence of the tumor emboli at secondary 
sites is also mediated by integrins, which establish tumor cell-ECM interactions (Hood 
and Cheresh 2002).  Finally, extravasion occurs and tumor cells move through the blood 
vessel wall into the organ tissue and establish a tumor at this secondary location, 
finalizing the metastatic cascade.  The growth of a tumor at a secondary site is 
dependent on the microenvironment of the secondary organ, which can influence 
cellular proliferation, gene expression and angiogenesis of the metastases (Chambers et 
al., 2002; Fidler, 2002; Fidler, 2003).   
 
2.2 COLON CANCER 
 Colorectal cancer remains one of the most prevalent epithelial cancers, 
resulting in nearly 70, 000 deaths annually in North America (Weir et al., 2003; Ellison 
and Gibbons, 2004). It is estimated that approximately half of the western population 
will develop a colorectal tumor by the age of 70 with 1 in 10 of theses cases leading to 
malignancy (Kinzler and Vogelstein, 1996). Colorectal cancer affects both the rectum 
and colon, which consists of the cecum, the ascending colon, the transverse colon, the 
descending colon and the sigmoid colon (Figure 2.2).  The large intestine is composed 
of layers of tissue consisting of the epithelium, lamina propria, the muscularis mucosae 
and the submucosa. The epithelium layer consists of crypts that are composed of a 
number of different types of cells.  Stem cells are located at the base of intestinal crypts 
and have the ability to differentiate into columnar epithelial cells, mucous cells or 
endocrine cells (Figure 2.3).  Upon differentiation, cells migrate from the base of the 
crypt to the lumen of the large intestine.  Columnar epithelial cells are found lining the 
lumen of the large intestine and are responsible for its absorptive function. These cells 
are frequently shed into the lumen of the intestine and continually replaced by the 
differentiating stem cells located at the crypt base. Mucous cells are secretory cells that 
produce, store and secrete mucous into the lumen of the large intestine.  Finally, 
endocrine cells secrete hormones that are necessary for maintenance of intestinal 
cellular function (reviewed in Tejpar and Van Cutsem, 2002).  The lamina propria is 
composed of connective tissue containing cells such as fibroblasts, lymphocytes and  
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Figure 2.2:  Anatomy of the human colon. Anatomy of the human colon and rectum 
indicating the subdivision into various segments. From Ponz de Leon and Di Gregorio 
(2001). 
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 Figure 2.3:  Structure of the colon. The cellular composition of the crypts, indicating 
the location of the stem cells making up the colon. From McDonald et al., 2006. 
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macrophages.  It extends between the crypts and the muscularis mucosae, which is 
comprised of a thin layer of smooth muscle.  The submucosa is similar in composition 
to the lamina propria, however it also contains vascular elements such as arterioles, 
venules and lymphatic vessels (reviewed in Ponz de Leon and Di Gregorio, 2001). 
 Colorectal cancer arises as a result of the accumulation of both genetic and epigenetic 
events that result in the transformation of normal colonic epithelium. The process of 
colorectal tumorigenesis proceeds according to well characterized and discreet 
morphological and genetic stages (Figure 2.4) (Fearon and Vogelstein, 1990). 
 
2.2.1 Genetic and epigenetic modifications in sporadic and inherited colorectal 
cancers 
 Colorectal cancer can arise sporadically following alterations to somatic cells 
induced by endogenous factors such as DNA replication errors, reactive oxygen species 
that are generated by cellular metabolism and by exogenous factors such as exposure to 
carcinogens (reviewed in Tejpar and Van Cutsem, 2002). Colorectal cancer occurs 
following activation of oncogenes and inactivation of tumor suppressor genes and 
stability genes.  One of the most common oncogenes activated during colorectal 
carcinogenesis is ras (Fearon and Vogelstein, 1990).  As previously mentioned, 
activation of the ras oncogene product results in enhanced cellular proliferation 
allowing for the clonal expansion of aberrant cells.  Inactivation of the tumor suppressor 
gene adenomatous polyposis coli (APC) is one of the most frequent alterations observed 
in colorectal cancer, present in over 80 % of colorectal carcinomas (Powell et al., 1992). 
The wildtype APC protein binds to cytosolic β-catenin mediating its interaction with the 
cytoplasmic domain of E-cadherin resulting in the establishment of cell-cell contacts 
(Wang et al., 2006).  APC also plays a role in regulating the cytoplasmic levels of β-
catenin by targeting it for ubiquitination. When APC is mutated in cancer, the level of 
free cytosolic β-catenin is elevated resulting in its subsequent translocation to the 
nucleus and activation of transcription factors including T cell factor (TCF) 
transcription factors (Figure 2.5) (Molatore and Ranzani, 2004).  These transcription 
factors are responsible for the transcription of genes that regulate cellular proliferation 
in addition to genes involved in the regulation of apoptosis, cellular invasion and 
chromosomal segregation (Molatore and Ranzani, 2004).  Interestingly, the remaining  
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Figure 2.4: Stages and mutations associated with colorectal cancer. Initial 
transformation of normal colonic mucosa is associated with loss of                 
adenomatous polyposis coli (APC)/β-catenin interaction. Progression                            
to small and large colonic adenomas is associated with genomic instability                  
and the accumulation of further genetic mutations including activation of the ras 
oncogene and loss of p53. Adapted from Kinzler and Vogelstein (1996).  
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Figure 2.5:  Interaction between APC and β-catenin in the Wnt signaling pathway.  
In the absence of Wnt binding to its frizzled receptor (Fz), β-catenin is found in 
complex with APC and E-cadherin to mediate cell-cell contacts (not shown).  Free β-
catenin in the cytosol is targeted for ubiquitination by APC in complex with other 
cellular factors.  Upon Wnt signalling, β-catenin ubiquitination is blocked and it 
translocates to the nucleus where it binds TCF transcription factors and activates the 
transcription of genes.  From Radtke and Clevers (2005).
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cases of sporadic tumors that retain functional APC often have mutated β-catenin with 
an elevated activity (Molatore and Ranzani, 2004). Other significant alterations 
observed in colorectal carcinogenesis include allelic losses of tumor suppressor genes. 
For example, loss of a portion of chromosome 17p which contains the gene for the 
tumor suppressor p53, is observed in more than 75 % of colorectal carcinomas 
(Vogelstein et al., 1988).  In addition, loss of the tumor suppressor gene deleted in 
colorectal cancer (DCC) is observed in more than half of colorectal cancers when 
regions of chromosome 18q are lost (Vogelstein et al., 1988). The normal DCC gene 
product plays a role in the induction of apoptosis.  Upon loss of active DCC gene 
product, cells become resistant to apoptosis resulting in increased resistance to 
chemotherapeutic agents (Rivka et al., 2004). In addition to tumor suppressor gene 
inactivation, down regulation of mismatch repair (MMR) genes has been observed in 
10-15 % of sporadic colorectal carcinomas.  The loss of these genes including MLH1 or 
MSH2 results in the expansion or deletion of repetitive microsatellite sequences 
throughout the genome having a deleterious effect on the expression of a number of 
gene products (Ionov et al., 1993).   
 In addition to genetic mutations, epigenetic modifications of genomic DNA are 
frequently observed in colorectal carcinomas (reviewed in Kondo and Issa, 2004). 
Increased levels of DNA methylation have been observed in colorectal carcinomas 
compared to normal colonic mucosa.  This hypermethylator phenotype is referred to as 
CpG island methylator phenotype (CIMP) and is observed in 50 % of sporadic 
colorectal carcimonas (Grady, 2004).  In addition to DNA methylation, histone 
modifications including hypoacetylation and methylation of lysine 9 on histone 3 have 
been shown to contribute to tumor suppressor gene inactivation in colorectal 
carcinomas (reviewed in Kondo and Issa, 2004). 
 Although the majority of colorectal cancer cases are sporadic in nature, 15 % of 
colorectal cancer cases are hereditary where mutations exist in germline cells and are 
passed on from one generation to the next (Kinzler and Vogelstein, 1996).  The two 
main types of hereditary colorectal cancer are familial adenomatous polyposis coli 
(FAP) and hereditary non-polyposis colorectal cancer (HNPCC). FAP is an autosomal 
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dominantly inherited disease that affects approximately 1 in 7000 individuals (Bodmer 
et al., 1987; Solomon et al., 1987).  These individuals have inherited a mutated copy of 
the APC gene which codes for a truncated protein.  Following the accumulation of 
further mutations including inactivation of the remaining APC allele, these individuals 
in their teens and young adulthood develop hundreds to thousands of adenomatous 
polyps that are benign, but have the potential to progress to a more invasive stage of 
carcinogenesis if the colon is not removed (Kinzler and Vogelstein, 1996). HNPCC is 
also an autosomal dominant disorder, however it arises from the inheritance of 
mutations of the mismatch repair genes (MMR) resulting in allelic losses of 
microsatellite regions and microsatellite instability (Lynch et al., 1985).  Hallmarks of 
this disease include the presence of up to 100 colonic polyps with the average age of 
onset of colorectal carcinoma occurring at 40 years of age (Wang et al., 2006).  
 
2.2.2 Stages of tumorigenesis 
  An immense amount of research has focused on identifying the genetic and 
morphological changes associated with the process of colorectal carcinogenesis, 
beginning with the initial transformation of normal colonic epithelial cells (Figure 2.6) 
(Fearon and Vogelstein, 1990). The first observable indication of colorectal neoplasia is 
the development of pre-neoplastic lesions called aberrant crypt foci (ACF) which arise 
from hyperproliferating colonic epithelial cells and consist of cells of either normal or 
dysplastic morphology (Molatore and Ranzani, 2004). Although not all ACF progress to 
colorectal cancer, studies have shown that ACF, which are dysplastic in nature, are 
precursors of colorectal cancer (Cheng and Lai, 2003). Microscopically, ACF are 
characterized by the clustering of aberrant crypts that are distinguishable from normal 
colonic crypts by having a thicker epithelial lining (Figure 2.7) (Bird and Good, 2000; 
Cheng and Lai, 2003).  Analysis of genetic alterations in these early ACF lesions 
revealed elevated levels of ras oncogene product as well as mutations in APC and p53 
genes (Vogelstein et al., 1988).  
 Previous work by Sugarbaker et al. (1985) revealed that most colorectal 
carcinomas arise from adenomas that progressively increase in size, dysplasia and  
 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Transformation of normal mucosa and colon cancer progression. 
Panel A indicates the difference between the proliferative epithelium in normal mucosa 
as compared to transformed colonic mucosa.  Panel B depicts the morphological 
changes that result during colon cancer progression. 
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Figure 2.7:  Visualization of aberrant crypt foci (ACF) in fixed colon.  
Stained ACF show crypts with thicker epithelial lining. From Bird and  
Good (2000). 
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villous morphology. After development of dysplastic ACF, further genetic and 
epigenetic events lead to the development of an early adenoma (Figure 2.4). Early 
adenomas are defined as those equal to or less than 1.0 cm in size.  Progression to 
intermediate stage adenomas that are greater than 1.0 cm in diameter requires enhanced 
cellular proliferation, which is often accounted for by activation of the ras oncogene. 
Chromosomal losses, including loss of 18q which contains genes encoding the tumor 
suppressor gene deleted in colon cancer (DCC) as well as SMAD2 and SMAD4 genes 
can lead to progression to late stage adenomas, characterized by a size greater than 1.0 
cm and acquisition of a villous morphology (Vogelstein et al., 1988).  Further 
chromosomal loss, including loss of the p53 gene on chromosome 17p, has been 
associated with the transition from adenoma to carcinoma characterized by local 
invasion and the potential for metastasis (Fearon and Vogelstein, 1990). Although 
genetic and epigenetic alterations have been associated with discreet changes in 
morphology (Figure 2.6) and stages of colorectal carcinogenesis, it was postulated that 
it is the accumulation of mutations, rather than the order in which they occur that is 
most significant to the development of colorectal cancer  (Figure 2.4) (Fearon and 
Vogelstein, 1990). 
  
2.2.3 Invasion and metastasis 
 Local invasion of malignant colon carcinoma into the surrounding stromal tissue 
is followed by intravasion into lymphatic and blood vessels and the establishment of a 
tumor at a secondary site.  At the time of diagnosis it has been documented that 30-50% 
of patients with colorectal carcinoma exhibit metastasis in regional lymph nodes and 
10-30% of patients exhibit hepatic metastases (Jemal et al., 2005).  Although liver is the 
main site of metastasis in patients with colorectal carcinoma, metastatic disease can be 
present in other organs including the lung, brain and bone marrow (reviewed in Zucker 
and Varcirca, 2004).  
In order for metastasis to occur, cells with metastatic potential must escape from 
the primary tumor by reducing cell-cell contacts with neighbouring cells as well as 
reduce cell-ECM contacts.  If metastasis is to occur, cells must attain a more motile 
phenotype.  In colorectal cancer, it has been observed that invasion by carcinomas 
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involves a loss of epithelial cell characteristics and a gain of mesenchymal cell 
characteristics (Brabletz et al., 2005). This process, referred to as the epithelial-
mesenchymal transition (EMT), involves a dedifferentiation process that allows cells to 
become invasive. In fact, Jass et al. (2003) have shown that dedifferentiation of 
colorectal carcinomas correlates with poor clinical prognosis. Dedifferentiation involves 
the activation of the Wnt pathway (Figure 2.5).  When the Wnt pathway is not 
stimulated, β-catenin is found in the cytoplasm of cells complexed with the cytoplasmic 
domain of E-cadherin cell surface receptors.  This complex is necessary for the 
maintenance of cell-cell contacts between epithelial cells in normal tissues. The 
inactivation of the tumor suppressor APC in colorectal cancer results in the 
accumulation of cytosolic β-catenin which is translocated to the nucleus, resulting in 
enhanced transcription of a number of genes such as Id2 (Rockman et al., 2001) and 
Cdx-1 (Lickert et al., 2000) that have been implicated in the EMT process. Loss of 
cytosolic β-catenin also results in reduced binding to E-cadherin, resulting in decreased 
cell-cell contacts. Previous studies have shown that Wnt signaling as well as the nuclear 
accumulation of β-catenin can result in the dedifferentiation of epithelial cells to 
mesenchymal cells during embryogenesis (Logan et al., 1999). This pathway likely 
plays a role in the dedifferentiation of colorectal carcinoma cells during invasion.  After 
invasion of carcinoma cells, redifferention occurs resulting in metastatic tumor cells at a 
secondary site assuming once again an epithelial phenotype (Brabletz et al., 2005). 
Once carcinoma cells have acquired a motile phenotype they must be able to 
invade into the surrounding stromal tissue.  There are a number of proteinases that are 
involved in the degradation of the extracellular matrix during the invasion of colorectal 
carcinomas. For example, overexpression of the serine proteinase trypsin results in 
enhanced digestion of type I collagen in the ECM in colorectal carcinomas and is 
associated with poor prognosis and shorter disease-free survival (Soreide et al., 2006).  
In addition to the cleavage of type I collagen, trypsin is responsible for activating matrix 
metalloproteinases MMP-2, -7 and -9 resulting in enhanced degradation of the 
extracellular matrix.  In fact, the co-expression of trypsin with MMP-2, -7 and -9 in 
colorectal carcinomas has been implicated in enhanced cellular proliferation, 
progression and invasion (Soreide et al., 2006).  
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Previous studies have revealed that MMPs are the main proteinases involved in 
the invasion of colorectal carcinomas. Specific MMPs that have been implicated in 
colorectal cancer include MMP-1, -2, -3, -7, -9, -12, -13 and MT1-MMP (reviewed in 
Zucker and Vacirca, 2004). Although MMPs play a role in colorectal cancer, MMP-7 
appears to have the most significant effect not only on colorectal tumorigenesis, but also 
in invasion and metastasis. The expression of MMP-7 is observed at early stages of 
tumor progression and has been implicated in enhanced cellular proliferation as well as 
the progression from adenoma to invasive carcinoma. This MMP-7 expression was 
observed to be localized in the lumen of dysplastic colon tumors isolated from mice 
(Wilson et al., 1997). Studies have revealed that MMP-7 is expressed by 90% of 
colonic adenocarcinomas and its expression is correlated with the presence of lymph 
node as well as distant metastases (Newell et al., 1994). One possible explanation for 
the enhanced expression of MMP-7 is that its gene is a target of transcription factors 
activated by nuclear accumulation of β-catenin, which occurs when functional APC is 
absent (Aberle et al., 1997).  
As previously mentioned, MMPs are not only involved in the degradation of the 
ECM, but they are also responsible for the cleavage of non-ECM proteins resulting in 
an altered function of the cleaved protein.  For example, cleavage of Fas ligand (FasL) 
from the cell surface by MMP-7 results in release of soluble FasL from the cell surface 
and altered cell survival (Powell et al., 1999).  In addition, MMP-7 and MMP-3 cleave 
osteopontin, a secreted glycoprotein that interacts with cell surface receptors such as 
integrins and CD44 resulting in enhanced migration of cells towards cleaved 
osteopontin (Agnihotri et al., 2001).  
The activity of MMPs is tightly regulated by inhibitors of MMP activity, which 
include tissue inhibitors of matrix metalloproteinases (TIMPs) as well as α2-
macroglobulin. There are four TIMPs (1-4) that are responsible for inhibiting the 
activity of various MMP activities. The ratio of TIMP: MMP is important for the 
regulation of MMP activity.  For example, when TIMP levels are elevated, MMP 
activity is suppressed and when TIMP levels are reduced, the MMP activity is elevated 
(reviewed in Zucker and Vacirca, 2004).  Specifically, TIMP-2 binding to proMMP-2 
aids in the formation of a complex with membrane-bound MT1-MMP, thereby 
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enhancing the activation of MMP-2 (Sato et al., 1994).  Another inhibitor of soluble 
MMPs is the plasma protein α2-macroglobulin. Alpha-macroglobulins form complexes 
with a wide range of proteinases effectively reducing their proteolytic activities 
(Sottrup-Jensen and Birkedal-Hansen, 1989). 
Once tumor cells have accessed lymphatic or blood vessels, this usually leads to 
the establishment of hepatic metastases in patients with colorectal cancer (Rudmik and 
Magliocco, 2005).  Embolization of tumor cells in the vasculature allows for enhanced 
cell survival by reducing detection by the immune system. The expression of cancer cell 
surface integrins plays a role in mediating tumor cell arrest in hepatic vessels, allowing 
the development of hepatic metastases (Rudmik and Magliocco, 2005).  Another 
colorectal carcinoma cell surface protein involved in the establishment of hepatic 
metastasis is carcinoembryonic antigen (CEA), which binds to specific receptors 
present on hepatic cells.  This interaction stimulates the secretion of cytokines that act 
to elevate the expression of intercellular adhesion molecule-1 (ICAM-1) on the hepatic 
endothelium, which enhances the binding of colorectal carcinoma cells (Wagner et al., 
1992).   
 
2.2.4 Detection and treatment  
 The establishment of metastatic disease accounts for the majority of cancer-
related deaths (Weigelt et al., 2005).  Thus, early detection of cancer before metastasis 
has occurred is critical to decreasing cancer mortality rates.  In the case of colorectal 
carcinoma, screening of the colon for potential lesions does not usually occur until after 
the age of 50, unless there is a history of hereditary colorectal cancer.  Common 
screening procedures for colorectal cancer include the fecal occult-blood test, 
sigmoidoscopy, colonoscopy and double-contrast barium enema (reviewed in Kahi and 
Rex, 2004).  The fecal occult-blood test (FOBT) is the most common type of screening 
procedure performed in the United States.  FOBT involves examining feces for the 
presence of blood, which may indicate the presence of a colorectal polyp.  A positive 
result would be followed by a sigmoidoscopy or colonoscopy.  One disadvantage of this 
screening procedure is that colorectal polyps can bleed intermittently, so the inability to 
detect blood in the feces does not conclusively indicate a colon free of lesions.  
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Another screening procedure is sigmoidoscopy, which examines the distal 
colon.  This procedure is easier to perform than a colonoscopy as it does not require that 
the patient be sedated, however it is less sensitive and is not able to detect potential 
lesions in the proximal colon (reviewed in Kahi and Rex, 2004). The double-contrast 
barium enema (DCBE) is a screening procedure involving the radiologic examination of 
the entire colon.  The use of this procedure is on the decline because it is not as 
sensitive as colonoscopy in detecting colorectal lesions and it is uncomfortable for 
patients (reviewed in Kahi and Rex, 2004).  
Colonoscopy is currently the most sensitive procedure for screening for the 
presence of colorectal lesions.  This procedure is able to scan the whole colon and is 
used in combination with a polypectomy to remove any potential polyps observed at the 
time the colonoscopy is performed.  Some disadvantages of this procedure is that it 
requires extensive preparation of the bowels which can be cumbersome for the patient 
and it also requires sedation of the patient (reviewed in Kahi and Rex, 2004).   
 Some emerging techniques in the detection of colorectal lesions involve fecal 
DNA tests.  These assays involve examination of feces for the presence of DNA 
containing mutations in oncogenes and tumor suppressor genes that would be shed by 
colorectal neoplasms.   A multi-target assay is currently being tested that examines 
feces for the presence of DNA mutations in APC, K-ras, and p53 which account for all 
cases of FAP and approximately 85% of sporadic colorectal cancers.  Advantages of 
this screening procedure are that it is sensitive and non-invasive. Unfortunately, at the 
moment this screening procedure is quite expensive and not as sensitive as a 
colonoscopy (reviewed in Kahi and Rex, 2004).  Analysis of serum markers for 
colorectal cancer revealed carcinoembryonic antigen (CEA) as well as carbohydrate 
antigen 19-9 (CA19-9) serum levels were elevated in patients with colorectal cancer 
(Srivastava et al., 2001).  Following immunohistochemical analysis of colorectal 
tumors, it was revealed that the increased expression of CEA by colorectal carcinomas 
correlated with poor prognosis and disease recurrence making CEA the only reliable 
serum marker to date for determining the prognosis of colorectal cancer (Hilska et al., 
2005). 
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 Once a colorectal polyp is detected and removed via polypectomy, histological 
analysis is performed to determine the stage of progression, course of treatment and 
prognosis.  Initially, colorectal cancer was staged according to Duke’s staging, which 
was further modified by Astler and Coller (Figure 2.8).  In this staging system, tumors 
are classified as either Duke’s A, B1, B2, C1, C2 or D.  Duke’s A tumors are restricted 
to the mucosa.  Duke’s B1 tumors display invasion through to the muscularis propria 
while B2 tumors invade through the serosa.  Duke’s C1 and C2 tumors display invasion 
similar to B1 and B2 tumors, respectively, but also include lymph node involvement.  
Finally Duke’s D tumors are those associated with the presence of distant metastases 
(Astler and Coller, 1954). 
 A more current method of classification system has been implemented and is 
referred to as the TNM (tumor, node, metastasis) classification system where T refers to 
the stage of the tumor.  In this classification system, Duke’s A, B1, B2 are replaced by 
T1, T2 and T3 respectively.  In addition, Duke’s C tumors are described by N, which 
refers to the number of lymph nodes that are involved with N1 corresponding to 1-3 
lymph nodes and N2 corresponding to more than 3 lymph nodes.  Duke’s D tumors with 
the presence of distant metastasis are referred to as M1 tumors in this classification 
system.   
Cancer is often classified according to stages, which dictate future treatment 
options and prognosis.  In colorectal cancer, stage I disease indicates the presence of T1 
or T2 tumors.  Stage II disease refers to tumors described as T3. Stage III disease 
involves the presence of metastatic disease in the lymph nodes and stage IV disease 
involves the presence of distant metastases to the liver or other organs (Figure 2.8). 
Patients with stage I colorectal cancer exhibit no signs of invasive disease and removal 
of the polyp or tumor completes the course of treatment.  In contrast, patients with stage 
II, III or IV disease require removal of the primary tumor followed by adjuvant therapy 
in an attempt to eliminate metastases.  The presence of local invasion of the primary 
tumor in patients with advanced stages of colorectal cancer requires that entire sections 
of the colon be removed in order to eliminate as much of the invaded tissue as possible.  
Following surgical resection of the colon, patients are commonly treated with the  
 
 27 
 
 
 
 
 
 
 
     
Mucosa 
 
Muscular mucosa 
 
Submucosa 
 
Muscularis propria 
 
Serosa or 
Perirectal fat 
 
Adjacent structures 
 
Lymph nodes 
 
Distant spread 
A         B1       B2        C1       C2       D 
I                 II                      III             IV 
Figure 2.8:  Astler-Coller modified Duke’s and TNM staging for colorectal 
cancer. 
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chemotherapeutic agents 5-fluorouracil and leucovorin that inhibit DNA synthesis in an 
attempt to eliminate metastases (reviewed in Xiong and Ajani, 2004).  
 
2.3 ROLE OF GLYCOSYLATION IN CANCER AND METASTASIS 
In order to reduce the incidence of death associated with cancer, it will be 
necessary to develop improved methods for the detection, prevention and treatment of 
cancer. One approach could involve the identification of novel biomarkers as well as 
cancer cell-specific alterations.  The aberrant expression of oncogenes and tumor 
suppressor genes occur in all types of cancer and collectively these alterations result in 
the generation of transformed cancer cells with altered characteristics (reviewed in 
Hanahan and Weinberg, 2000). Cell surface carbohydrates are differentially expressed 
during normal processes such as embryogenesis and cellular differentiation, however, 
cellular transformation is also accompanied by altered expression of cell surface 
glycans which results in enhanced motility and malignant potential (Dennis, 1992; 
Saitoh et al., 1992). In fact, one of the most consistent biochemical changes associated 
with colon tumorigenesis and metastasis is altered expression and/or structure of cell-
associated complex carbohydrates (Dennis et al., 1987; Fernandes et al., 1991). 
Moreover, cancer progression is directly associated with increased levels of aberrant 
oligosaccharides which are believed to contribute to tumor cell motility and invasion by 
altering cell-cell and cell-extracellular matrix interactions (Kannagi 1997; Ochwat et al., 
2004). 
 
2.3.1 Types of cell-surface carbohydrates 
Carbohydrates are generally linked to macromolecules to generate glycoproteins 
and glycosphingolipids. The glycosylation of proteins is important in mediating proper 
folding, subcellular localization, rate of degradation and function (Opdenaker et al., 
1993).  Glycoproteins are glycosylated in the ER and Golgi apparatus and are usually 
secreted extracellularly or embedded into membranes, including the plasma membrane.  
The plasma membrane of the cell is composed of glycosphingolipids where the extent 
of glycosylation of the lipids can affect membrane rigidity and functions of membrane 
receptors (Chammas et al., 1991).  Cell-surface carbohydrates on both 
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glycosphingolipids and glycoproteins have been shown to be important in mediating 
cell-cell and cell-ECM interactions (Kornfeld, 1980).   
 
2.3.2 Changes in cell surface carbohydrates  
2.3.2.1 Alterations to glycosphingolipids 
 The lipid bilayer of the plasma membrane is composed of glycosphingolipids, 
which are composed of ceramide molecules modified by core carbohydrate structures. 
Glycosphingolipids are classified as either ganglio-series, globo-series, lacto-series type 
I or lacto-series type II based on the core structure that is present (Figure 2.9) 
(Hakomori, 2003).  The carbohydrate structures present on cell surface 
glycosphingolipids serve as ligands for lectins such as selectins, which play a role in 
mediating cellular adhesion (Fukada 1996; Fukada et al., 1999).  In addition, 
carbohydrate structures also have the potential to form interactions with other 
carbohydrates mediating cell-cell interactions as well as cellular adhesion (Hakomori, 
2003). Further modification of glycosphingolipids by negatively charged sialic acid 
residues results in the generation of acidic gangliosides. Studies have revealed that 
glycosphingolipids and specifically gangliosides in the lipid bilayer can affect the 
activity of cell surface receptors including growth factor receptors and integrins 
resulting in altered cell growth and motility (Weis and Davis, 1990).  The elevated 
expression of aberrant carbohydrate structures including poly-N-acetyllactosamine [i.e. 
repeating type 2 (Galβ1-4GlcNAcβ-R) chains] and Lewis antigens (Figure 2.10) 
modifying glycosphingolipids have been attributed to the promotion of invasive cells 
and enhanced metastasis with reduced survival in many types of cancer (Hakomori, 
2002).  In addition to elevated tumor-associated carbohydrate structures, the increased 
production of ganglioside GD3 by cancer cells promotes tumor motility and growth by 
enhancing angiogenesis through increased expression of VEGF (Zeng et al., 2000).  
 
2.3.2.2 Alterations to glycoproteins 
 Glycoproteins consist of carbohydrate moieties attached to a polypeptide 
backbone with two main types of glycosidic linkages observed. O-linked 
oligosaccharides result from an O-glycosidic bond between the hydroxyl group of  
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A.   Lacto-series type 1:  Lc4  Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-Cer 
 
B.    Lacto-series type 2:  nLc4 Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-Cer  
 
                     nLc6  Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3 
              Galβ1-4Glcβ1-Cer 
 
C.     Globo-series:          Gb3 Galα1-4Galβ1-4Glcβ1-Cer 
               Gb4 GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-Cer 
                   Gb5 Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-Cer 
 
D.     Ganglio-series:      Gg3  GalNAcβ1-4Galβ1-4Glcβ1-Cer 
                   Gg4  Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-Cer 
 
 
 
Figure 2.9: Core carbohydrate structures of glycosphingolipids.  
Carbohydrate structures consisting of galactose (Gal), N-acetylglucosamine  
(GlcNAc), glucose (Glc), N-acetylgalactosamine (GalNAc) monosaccharides  
are linked to ceramide (Cer) molecules. From Hakomori, 2003. 
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 Figure 2.10:  Schematic of the biochemical pathways leading to the  
 production of Lewis and histo-blood group antigen from precursor  
 antigens.  From Hittelet et al. (2003). 
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serine or theonine residues in the polypeptide backbone and the sugar structure.  On the 
other hand, carbohydrate moieties which form an N-glycosidic bond with the amide 
group of asparagine residues in the polypeptide backbone, are referred to as N-linked 
oligosaccharides.  The expression of glycoproteins bearing elevated levels of cancer-
associated carbohydrates or carbohydrates with altered structures, is a common 
alteration in cancer (Ogata et al., 1976; Dennis et al., 1987; Fernandes et al., 1991).  
 
2.3.2.2.1 Biosynthesis of O-linked oligosaccharides 
 O-linked glycans have been implicated in a number of processes including cell 
adhesion, protecting epithelial surfaces, blood clotting and development during 
embryogenesis (Varki, 1993; Brockhausen and Kuhns, 1997). The addition of O-linked 
oligosaccharides occurs post-translationally in the Golgi apparatus and involves 
glycosyltranferases, sulfotransferases and nucleotide sugar donors.   Initially an N-
acetylgalactosamine (GalNAc) residue is joined through an O-glycosidic linkage to the 
hydroxyl group of a serine or threonine residue by the enzyme α−GalNAc-transferase.  
This structure, referred to as the Tn antigen, is elongated to generate one of eight 
different core structures that have been identified in mammalian glycoproteins (Figure 
2.11) (reviewed in Brockhausen, 1999).  Once the O-glycan core has been generated, it 
can be further elongated by the addition of poly-N-acetyllactosamine repeating units 
(Ujita et al., 2000), which can be terminated with either sialic acid residues (Kuhns et 
al., 1993), histo-blood group ABH antigens (Hitoshi et al., 1996) or Lewis antigens 
(Kufowska-Latallo et al., 1990) (Figure 2.10).  O-glycan core glycosylation can also be 
terminated by addition of sialic acid residues, which prevents further elongation of 
carbohydrate chains.  Finally, GlcNAc or Gal residues present in O-glycans can be 
sulfated by various sulfotransferases (Capon et al., 1997).    The over-expression of O-
linked oligosaccharides, including sialyl-Tn (STn) has been observed in a number of 
different types of cancer (Itzkowitz et al., 1990; Kakeji et al., 1995). Recently, Biomira 
Inc. (Edmonton, AB, Canada) developed a therapeutic cancer vaccine by targeting 
cancer cells which express enhanced STn antigen.  This vaccine has been shown to 
enhance the immune response to STn antigen in patients suffering from breast, ovarian  
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Core 8 Galα1-3GalNAc- 
 
Figure 2.11: O-glycan core structures. Adapted from Brockhausen  
(1999).
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and colon cancer resulting in enhanced survival compared with control patients.  This 
vaccine is currently in phase III clinical trials (Biomira Inc., 2003). 
 
2.3.2.2.2 Biosynthesis of N-linked oligosaccharides 
 In contrast to O-linked oligosaccharides, N-linked oligosaccharides are added to 
proteins co-translationally in the ER by the oligosaccharidyl transferase complex, which 
transfers a pre-assembled 14-sugar oligosaccharide moiety from its membrane-anchored 
dolichol-phosphate linked precursor  (Glc3Man9GlcNAc2-P-P-Dol) to accessible 
asparagine residues located within the consensus sequence Asn-X-Ser/Thr, where X is 
any amino acid except proline (Figure 2.12)  (Gavel and von Heijne, 1990; reviewed in 
Kelleher and Gilmore 2006).  Synthesis of the 14-sugar oligosaccharide precursor 
begins in the cytosol by the transfer of GlcNAc and subsequently Man from the  
nucleotide sugar donors GDP-GlcNAc and GDP-Man, respectively, to membrane 
anchored dolichol-phosphate by cytosolic N-acetylglucosaminyl transferases and 
mannosyl transferases, respectively. The resulting Man5GlcNAc2-P-P-Dol intermediate 
is flipped across the ER membrane where lumenal glycosyltransferases modify the 
oligosaccharides with additional mannose and glucose residues (Varki et al., 1999; 
Helenius and Aebi, 2002).  
 If the protein is properly folded, the terminal glucose residues and one of the 
α1,2-linked mannose residues are removed by glucosidases I and II and α-mannosidase 
I, respectively.  Glycoproteins modified with the resulting high-mannose type 
oligosaccharides (Figure 2.12 and Figure 2.13, panel A) are transported to the cis-Golgi 
where they are modified by additional glycosidases and glycosyltransferases (reviewed 
in Helenius and Aebi, 2004).  This includes removal of the remaining α1,2-linked 
mannose residues by Golgi α-mannosidase I and addition of a GlcNAc residue by N-
acetylglucosaminyltransferase I (GnT-I) resulting in the formation of hybrid-type 
oligosaccharides (Figure 2.12 and Figure 2.13, panel B) (Kornfeld and Kornfeld 1985). 
Removal of α-3 and α-6-linked mannose residues by Golgi α-mannosidase II and 
subsequent addition of GlcNAc residues by N-acetylglucosaminyltransferases result in 
the formation of complex-type oligosaccharide structures (Figure 2.13, panel C).  These 
oligosaccharides can be further modified by addition of polylactosamine structures,  
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Figure 2.12: Biosynthesis of N-linked oligosaccharides. Schematic representation of 
N-linked biosynthesis where blue squares correspond to GlcNAc residues, white circles 
represent mannose residues, red triangles represent glucose residues, green circles are 
galactose residues and grey diamonds represent terminal structures such as sialic acid or 
fucose residues.  Enzymes are numbered as 1 (ER α-glucosidase I), 2 (ER α-
glucosidase II), 3 (ER α-mannosidase), 4 (Golgi α-mannosidase I), 5 (N-
acetylglucosaminyltransferase I), 6 (Golgi α-mannosidase II), 7 (N-acetylglucosaminyl 
transferase II), 8(N-acetylglucosaminyltransferase III), 9 (galactosyltransferases) and 10 
(sialyltransferases or fucosyltransferases).  Inhibitors of carbohydrate processing are 
indicated: T, tunicamycin; C, castanospermine; DNJ, 1-deoxynojirimycin; DMJ, 1-
deoxymannojirimycin and SW, swainsonine. Adapted from Helenius and Aebi (2001). 
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Figure 2.13: Examples of branching structures observed in N-linked  
oligosaccharides. Monosaccharides are represented as: GlcNAc, grey squares; Man, 
black circles; Gal, white circles; sialic acid, white diamonds.
A.  
High mannose-type 
B. 
Hybrid-type 
C. 
Complex-type 
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Lewis antigens and sialic acid residues (Figure 2.10, Figure 2.12 and Figure 2.13, panel 
C) (reviewed in Dennis et al., 1999a ; reviewed in Jones et al., 2005). 
 
2.3.2.2.2.1 Altered expression of β1-6 branched N-linked oligosaccharides in 
cancer 
 One of the earliest changes associated with cellular transformation is the 
presence of increased levels of highly branched complex-type N-linked 
oligosaccharides resulting in the production of glycoproteins with elevated molecular 
weights (Ogata et al., 1976). Upon further examination, it was revealed that elevated 
levels of these complex-type N-linked oligosaccharides were associated with increased 
levels of the Golgi enzyme N-acetylglucosaminyl transferase V (GnT-V), also known as 
mannoside acetyl glucosaminyl transferase 5 (Mgat5) (Cummings and Kornfeld, 1982).  
This enzyme initiates the synthesis of β1-6 branching of N-linked oligosaccharides 
(Figure 2.14) (reviewed in Pierce et al., 1997). The extent of β1-6 branching of N-
linked oligosaccharides expressed by cancer cells was determined by employing the 
plant lectin phytohemagglutinin-leukoagglutinin (L-PHA) from Phaseolus vulgaris 
which binds to the Galβ1,4GlcNAcβ1,6 (Galβ1,4GlcNAcβ1,2)Manα portion of tri- and 
tetraantennary N-glycans formed by GnT-V (Cummings and Kornfeld, 1982). The 
increased expression of β1-6 branched N-linked oligosaccharides on the cell surface 
was observed following transformation of cells with an oncogenic virus such as 
polyoma virus or following transfection with the ras oncogene (Yamashita et al., 1985; 
Dennis et al., 1987,1989).  In addition to being present on the surface of cells 
transformed in vitro, elevated amounts of β1-6 branched N-linked oligosaccharides 
were also observed in a number of human cancers, including melanoma as well as 
breast and colon cancer (Fernandes et al., 1991).  In fact, the amount L-PHA staining 
detected in human colorectal cancer sections correlated with tumor recurrence, patient 
survival, and lymph node metastasis (Fernandes et al., 1991; Seelentag et al., 1998). 
Elevated levels of β1-6 branched N-linked oligosaccharides are believed to contribute to 
tumor cell motility and invasion by altering cell-cell and cell-extracellular matrix 
interactions (Saitoh et al., 1992 ; Zheng et al., 1994).  
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 Further evidence in support of the contribution of β1-6 branched N-linked 
oligosaccharides to increased metastatic potential of cancer cells is their role in 
mediating the loss of cell-cell and cell-ECM contacts.  For example, the presence of 
increased β1-6 branched N-linked oligosaccharides on CD44, the cell surface receptor 
for hyaluronic acid, reduces the affinity of the receptor for its substrate, effectively 
reducing the contact of the cell surface with the ECM (Schmits et al., 1997).  Similarly, 
cells transfected with GnT-V exhibited reduced binding to ECM proteins which was 
associated with increased expression of β1-6 branched oligosaccharides on integrin 
subunits β1, α5 and αv (Demetriou et al., 1995; Guo et al., 2002). Loss of cell-cell 
contacts has also been observed with increased expression of these oligosaccharides on 
the extracellular domain of E-cadherin which reduces the binding to E-cadherins on the 
surface of adjacent cells, resulting in enhanced cell motility (Birchmeier, 1995).  
Consistent with increased levels of β1-6 branched N-linked oligosaccharides in 
cancer cells, elevated expression of GnT-V was observed in a number of cancers where 
it was associated with increased metastatic potential (Seberger and Chaney 1999; 
Murata et al., 2000). For example, the extent of metastasis observed in human 
colorectal cancer tumors correlated with the amount of GnT-V expressed by cancer 
cells (Murata et al., 2000). In addition, non-tumorigenic cells that were transfected with 
GnT-V displayed characteristics of transformed cells, including loss of contact 
inhibition and enhanced motility in tissue culture. Furthermore, in experimental 
metastasis studies, injection of GnT-V-transfected mammary carcinoma cell lines into 
nude mice resulted in enhanced establishment of lung metastases compared to non-
transfected controls (Seberger and Chaney 1999). Although the mechanism responsible 
for increased GnT-V in cancer is not clear, this may be due in part to enhanced 
transcription of the GnT-V gene. For example, studies have revealed that the promotor 
region for the GnT-V gene contains a src-responsive element.  In addition, this 
promoter contains binding sites for AP1 and Ets transcription factors (Pierce et al., 
1997; Buckhaults et al., 1997) whose activity is enhanced upon signaling of the Ras-
Raf-MAPK pathway, which is upregulated in a number of cancers (Medema and Bos, 
1993).  
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  One approach to examining the contribution of GnT-V to metastasis is to 
examine the effect of reduced expression of β1-6 branched N-linked chains on the cell 
surface. Reduced expression of these glycans can be achieved by treating cells with 
swainsonine, a competitive inhibitor of Golgi α-mannosidase II which blocks the N-
linked glycan synthesis pathway prior to initiation of β1-6 branching (Elbein, 1987). 
Swainsonine effectively prevents the formation of β1-6 branching, resulting in reduced 
binding of treated cells to endothelial cells and inhibition of tumor cell invasion in vitro 
(Cornil et al., 1990; Yagel et al., 1989).  Treatment of cancer cells with swainsonine 
also reduced the metastatic potential of cells in vivo since the extent of both 
experimental and spontaneous metastases was reduced following injection of treated 
cells into mice (Humphries et al., 1986). Other studies demonstrated that swainsonine-
treated cells display increased production of TIMP-1 and decreased expression of 
MMP-2, both of which were hypothesized to reduce the invasive potential of treated 
cells (Korczak and Dennis, 1993; Seftor et al., 1991). These results suggested that β1-6 
branched N-linked oligosaccharides may contribute to metastasis by mediating the 
expression of genes that contribute to enhanced metastatic potential. These effects could 
be mediated by altering receptor/ligand interactions on the cell surface, which would 
affect cellular signaling events and subsequent activation of transcription of a subset of 
genes.  
An alternate approach to determine the contribution of GnT-V to metastasis 
involved examining the development of mammary tumors in GnT-V (a.k.a. Mgat5) 
knock-out mice. These studies revealed that Mgat5-/- mice developed tumors at a 
reduced rate and exhibited reduced incidence of lung metastases in the absence of GnT-
V expression. After isolation of mammary tumor cells from Mgat5-/- mice, it was 
revealed that they exhibit reduced ability to develop focal adhesions, which may 
account for the reduced metastatic potential of these cells (Granovsky et al., 2000). 
Thus, the expression of β1-6 branched N-linked oligosaccharides appears to play a role 
in mediating receptor-ligand interactions, which in turn results in altered signaling 
pathways leading to reduced formation of focal adhesions and subsequent cell motility.  
In light of these findings, it may be desirable to decrease the expression of   β1-6 
branched N-linked oligosaccharides on glycoconjugates produced by cancer cells.  To 
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this end, patients suffering from cancer were treated with swainsonine in clinical trials.  
Treatment with swainsonine showed encouraging results, including low toxicity and 
tumor shrinkage in some patients (Goss et al., 1994; reviewed in Dennis et al., 1999b).  
 
2.3.2.3. Poly-N-acetyllactosamine 
 Poly-N-acetyllactosamine structures can be found on glycolipids as well as 
glycoproteins bearing both O-linked or N-linked oligosaccharides.  Poly-N-
acetyllactosamine structures are attached to core 2 or 4 structures of O-linked glycans or 
are attached preferentially to the β1-6 branch of N-linked oligosaccharides  (Figure 
2.10) (van den Eijnden et al., 1988; Ujita et al., 2000). There are two types of poly-N-
acetyllactosamine structures. Type I poly-N-acetyllactosamine chains consist of 
repeating units of Galβ1-3GlcNAc and are synthesized by β-1,3-N-
acetylglucosaminyltransferases whereas type II chains consist of repeating units of 
Galβ1-4GlcNAc and are synthesized by β-1,4-N-acetylglucosaminyltransferases 
(reviewed in Zhou, 2003; Togayachi et al., 2001). Recently, Ishida et al. (2005) 
identified a glycosyltransferase β−1,3-N-acetylglucosaminyltransferase-8, which 
catalyzes the biosynthesis of poly-N-acetyllactosamine structures on β1-6 branched N-
linked oligosaccharides.  Levels of this enzyme are elevated in human colorectal cancer 
tissue compared to normal colonic mucosa. After the elongation of glycan chains by 
poly-N-acetyllactosamine structures, further modifications are made at the terminal 
ends of these chains, as described below.  
 
2.3.2.4 Alterations to terminal glycosylation 
 Terminal carbohydrate structures on oligosaccharides can serve as ligands for a 
number of lectins, which interact with specific carbohydrate structures and mediate 
many of the effects associated with glycosylation (reviewed in Gorelik et al., 2001).  
These terminal structures are found on both glycosphingolipids as well as glycoproteins 
modified by either N-linked or O-linked glycans.  The aberrant expression of terminal 
glycan structures is often associated with cancer progression and metastasis 
(Yogeeswaran and Salk, 1981).  
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2.3.2.4.1 Sialylation 
 Sialylation of N-linked, O-linked and glycosphingolipids results in the addition 
of negatively charged sialic acid residues by sialyltransferases.  Elevated levels of 
sialyltransferases have been observed in a number of cancers (Yang et al., 1994). The 
presence of sialic acid residues at the ends of carbohydrate branches correlates with 
enhanced malignancy in experimental metastasis models (Yogeeswaran and Salk, 
1981). For example, elevated sialylation of glycosphingolipids has been observed in a 
number of colorectal carcinoma tumors (Kudo et al., 1998).   
As previously mentioned, the metastatic potential of cells is associated with 
increased expression of β1-6 branched N-linked oligosaccharides which serve as 
scaffold for the addition of poly-N-acetyllactosamine repeats and sialic acid. Studies 
have shown that elevated levels of β1-6 branching resulted in the presence of more 
poly-N-acetyllactosamine chains and enhanced capping of termini with sialic acid 
residues. This in turn increased the metastatic potential of cancer cells (Dennis et al., 
1987). In support of this, inhibition of β1-6 branching led to reduced levels of poly-N-
acetyllactosamine and a reduction in the overall sialylation of cells, decreasing motility 
and invasiveness (Yoshimura et al., 1995).  The enzyme responsible for the addition of 
sialic acid residues to the terminal ends of β1-6 branched N-linked oligosaccharides is 
the α2-6 sialyltransferase ST6Gal-I. The elevated expression of ST6Gal-I and 
subsequent increase in sialylation has been observed in a number of human cancers and 
is associated with poor prognosis in patients suffering from colorectal or breast cancer 
(Recchi et al., 1998; Lise et al., 2000).  
 Elevated sialylation has also been observed at the ends of elongated chains such 
as poly-N-acetyllactosamine or at the end of short branches of O-linked glycans 
(reviewed in Brockhausen, 1999).  For example, the elevated presence of shorter and 
more heavily sialylated O-glycans on the MUC1 mucin protein has been observed in 
breast cancer (Lloyd et al., 1996).  In addition, sialylation of the Tn O-linked antigen 
has also been identified as a tumor-associated carbohydrate structure as it was observed 
on a number of glycoproteins isolated from tumors, but not from normal mucosa (Thor 
et al., 1986). Furthermore, loss of sialylation following treatment of cells with sialidase 
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which removes terminal sialic acid residues, resulted in the generation of cells with 
decreased  metastatic potential (Finne et al., 1982). 
   
2.3.2.4.2 Blood group antigens 
 Other examples of terminal glycosylation include the addition of blood group 
antigens which consist of histo-blood group ABH antigens and tissue-specific Lewis 
antigens (Figure 2.12).  These carbohydrate antigens are aberrantly expressed by cancer 
cells and result in altered cellular function, usually through interaction with endogenous 
lectins (reviewed in Gorelik et al., 2001). 
 Lewis antigens are carbohydrate structures which are added to the termini of  
glycan chains of both glycoproteins and glycolipids (Figure 2.10). Lewis antigens are 
added to carbohydrate structures containing elongated poly-N-acetyllactosamine 
repeats.  Lewis x (Lex), Lewis y (Ley) and sialyl-Lewis x(sLex) are added to poly-N-
acetyllactosamine type II chains whereas Lewis a(La) and sialyl-Lewis a (sLea) are found 
terminating type I poly-N-acetyllactosamine chains  (reviewed in Gorelik et al., 2001).  
The enhanced expression of Lewis blood group antigens has been observed in a number 
of human carcinomas and often correlated with advanced malignancy.  For example, 
there is a positive correlation between expression of sLex and liver metastasis and poor 
prognosis in colorectal cancer patients (Nakamori et al., 1993). As previously 
mentioned, enhanced sialylation of cell surface carbohydrates has been implicated in the 
establishment of metastatic disease.  Not surprisingly, elevated expression of sLex and 
sLea carbohydrate antigens on both N-linked and O-linked glycans have been 
implicated in enhanced metastatic potential of cancer cells (Shimodaira et al., 1997).  
Histo-blood group ABH antigens are expressed on the surface of red blood cells 
and dictate blood-type (Figure 2.10). During oncogenic transformation, tumor cells 
express altered histo-blood group antigens at the ends of poly-N-acetyllactosamine 
chains affecting metastatic potential (Hakomori, 1999). For example, loss of A and B 
antigen expression has been observed in a number of malignancies and is associated 
with reduced survival in these patients (Mandel et al., 1992). Loss of these carbohydrate 
antigens is hypothesized to result in enhanced binding of growth factors to cell surface 
receptors resulting in elevated cell proliferation and motility. Altered expression of 
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histo-blood group H antigen has also been observed in cancer.  In fact, colorectal 
carcinoma tumors have been observed to express elevated levels of histo-blood group H 
antigen (Yang et al., 1994). Cancer cells expressing elevated levels of histo-blood group 
H carbohydrate antigen are more aggressive and tumorigenic than those expressing 
reduced levels (Goupille et al., 1997).  
 
2.3.2.5 Lectins  
 The presence of carbohydrates on glycoproteins or glycolipids not only directly 
affects the function of the macromolecule they are attached to (Opdenaker et al., 1993; 
Chammas et al., 1991; Kornfeld, 1980), but they also have the ability to bind lectins.  
Lectins are proteins that bind to specific carbohydrate structures and may mediate the 
effects that are associated with the presence of carbohydrates. Initially lectins were 
isolated from a number of different plant species, however, a number of  mammalian 
lectins have been identified in recent years.  Some examples of endogenous human 
lectins include C-type lectins and S-type lectins.   
C-type lectins are calcium-dependent cell surface lectins such as selectins. 
Selectins are normally involved in tissue injury or inflammation, but have been 
implicated in the metastatic spread of cancer cells (Fukada, 1996). Examples of 
selectins include L-selectin which is expressed on the surface of leukocytes, E-selectin 
which is expressed mainly on endothelial cells and P-selectin which is expressed on 
endothelial cells as well as platelets  (Fukada, 1996).  
Carbohydrate ligands for selectins consist of terminal sialylated Lewis antigens 
such as sLex and sLea (Fukada et al., 1999).  The ability of cancer cells to establish 
metastasis at a secondary organ requires that the tumor cells be able to adhere to the 
vascular endothelium at this secondary sight.  This adhesion is mediated by the 
interaction between selectins such as E-selectin or P-selectin expressed by the vascular 
endothelium and sialylated Lewis antigens expressed on the tumor cell surface (Biacone 
et al., 1996).  In order to enhance the adherence of tumor cells to the vasculature at the 
secondary site, tumor cells stimulate the release of cytokines from endothelial cells 
resulting in elevated expression of E-selectin by these endothelial cells (Khatib et al., 
1999).  In support of the role of sialylated Lewis antigens in the establishment of distant 
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metastasis, studies have shown that blocking the synthesis of sLex and sLea by over 
expressing a fucosyltransferase that competes with Lewis antigen synthesis prevented 
liver colonization by colorectal carcinomas (Weston et al., 1999). It was suggested that 
a decrease in metastatic potential of the cancer cells resulted from decreased 
adhesiveness of cancer cells expressing reduced sialylated Lewis antigens and E-
selectin (reviewed in Brockhausen, 1999).  
 In addition to playing a role in mediating adhesion to the vascular endothelium, 
selectin-ligand interactions have also been implicated in maintaining homotypic 
interactions between tumor cells, a necessary step for tumor cell embolization and 
survival in the vasculature.  The expression of both selectins and their sialylated Lewis 
antigen ligands have been found on the cell surface of cancer cells, suggesting that this 
dual expression may be involved in the clustering of cells (Hittelet et al., 2003a).  In 
support of this hypothesis, some tumor cells express P-selectin, which is normally 
present on the surface of activated platelets or endothelial cells.  The presence of P-
selectin on the tumor cell surface may also enhance embolization by mediating 
interactions between platelets and tumor cells (Stone and Wagner, 1993).  
 In addition to selectins, other types of endogenous lectins exist and play 
important roles in a number of cellular functions.  For example, galectins are S-type 
lectins that have been implicated in cell adhesion, apoptosis, cell growth, inflammation, 
embryogenesis, immune function and tumor metastasis formation (reviewed in Gorelik, 
2001). Fourteen mammalian galectins have been identified to date, all of which bind to 
type I or type II N-acetyllactosamine structures (reviewed in Hughes, 2001). Binding of 
galectins to their carbohydrate ligands is mediated by a carbohydrate recognition 
domain (CRD).  Most galectins have only one CRD, however galectin-4, -6, -8, -9 and -
12 have two such domains (reviewed in Dumic et al., 2006).  Galectins can function as 
monomers, dimers or oligomers and they have been detected in the nucleus, cytoplasm 
as well as extracellularly. Extension of glycan chains with poly-N-acetyllactosamine 
and capping with terminal carbohydrate structures may alter the binding affinity of 
galectin family members.  For example, galectin-3 has a high affinity for the human 
blood group A epitope Galα1,3[Fuc1,2]Galβ1,4GlcNAc however galectin-1 does not 
(Sparrow et al., 1987).  
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 Galectins-1 and -3 have been the subject of numerous studies as both have been 
implicated in a number of cancers (reviewed in van den Brûle et al., 2004).  Galectin-1 
is a 14 kDa homodimer that binds to carbohydrate structures on glycoproteins including 
fibronectin, laminin and lysosome-associated membrane proteins (LAMPs) (reviewed 
in Gorelik, 2001). Expression of galectin-1 has been associated with the induction of 
apoptosis (Perillo et al., 1996). Studies have revealed elevated levels of galectin-1 in a 
number of cancers compared to normal tissues (reviewed in van den Brûle et al., 2004).  
In addition, elevated levels of cytoplasmic galectin-1 were associated with increasing 
dysplasia and malignancy in human colorectal carcinoma specimens (Hittelet et al., 
2003b).    
 Galectin-3 is a 31 kDa β-galactoside binding protein composed of three domains 
including an amino terminal domain, a repetitive collagen-like domain and a carboxy- 
terminal domain which contains the carbohydrate recognition domain (CRD) (Barondes 
et al., 1994). Galectin-3 can function as a monomer, however self-association mediated 
by the amino terminal domains of monomers results in oligomerization and enhances 
the binding affinity to ligands (Barboni et al., 2000). Galectin-3 has been identified in 
the nucleus, cytoplasm as well as extracellularly. Galectin-3 binds to carbohydrate 
structures on glycoproteins such as laminin, Mac-2 binding protein/tumor-associated 
antigen 90K (TAA90K), integrins, CEA and mucin and has been identified as a 
substrate for MMP-2 and MMP-9 (Sasaki et al., 1998; Ohannesian et al., 1995; Ochieng 
et al., 1994).  Cleavage of galectin-3 by MMPs results in the generation of cleavage 
products that can bind more tightly to glycan ligands (Ochieng et al., 1998). 
 Galectin-3 is ubiquitously expressed by epithelial cells and immune cells, 
including surface expression on activated macrophages (reviewed in Dumic et al., 
2006). Elevated expression of galectin-3 has been associated with tumor progression in 
a number of cancers. For example, elevated levels of galectin-3 in colorectal cancer 
have correlated with Duke’s staging and poor survival (Lee et al., 1991).  Furthermore, 
studies have shown that transfection of non-tumorigenic breast carcinoma cell lines 
with the cDNA encoding galectin-3 results in enhanced tumorigenicity following 
injection into nude mice (Nangia-Makker et al., 1995).  
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 Unlike other galectins which have been shown to induce apoptosis, galectin-3 
actually exhibits an anti-apoptotic effect (Akahani et al., 1997).  Studies have revealed 
that the anti-apoptotic effect of galectin-3 is mediated by a NWGR motif.  This motif 
has also been identified in the protein Bcl-2 and is required for mediation of its anti-
apoptotic effects (Akahani et al., 1997).  Thus, galectin-3 may contribute to tumor 
progression by inhibiting apoptosis of tumor cells.  The anti-apoptotic function of 
galectin-3 is regulated by its phosphorylation state.  Galectin-3 present in the cytoplasm 
becomes phosphorylated by casein kinase I resulting in the translocation of galectin-3 
into the nucleus where it elicits its anti-apoptotic effects and protects cells from death 
induced by chemotherapeutic agents (Takenada et al., 2004).  The anti-apoptotic effect 
of galectin-3 is believed to be mediated through its interaction with the mitrochondrial 
membrane, thereby preventing the release of cytochrome c and subsequent activation of 
the caspase cascade (Yu et al., 2002). Thus, galectin-3 may contribute to tumorigenesis 
by inhibiting apoptosis. 
 Enhanced expression of galectin-3 by cancer cells may result in enhanced 
tumorigenicity by stimulating cellular proliferation.  Shimura et al. (2004) have 
identified β-catenin as a ligand for galectin-3. Upon translocation to the nucleus, β-
catenin and galectin-3 co-localize and activate the transcription factor TCF-4 resulting 
in transcriptional activation of genes that enhance cellular proliferation such as cyclin 
D1, cyclin A, cyclin E, p21WAF1/CIP1 and p27KIP1. Galectin-3 may also stimulate cellular 
proliferation by binding to the activated ras oncogene product resulting in the activation 
of the Ras-MAP kinase pathway (Shalom-Feuerstein et al., 2005). 
 Galectin-3 may also enhance tumorigenesis by stimulating angiogenesis.  
Galectin-3 was able to stimulate in vitro capillary tube formation as well as the 
chemotaxis of human umbilical vascular endothelial cells (HUVEC).  In addition, 
galectin-3 was able to initiate in vivo neovascularization.  These effects were shown to 
be inhibitable by lactose, which competes with ligands for galectin-3 binding, 
implicating galectin-3 binding to glycan structures in these processes (Nangia-Makker 
et al., 2000).  
 In addition to enhancing tumorigenesis, galectin-3 has also been implicated in 
mediating cell adhesion as well as cell-cell interactions. For example, breast cancer cell 
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lines that have been transfected with a cDNA encoding galectin-3 exhibited enhanced 
adhesion to ECM proteins including laminin and collagen IV (Warfield et al., 1997).  In 
addition, these cells exhibited enhanced invasion through a reconstituted basement 
membrane known as Matrigel in in vitro invasion assays and was associated with an 
increased expression of α6β1 integrin (Warfield et al., 1997). Furthermore, increased 
expression of galectin-3 in poorly metastatic cell lines resulted in enhanced metastatic 
potential (Raz et al., 1990).  
Since aggregation of cells is an important requirement for embolization and 
survival in the vasculature, leading to increased incidence of metastases (Liotta et al., 
1976), it was hypothesized that galectin-3 may enhance the spread of cancer cells by 
establishing cell-cell contacts. The addition of asialofetuin, a glycoprotein bearing poly-
N-acetyllactosamine structures, resulted in galectin-3-mediated aggregation of cells 
(Inohara and Raz, 1995). Similarly, addition of Mac-2-binding protein/TAA90K, which 
is a major ligand for galectin-3, resulted in the homotypic aggregation of melanoma 
cells, suggesting that Mac-2 binding protein/TAA90K and galectin-3 interact on the cell 
surface to promote the formation of homotypic interactions (Inohara et al., 1996). The 
cellular aggregates formed in both of these studies were inhibited by lactose, indicating 
that galectin-3 binding to glycan structures on these glycoproteins was responsible for 
the mediation of aggregate formation. It is through the formation of homotypic 
interactions that galectin-3 is hypothesized to enhance emboli formation and prevent 
anoikis resulting in enhanced metastatic potential (Kim et al., 1999).  
 Galectin-3 may also contribute to metastasis by enhancing cell motility through 
its interaction with glycans expressed on integrin receptors.  Galectin-3 interacts with 
glycoconjugates bearing poly-N-acetyllactosamine repeats that are added preferentially 
to β1-6 branched N-linked oligosaccharides generated by GnT-V (a.k.a. Mgat5). For 
example, recent research has examined the effect of Mgat5 activity on the formation of 
focal adhesions required for cell motility. Mammary epithelial tumor cells isolated from 
Mgat5-/- mice which lack β1-6 branched oligosaccharides exhibited impaired 
fibronectin fibrillogenesis as well as fibronectin-dependent cell spreading.  These 
results were also observed in mammary tumor cells from Mgat5+/+ mice that were 
treated with either swainsonine or competitive inhibitors of galectin-3 binding. Further 
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analysis revealed that galectin-3 interacts with Mgat5 modified N-glycans expressed on 
α5β1 integrin receptors involved in fibronectin binding.  Binding of galectin-3 initiated 
integrin activation resulting in clustering of cell surface integrins as well as receptor 
tyrosine kinases and subsequent translocation to fibrillar adhesions.  In addition, 
activation of cell surface receptors initiated signaling events which led to the activation 
of focal adhesion kinase (FAK), phosphatidylinositol 3 kinase (PI3K) and increased 
turnover of F-actin.  Thus, binding of galectin-3 to Mgat5-modified N-glycans on α5β1 
integrin resulted in fibronectin polymerization and enhanced tumor cell mobility 
through stimulation of focal adhesion remodeling (Lagana et al., 2006).  Another study 
revealed that galectin-3 also interacts with Mgat5 modified N-glycans on cell surface 
cytokine receptors including epidermal growth factor and transforming growth factor β 
receptors, delaying their removal by endocytosis (Partridge et al., 2004).  
  
2.4 GLYCOPROTEINS ASSOCIATED WITH CANCER  
 The identification of novel targets to aid in the detection, prevention and 
treatment of cancer is a challenging task.   Since altered glycosylation of lipids and 
proteins has been implicated in tumor progression and metastasis, identification of  
glycoconjugates modified by cancer-associated glycan chains may uncover novel 
cancer markers and provide new approaches for cancer management.    
 
2.4.1 The role of glycoproteins modified by β1-6 branched N-linked 
oligosaccharides 
 Cancer cells expressing elevated levels of β1-6 branched N-linked 
oligosaccharides have enhanced metastatic potential (Dennis et al., 1987; Fernandes et 
al., 1991).  The identification of glycoproteins that are modified with these cancer-
associated carbohydrates may provide insight about their contribution to increased 
invasion and metastasis.   In addition, the identification of proteins modified by β1-6 
branched oligosaccharides may uncover tumor markers that will aid in the diagnosis 
and/or treatment of cancer. For example, carcinoembryonic antigen (CEA) has been 
identified as a major carrier of β1-6 branched N-linked oligosaccharides 
(Chandrasekaran et al., 1983 Wojciechowicz et al., 2000). Serum levels of CEA are 
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used to monitor prognosis of patients with colon, breast or lung cancer after surgery.  
Elevated serum levels of CEA are a factor for poor prognosis and cancer recurrence 
(Goldenberg et al., 1981). CEA is expressed in adenocarcinomas of the digestive tract 
and fetal gastrointestinal tissue where it mediates homotypic cell adhesion (Benchimol 
et al., 1989). Overexpression of CEA has been observed in a number of cancers 
including colorectal cancer where it is implicated in the establishment of hepatic 
metastases. Specifically, tumor cells expressing CEA on their surface bind to receptors 
on hepatic cells, stimulating the release of cytokines that increase ICAM-1 expression 
on vascular endothelium, which enhances the adhesion of cancer cells (Wagner et al., 
1992). The presence of oncodevelopmental carbohydrates such as β1-6 branching on 
CEA produced by cancer cells may result in enhanced cell-cell mediated adhesion 
compared to CEA produced by normal cells (Charbonneau and Stanners, 1999).  
 Other examples of glycoproteins bearing cancer-associated carbohydrates are 
the lysosomal membrane associated proteins -1 and -2 (Lamp-1 and Lamp-2), which are 
normally localized in the membrane of lysosomes.  However, they have also been 
observed on the cell surface of cancer cells (Hughes and August 1981; Mane et al., 
1989).  Both Lamp-1 and Lamp-2 are heavily glycosylated and have been identified as 
carriers of β1-6 branched N-linked oligosaccharides (Laferté and Dennis, 1989; Ochwat 
et al., 2004). The presence of sialic acid and poly-N-acetyllactosamine on β1-6 
branches of N-linked oligosaccharides resulted in decreased binding of Lamp-1 to ECM 
proteins and increased motility and invasiveness (Laferté and Dennis, 1988). The 
overexpression of Lamp-1 by tumor cells has been associated with enhanced tumor 
invasion in pancreatic carcinomas  (Künzli et al., 2001). In addition, elevated 
expression of Lamp-1 and Lamp-2 by colorectal cancer cell lines was associated with 
enhanced metastatic potential of these cells (Saitoh et al., 1992). 
 Integrins are another example of glycoproteins that are carriers for β1-6 
branched N-linked oligosaccharides. Integrins are heterodimeric cell surface receptors 
that are composed of both α and β subunits (reviewed in Hood and Cheresh, 2002). 
These receptors bind to extracellular ligands and mediate cell-cell as well as cell-ECM 
interactions.  The increased expression of β1-6 branched N-linked oligosaccharides on 
integrins has been observed to result in altered cell-cell and cell-ECM interactions 
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resulting in cells with enhanced motility and metastatic potential (reviewed in Gu and 
Taniguchi, 2004) . Integrin subunits that have been identified as targets of GnT-V and 
carriers of β1-6 branched N-linked glycans include α2, α3, α5 and β1 integrin subunits 
(Prokopishyn et al.,1999; Ochwat et al., 2004). For example, elevated expression of β1-
6 branched N-linked oligosaccharides on β1 integrin subunits resulted in the inhibition 
of α5β1-mediated spreading of cells on fibronectin, resulting in enhanced migration and 
invasion. It was observed that enhanced motility was the result of decreased clustering 
of α5β1 integrins on the cell surface as a result of elevated levels of β1-6 branching 
(Zheng et al., 1994).  
 
2.4.1.1 Tumor-associated antigen 90K 
In an effort to identify glycoproteins that contribute to colon cancer progression, 
Laferté and Loh (1992) identified the tumor-associated antigen 90K (TAA90K; a.k.a 
Mac-2-binding protein; galectin-3-binding protein) as a major carrier of β1-6 branched 
N-linked oligosaccharides.  In addition, Ochwat et al., (2004) identified TAA90K as a 
carrier of β1-6 branching in melanoma cells. These findings were recently confirmed by 
Kim et al. (2006) who identified TAA90K as a substrate for N-
acetylglucosaminyltransferase V activity, the enzyme responsible for catalyzing β1-6 
branching.  
In an attempt to examine the regulation of TAA90K expression, the promoter 
for the TAA90K gene has been analyzed (Brakebusch et al., 1997, 1999).  The gene for 
TAA90K was found to be 8.8-kilobase pairs consisting of 6 exons and was found to be 
localized on chromosome 11, region E (Brakebusch et al. 1997).  Analysis of the gene 
for TAA90K revealed a TATA-less promoter with several unique features.  For 
example, the promoter was found to be neither GC-rich nor was it dependent on SP1 
sites.  Further study revealed the presence of one major transcriptional start site as well 
as a minimal promoter, which contains an interferon responsive element (IRF-E) 
(Brakebusch et al., 1999). In support of this, TAA90K expression was found to be 
induced by interferons (IFNs) –α and –γ (Marth et al., 1994; Brackebusch et al., 1997). 
Following the isolation and analysis of the cDNA for TAA90K, it was revealed 
that the open reading frame encodes a 585 amino acid protein (Koths et al., 1993; 
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Ullrich et al., 1994). Based on the amino acid sequence of TAA90K, four putative 
domains were predicted (Müller et al., 1999).  Figure 2.15 is a schematic diagram of the 
putative TAA90K domains including potential N-linked oligosaccharide sites and 
protease cleavage sites.  The N-terminal domain 1 begins after the signal sequence 
(amino acids 19-133) and is homologous to the scavenger receptor cysteine-rich domain 
(SRCR) found in members of the macrophage scavenger receptor superfamily (Pearson 
et al., 1996).    Domain 2 spans amino acids 127-250 and corresponds to a putative 
BTB/POZ domain (Broad complex, tramtrack, bric-a-brac/poxvirus and zinc finger) 
found in developmentally regulated zinc finger proteins and the kelch family of actin-
associated proteins thought to mediate protein-protein interactions (Carim-Todd et al., 
2001).  Domain 3 consists of amino acids 251-408 which has homology with an IVR 
domain (intervening sequence between BTB and kelch) (Robinson et al., 1997).  The 
remaining amino acid sequence consists of a 40 amino acid link region followed by 
domain 4 (amino acids 451-585) whose sequence is consistent with a globular fold. It 
has been shown that domains 2, 3 and 4 are important in forming the oligomeric 
complex and mediating adhesion to extracellular matrix proteins (Müller et al., 1998; 
Hellstern et al., 2002).  
Although the amino acid sequence of TAA90K predicts a polypeptide size of 
approximately 60 kDa (Koths et al., 1993; Laferté et al., 2000), TAA90K is synthesized 
initially as a 74 kDa glycoprotein modified with high-mannose type oligosaccharides 
(Laferté and Loh, 1992; Koths et al., 1993).  Further processing of the glycans in the 
Golgi results in the generation of a 90-100 kDa glycoprotein modified with complex-
type N-linked oligosaccharides which is secreted extracellularly and forms large 
homopolymers that assemble into ring-like structures (Sasaki et al., 1998). Although 
TAA90K was found to be heavily modified by oligosaccharide structures, no O-linked 
oligosaccharides were detected (Laferté and Loh, 1992; Laferté et al., 2000; Hellstern et 
al., 2002).  
Studies have identified cyclophilin-C associated protein (CyCAP) as the murine 
orthologue of TAA90K. CyCAP is a 77 kDa protein that shares 69% protein sequence 
identity with TAA90K (Figure 2.16) (Trahey and Weissman, 1999). It binds cyclophilin 
C, a peptidylprolyl cis-trans isomerase that is involved in mediating protein folding 
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Figure 2.15: Schematic of the putative TAA90K domains and potential 
asparagine-linked glycosylation sites. The signal sequence is indicated in 
black. Putative domains are represented by boxes and the amino acid residues 
involved at the boundaries of the domains are indicated.  Potential asparagine-
linked glycosylation sites are indicated by asterisks (*). Protease cleavage sites 
for trypsin and plasmin are indicated. 
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Figure 2.16: Alignment of amino acid sequences for human TAA90K/M2BP, 
Hamster PCAP, mouse CyCAP/PIBP and rat MAMA protein. The signal 
sequence and domains 1-4 are indicated.  Putative glycosylation sites are marked  
with astericks (*) and plasmin cleavage site in TAA90K with a +. From Müller et al. 
(1999). 
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(Friedman et al., 1993).  Both TAA90K and CyCAP share an amino-terminal signal 
sequence followed by a scavenger receptor cysteine-rich domain as well as several 
putative asparagine-linked glycosylation sites (Figure 2.15). Despite the sequence 
similarities between CyCAP and TAA90K, these two proteins exhibit differences in 
ligand binding. CyCAP binds to human and mouse cyclophilin C, however, it cannot 
bind to mouse or human Mac-2.  On the other hand, TAA90K is unable to bind to either 
mouse or human cyclophilin C (Jalkanen et al., 2001).  These biological differences 
may result from conformational differences between individual or multiple domains of 
these two proteins.  
 
2.4.1.1.1 Expression of TAA90K in normal and cancerous tissues  
 TAA90K is a secreted glycoprotein that is present in normal human fluids 
including plasma, breast milk, saliva, tears and urine, a wide range of epithelial tissues 
(Iacobelli et al., 1986; Linsley et al., 1986; Koths et al., 1993; Jallal et al., 1995), but 
elevated in the serum of patients suffering from cancer (Linsley et al., 1986; Natoli et 
al., 1993; Ullrich et al., 1994; Jallal et al., 1995; Iacobelli et al., 1986, 1993, 1994) and 
viral infections including acquired immunodeficiency virus and hepatitis C (Natoli et 
al., 1993; Artini et al., 1996). 
Analysis of TAA90K expression by Northern blotting and 
immunohistochemistry has revealed elevated levels of TAA90K in pancreatic, breast 
lung, and gastric cancers (Fusco et al., 1998; Künzli et al., 2002; Marchetti et al., 2002; 
Ozaki et al., 2002; Park et al., 2006).  In the cases of non-small cell lung cancer and 
malignant mesothelioma, TAA90K expression correlated with metastasis and predicted 
survival (Marchetti et al., 2002) or disease manifestation (Singhal et al., 2003), 
respectively. In breast cancer patients, serum levels ≥11µg/mL TAA90K correlated with 
poor prognosis (Iacobelli et al., 1994).  However in this case, TAA90K was expressed 
by the tumor as well as by peripheral blood mononuclear cells, indicating that TAA90K 
may play a role in host anti-tumor immune responses (Fusco et al., 1998). TAA90K 
levels were also elevated in patients suffering from biliary tract carcinoma and when 
analyzed in combination with CA19-9, the current marker for this type of cancer, the 
diagnostic significance was improved compared to the use of either marker individually 
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(Koopman et al., 2004). Elevated levels of TAA90K may also have diagnostic 
significance for patients suffering from nasopharyngeal carcinoma (Wu et al., 2005).  
 
2.4.1.1.2 Interaction with extracellular proteins  
Although the function of TAA90K is not known, there is evidence to suggest 
that it may be involved in the modulation of cell adhesion.  Sasaki et al. (1998) have 
shown that TAA90K is deposited in the extracellular space and is able to bind to 
extracellular matrix proteins including laminin-1, collagens and fibronectin as well as 
mediate cell adhesion in a β1-integrin-dependent manner.  These data suggested that 
TAA90K may act as a cross-linking bridge between tumor cells and the extracellular 
matrix, thereby modulating tumor cell adhesion.    
In addition to being modified by β1-6 linked oligosaccharides, TAA90K is also 
modified with poly-N-acetyllactosamine structures (repeating Galβ1-4GlcNAc units) 
(Laferté and Loh, 1992).  These oligosaccharides are potential binding sites for galectin-
3, a mammalian lectin and dominant ligand for TAA90K (Hughes, 2001). Binding of 
TAA90K to cell surface-associated galectin-3 via its domains 3 and 4 has been shown 
to cause tumor cell aggregation (Inohara et al., 1996). TAA90K is also a ligand for 
galectin-1 and is able to stimulate galectin-1 induced cellular aggregation (Tinari et al., 
2001). These results suggested that extracellular co-localization of TAA90K with 
galectin-3 and possibly galectin-1 may contribute to metastasis by enhancing tumor 
emboli formation.  
TAA90K may also contribute to tumor progression by modulating the 
expression or function of MMPs, proteolytic enzymes shown to play a key role in tumor 
invasion and metastasis (reviewed in Nagase et al., 2006). Recent studies have shown 
that in addition to being a potential tumor marker for prostate cancer, TAA90K induced 
the expression of promatrilysin (proMMP-7) when it was added to the culture medium 
of the prostate cancer cell line LNCaP (Bair et al., 2006). Other studies revealed that 
proMMP-7 expression in the LNCaP cell line is mediated by IL-1β induced IL-6 
expression and signaling through STAT-3 (Maliner-Stratton et al., 2001). Since 
proMMP-7 expression was blocked by both anti-TAA90K and anti-IL-6 antibodies 
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(Bair et al., 2006), this suggested that TAA90K may enhance the expression of 
proMMP-7 through the induction of IL-6 (Ullrich et al., 1994).  
In addition to an effect on MMP expression, TAA90K may also have an effect 
on ADAMTS (a disintigrin and metalloproteinase with thrombospondin motifs), another 
family of metalloproteinases that has been shown to be involved in the restructuring of 
the ECM (Sandy et al., 2001).  Recent studies employing proteomic screening to 
elucidate potential targets for ADAMTS1 activity have identified TAA90K as a 
potential substrate for this enzyme. In support of this hypothesis, overexpression of 
ADAMTS1 in human embryonic kidney 293T cells was associated with reduced levels 
of  TAA90K in the medium (Canals et al., 2006). The putative cleavage of TAA90K by 
ADAMTS1 and perhaps other metalloproteinases may alter the function of TAA90K, 
possibly through changes in three-dimensional structure. In this regard, cleavage of 
TAA90K in the linker region by trypsin and plasmin has been observed (Hellstern et al., 
2002; Sasaki et al., 1998).  
 
2.4.1.1.3 Immunomodulation 
In addition to binding to a number of extracellular proteins and mediating 
cellular adhesion, TAA90K has also been implicated in modulating immune responses.  
For example, elevated TAA90K levels in the serum of breast cancer patients were found 
to be the result of increased production of TAA90K by peripheral blood mononuclear 
cells (PBMC), suggesting that TAA90K may modulate immune responses (Fusco et al., 
1998).  Furthermore, the addition of TAA90K to PBMC led to the activation of T-cells, 
natural killer (NK) and lymphokine-activated killer (LAK) cells by stimulating PBMC 
to release cytokines including IL-1, IL-2 and IL-6 (Ullrich et al., 1994; Powell et al., 
1995). TAA90K was also found to contain a SRCR domain which is found in members 
of the macrophage scavenger receptor superfamily previously implicated in 
development and regulation of the immune system, including complement factor I, CD5 
and CD6 (Goldberger et al., 1987; Kodama et al., 1990; Aruffo et al., 1991). In 
addition, Jallal et al. (1995) revealed that the subcutaneous injection of TAA90K-
expressing tumors in nude mice resulted in elevated VCAM-1 and ICAM-1 expression 
on endothelial cells of blood vessels resulting in enhanced infiltration of leukocytes. 
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These results confirm previous studies by Powell et al., (1995) demonstrating that 
addition of purified TAA90K to a human monocytic cell line resulted in the 
upregulation of ICAM-1 expression. 
In other studies, Trahey and Weissman (1999) demonstrated that genetic knock-
out mice deficient in CyCAP expression were found to be more sensitive to the effects 
of bacterial endotoxin than wildtype mice, suggesting that CyCAP and possibly 
TAA90K are involved in the regulation of endotoxin and pro-inflammatory responses in 
vivo. In support of this, TAA90K was able to bind to the cell surface protein CD14 
when its ligand bacterial lipopolysaccharide (LPS, endotoxin) was bound (Yu and 
Wright, 1995). Thus, TAA90K may play a role in modulating the pro-inflammatory 
response which is characterized by elevated secretion of cytokines including tumor 
necrosis factor-α (TNF-α), Il-1β, IL-6 and IL-8 and has been implicated in the 
development of some cancers, including stomach and colon (Coussens and Werb, 
2002).  
Recent studies have revealed that the expression of CyCAP is elevated in 
keratinocytes as well as infiltrating immune cells during the process of wound repair in 
mice, suggesting a role in inflammation and subsequent wound healing. In support of 
this is the finding that wound healing is impaired in CyCAP null mice (Kong et al., 
2007). Matrix metalloproteinases including MMP-13 are involved in remodeling of the 
ECM during processes such as wound repair and have also been implicated in the 
progression of cancer and other diseases (Moore et al., 2000).  Previous work revealed 
that the expression of MMP-13 can be upregulated by the binding of fibronectin 
fragments to cell surface receptors (Stanton et al., 2002). Recently, it was revealed that 
fibroblasts from wildtype mice express elevated levels of MMP-13 following treatment 
with fibronectin fragments, whereas CyCAP null mice do not (Kong et al., 2004). These 
results would suggest that CyCAP is involved in mediating fibronectin fragment-
induced expression of MMP-13, possibly through interaction with fibronectin or 
integrin receptors.   
In summary, TAA90K was identified as a major carrier of cancer-associated 
carbohydrates and appears to be a marker for a number of types of cancer.  Although 
the function of TAA90K is not well understood, studies have revealed that it is a multi-
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adhesive protein with the potential to interact with ECM proteins, galectins and MMPs 
suggesting a role in modulating tumor cell adhesion to the ECM and galectins. In 
addition, TAA90K may also function in immunomodulation by stimulating the release 
of cytokines and activating accessory cells of the immune system. 
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3.0 RATIONALE AND OBJECTIVES 
 The elevated expression of β1-6 branched N-linked oligosaccharides by cancer 
cells has correlated with enhanced metastatic potential in both breast and colon cancer.   
Thus, the identification of glycoproteins carrying these cancer-associated glycans may 
contribute to our understanding of the role of these glycans in cancer progression. 
Previous work in our laboratory identified TAA90K, secreted by colon cancer cell lines, 
as a carrier of these cancer-associated carbohydrates.  Elevated expression of TAA90K 
has been shown to correlate with cancer progression and poor prognosis in a number of 
cancers. Although elevated levels of TAA90K have been observed in a number of 
cancers and viral infections, its role has yet to be elucidated. Thus, this thesis examines 
the expression of TAA90K in human colon cancer and attempts to clarify its role in 
cancer progression.  
 The specific objectives of these studies are as follows: 
(1) To examine the expression of TAA90K in human colon tumors and normal 
colonic mucosa 
(2) To examine the expression of TAA90K in human colon cancer cell lines 
(3) To purify TAA90K from human colon cancer cell lines for use in functional 
studies 
(4) To examine the interaction between TAA90K and ECM proteins, galectins 
and MMPs 
(5) To examine the effect of TAA90K on MMP expression by colon cancer 
cells 
(6) To examine the effect of TAA90K cleavage on its function, including 
binding to ECM proteins and galectins  
(7) To examine the role of TAA90K tumor cell adhesion, invasion and 
migration  
 
 
 
 61 
 
 
4.0 MATERIALS AND METHODS 
4.1 Cell lines   
 The human colon carcinoma cell lines HT-29 (HTB 38), SW403 (CCL 230) 
SW620 (CCL 227), LoVo (CCL 229), LS123 (CCL 255), Caco-2 (HTB 37), the normal 
rat fibroblast cell line Rat2 (CRL 1764) and the normal rat small intestinal epithelial cell 
line IEC-6 (CRL 1592) as well as COS-1 (CRL 1650) and the African green monkey 
cell line CV-1 (CCL-70) were obtained from the American Type Culture Collection 
(A.T.C.C., Rockville, MD). The human colon carcinoma cell line KM20C and the 
human breast epithelial cell line HBL-100 (HTB 124, ATCC) were obtained from Drs. 
I. J. Fidler (MD Anderson Cancer Centre, Houston, TX) and S. Carlsen (Saskatoon 
Cancer Research Unit, Saskatoon, SK), respectively. Cells were cultured in complete 
medium consisting of Dulbecco's minimum essential medium (DMEM, high glucose) 
supplemented with 10 % fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium 
pyruvate, 1% non-essential amino acids and 2% MEM vitamin solution (Invitrogen, 
Burlington, ON). In routine testing, all of the cell lines used were found to be free of 
mycoplasma contamination. For purification of TAA90K from HT-29-conditioned 
medium, cells were cultured in complete F12/DMEM serum-free medium (Invitrogen, 
Burlington, ON) supplemented with 2 µg/mL insulin, 20 ng/mL epidermal growth 
factor, 13 ng/mL triiodothyronine and 2 µg/mL transferrin (Sigma, Oakville, ON). 
 
4.2 Construction and expression of His-TAA90K 
 The entire open reading frame (ORF) of TAA90K was inserted in-frame behind 
the poly-histidine tag into the expression vector pRsetB (Invitrogen, Burlington, ON) 
for expression of His-TAA90K as described (Laferté et al., 2000). Briefly, the entire 
open reading frame for TAA90K was reconstructed by inserting the 1.174 kb KpnI-
EcoRI fragment from pTZ-KE and the 0.67 kb EcoRI-HindIII fragment from pTZ-EB  
behind a poly-histidine tag into KpnI and HindIII sites of the plasmid vector RsetB to 
create RsetB-90.  This construct was used to transform competent BL21 cells. 
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 Recombinant BL21 cells expressing His-TAA90K were grown at 30 oC in Luria 
broth to an optical density of 0.6-0.8 at 600 nm and induced for 4 hours with 1 mM 
isopropylthiogalactoside (IPTG) (Invitrogen, Burlington, ON). Bacteria were pelleted 
by centrifugation at 1500 x g and lysed by rocking for 30 minutes in buffer containing 
50 mM Tris HCl pH 7.4, 0.1% Triton X-100, 0.25 mM phenylmethylsulfonylfluoride 
(PMSF), and 0.03 mg/mL lysozyme. The sample was sonicated (1 x 15 sec bursts at 350 
watts) and centrifuged at 14,000 rpm in a Beckman microcentrifuge, in preparation of 
metal chelation affinity chromatography (see below). 
 
4.3 Preparation of recombinant vaccinia virus expressing TAA90K-His  
 For expression of TAA90K in eukaryotic cells, recombinant vaccinia virus 
encoding TAA90K containing a C-terminal poly-histidine tail was constructed. To this 
end, a histidine-tag consisting of 6 consecutive histidine residues was attached to the 3' 
end of the TAA90K open reading frame (Laferté et al., 2000), as follows. First, using 
the Quikchange mutagenesis kit (Stratagene, La Jolla, CA) and the mutagenesis primers 
Mac2.SalU (CTCCTCAGGTGTCGACTAGACGGCGTGG) and Mac2.SalL 
(CCACGCCGTCTAGTCGACACCTGAGGAG), a unique SalI site (underlined) was 
created at the 3' end of the TAA90K ORF just before the stop codon TAG (in italics) 
without altering its predicted amino acid sequence. The mutated nucleotide in the 
mutagenesis primer is shown in bold. Then, the 0.62 kb EcoRI-SalI fragment 
representing the mutated 3' end of the TAA90K ORF was inserted between the EcoRI 
and XhoI sites of the plasmid vector pCITE-2a to create pCITE-EB90His, thereby 
placing the coding sequence for the 6-histidine residues in frame with the 3' end of the 
TAA90K ORF. However, the destruction of the SalI site in the cloning process also 
resulted in a D to E conversion in the C-terminal amino acid residue of TAA90K.  
 The TAA90K ORF containing a C-terminal histidine tag (TAA90K-His) was 
reconstituted by replacing the 0.62 kb EcoRI-XbaI fragment of pCD90 (Laferté et al., 
2000) with the 0.62 kb EcoRI-XbaI fragment from pCITE-EB90His to create pCD 
TAA90His. Similarly, the TAA90K-His ORF was introduced into the pSLAVE vector  
(developed at Vaccine and Infectious Disease Organization) by replacing the EcoRI-
BglII fragment of pSL- TAA90K with the 0.63 kb EcoRI-BglII fragment from pCITE-
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EB90His to create pSL-TAA90K-His. In this way, the TAA90K-His ORF was inserted 
behind a synthetic vaccinia late promoter and a site in the vector flanked by coding 
regions of the wild-type vaccinia virus thymidine kinase (TK) gene.    
 Recombinant vaccinia virus encoding TAA90K-His was constructed by 
disrupting the TK gene in wild-type vaccinia virus with the TAA90K-His coding 
sequence via homologous recombination. CV-1 cells were infected with wild-type 
vaccinia virus and transfected with linearized pSL-TAA90K-His DNA by 
electroporation (Gene Pulser, BioRad, Mississauga, ON). Recombinant vaccinia virus 
was selected in Rat-2 cells (TK-) in the presence of 5-bromodeoxyuridine (BUdR) and 
isolated by plaque purification, as described previously (Loh et al., 1994). Similarly, 
recombinant vaccinia virus encoding wild-type TAA90K, without a histidine tag, was 
generated by inserting the entire open reading frame for TAA90K into the pSLAVE 
vector to create pSL-TAA90K.  
 Transfection of plasmids encoding wild-type or His-tagged TAA90K (i.e. 
pCD90 or pCDTAA90K-His) into COS-1 cells (15 µg DNA/2 X 106 cells) was carried 
out by electroporation with the Gene Pulser apparatus (BioRad, Mississauga, ON) as 
previously described (Chu et al., 1987).  Electroporation was carried out using a 0.4 cm 
cuvette at  a voltage setting of 250 V and a capacitance setting of 500 µF. 
 
4.4 Infection of cells with recombinant vaccinia virus expressing TAA90K or 
TAA90K-His 
 HT-29 cells grown to 70% confluency were cultured in complete medium 
containing 2% FBS and infected with recombinant vaccinia encoding TAA90K-
His/TAA90K at a multiplicity of infection (m.o.i) of 0.01. At 24 hours post-infection, 
cells were washed twice in PBS and cultured in complete F12/DMEM medium. At 48 
and 72 hours post-infection, conditioned medium was collected, centrifuged at 3000 
rpm in a Sorvall bench top centrifuge to remove cells. The supernatant was centrifuged 
for 4 hours at 16,300 x g to pellet virus. The resulting supernatant was filtered through a 
0.2 µm filter (Millipore Corporation, Bedford, MA), dialyzed against three changes of 
TBS pH 7.4 (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, and 0.02% sodium azide (NaN3)) 
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adjusted to 0.5 M NaCl and subjected to affinity chromatography on wheat germ 
agglutinin (WGA)-agarose, as described below. 
 In some experiments, HT-29 cells were treated with the glycosylation inhibitors 
1-deoxymannojirimycin (DMJ) (Sigma, Oakville, ON) or swainsonine (Sw) (Sigma, 
Oakville, ON), at concentrations of 0.3 mM and 5.8 µM respectively, approximately 6 h 
after plating. In these experiments, the inhibitors DMJ and Sw resulted in the generation 
of TAA90K glycoforms referred to as TAA90K-DMJ or TAA90K-Sw, respectively.  
 
4.5 Metal chelation chromatography of histidine-tagged proteins 
 The bacterial pellet  (from section 4.2) consisting of inclusion bodies containing 
His-TAA90K was solubilized in 20 mM Tris-HCl (pH 8.0), 0.5 M NaCl and 5 mM 
imidazole (binding buffer) containing 1 mM PMSF and 6 M guanidine-HCl. Following 
centrifugation, the solubilized samples were applied to 0.5 mL of His-bind resin 
charged with Ni2+ ions (Novagen, Madison, WI) pre-equilibrated in binding buffer 
containing 6 M guanidine-HCl.  The His-bind resins were washed with 20 column 
volumes of binding buffer and wash buffer (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 60 
mM imidazole) each containing 6 M urea.  His-TAA90K was eluted with 10 column 
volumes of elution buffer (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 1 M imidazole) 
containing 6 M urea.   Fractions containing recombinant proteins were identified 
employing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blotting analysis. The urea concentration of the pooled fractions containing 
bacterially expressed His-TAA90K was reduced in a stepwise manner by dialysis 
against solutions of TBS (pH 7.4) buffer containing decreasing concentrations of urea, 
down to a final concentration of 2 M urea. 
 A similar protocol was utilized for the isolation of TAA90K-His from the 
conditioned medium of HT-29 cells infected with recombinant virus.  Modifications 
included the use of a 5 mL His-bind resin column and buffers lacking guanidine-HCl or 
urea.   
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4.6 Monoclonal and polyclonal antibodies 
  TAA90K-specific monoclonal antibodies were prepared as described previously 
(Laferté and Loh, 1992; Laferté et al., 2000). IgG fractions were purified from mouse 
ascites by affinity chromatography on protein G-agarose according to manufacturer’s 
instructions (Amersham Biosciences, Baie D’Urfé, QC). Polyclonal antiserum specific 
for bacterially-expressed His-TAA90K was prepared in rabbits following an injection of 
50 µg of bacterially expressed His-TAA90K followed by two boosts with the 
recombinant protein at 4 week intervals, following protocols approved by the Canadian 
Council on Animal Care. Monoclonal antibodies to pro- and active MMP-7 were 
purchased from Chemicon (Temecula, CA) and the Penta-His antibody specific for the 
histidine tag was purchased from Qiagen (Mississauga, ON). 
 
4.7 Lectin-affinity chromatography  
 Conditioned medium containing TAA90K, TAA90K-His, TAA90K-DMJ or 
TAA90K-Sw was dialyzed against three changes of TBS pH 7.4 (50 mM Tris-HCl, pH 
7.4, 0.15 M NaCl, and 0.02% NaN3), adjusted to 0.5 M NaCl and applied to a 5 mL 
column of wheat-germ agglutinin (WGA)-agarose (E-Y Labs, San Mateo, CA) pre-
equilibrated in 50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 0.02 % NaN3 (WGA buffer). 
After washing the column with 10 volumes of WGA buffer, TAA90K, TAA90K-His or 
TAA90K-Sw were eluted with TBS (pH 7.4) containing 5 % N-acetylglucosamine 
(Sigma, Oakville, ON). Fractions containing the different forms of TAA90K, as 
determined by dot blot analysis employing the TAA90K-specific monoclonal antibody 
1H9 (Laferté and Loh, 1992) and SDS-PAGE, were pooled and dialyzed against 50 mM 
Tris-HCl (pH 7.0). 
 
4.8 Ion-exchange chromatography 
 WGA-agarose eluted fractions containing TAA90K/TAA90K-His or TAA90K-
Sw or the WGA-agarose flow through fraction containing TAA90K-DMJ were dialyzed 
against 50 mM Tris-HCl (pH 7.0), and applied to a 1 mL column of cation-exchange 
resin (HiTrap SP HP, Amersham Biosciences, Baie D’Urfé, QC), equilibrated in the 
same buffer. The eluted fractions containing TAA90K-DMJ or the flow-through 
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fractions containing TAA90K/TAA90K-His or TAA90K-Sw were adjusted to 0.2 M 
NaCl and purified further on a 1 mL column of anion-exchange resin (HiTrap Q HP, 
Amersham Biosciences, Baie D’Urfé, QC) equilibrated in 50 mM Tris-HCl (pH 7.0), 
0.2 M NaCl. After washing, the anion-exchange column was connected to a fast 
performance liquid chromatography system (FPLC, Amersham Biosciences, Baie 
D’Urfé, QC), and TAA90K was eluted with a linear gradient of 0.2 to 1M NaCl. The 
absorbance profile at 280 nm for the purification of TAA90K/TAA90K-His revealed a 
single peak eluting at 0.6 M NaCl which consisted of TAA90K/TAA90K-His, as 
detected by SDS-PAGE and matrix-assisted laser desorption ionization/time-of-flight 
mass spectrometry (Proteomics Laboratory, Plant Biotechnology Institute, Saskatoon, 
SK). Similarly, TAA90K-Sw eluted in a single peak at 0.6 M NaCl, however, 
TAA90K-DMJ bound more tightly to the anion-exchange column, eluting between 0.65 
M and 0.7 M NaCl. 
 Fractions containing TAA90K-His/TAA90K, TAA90K-DMJ or TAA90K-Sw 
were dialyzed against three changes of 50 mM Tris-HCl (pH 7.4), 0.15 M NaCl and 
concentrated by re-application of the sample to the anion-exchange column and elution 
in a minimum volume of column buffer containing 1 M NaCl.  The fractions containing 
TAA90K were desalted on a NAP-5 column (Amersham Biosciences, Baie D-Urfé, 
Qc). Typical yields of TAA90K isolated in the absence of glycosylation inhibitors 
ranged from 300-500 µg/L of conditioned medium.  
 
4.9 Proteolytic cleavage of TAA90K by MMPs 
 ProMMP-2 and proMMP-9 (Calbiochem, La Jolla, CA) were converted to their 
active forms following incubation with 1 mM p-aminophenylmercuric acetate (APMA) 
in dimethylsulfoxide (DMSO) at 37 oC for 24 hours. Activated MMP-2, MMP-9 or 
active MMP-7 (Calbiochem, La Jolla, CA) were each incubated with TAA90K at a ratio 
of 1:3 (w/w) respectively, in cleavage buffer consisting of 50 mM Tris-HCl (pH 7.5), 
0.2 M NaCl, 10 mM calcium chloride (CaCl2), 5 µM zinc sulfate (ZnSO4), 0.05% Brij-
35 (polyoxyethylene lauryl ether) and 0.02% NaN3 for 1 h at 37 oC. In order to inhibit 
metalloproteinase enzyme activity, samples were incubated in buffer consisting of 50 
mM Tris-HCl (pH 7.5), containing 0.2 M NaCl, 50 mM ethylenediaminetetraacetic acid 
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(EDTA), 0.05% Brij-35 and 0.02% NaN3. Inhibition of enzyme activity was also 
achieved by boiling the enzyme for 4 minutes in cleavage buffer prior to incubation 
with TAA90K. 
 
4.9. Purification of TAA90K proteolytic fragments for use in biological assays 
 MMP-7 and TAA90K combined at a ratio of 1:50 (w/w), respectively, were 
incubated in cleavage buffer for 24 h at 37 oC.  The digestion mixture was diluted 20-
fold with TBS pH 7.4 to lower the concentration of detergent, salt and divalent cations 
prior to anion-exchange chromatography on a 1mL HiTrap Q HP column equilibrated in 
TBS pH 7.4.  While the flow-through fraction contained the MMP-7, proteolytic 
fragments of TAA90K were eluted from the column with 50 mM Tris-HCl pH 7.0 
containing 1 M NaCl.  Fractions containing the TAA90K fragments were desalted on a 
NAP-5 column. 
 
4.10 Amino acid sequencing of proteolytic fragments of TAA90K cleaved by 
MMP-7 
 An aliquot containing 4 µg of cleaved TAA90K was resolved on a 10% SDS-
PAGE gel and stained with Coomassie Brilliant Blue.  After destaining the gel, the 79 
kDa and 22 kDa bands were excised, washed several times with HPLC-grade water and 
submitted to the Harvard Microchemistry and Proteomics Analysis Facility (Harvard 
University, Boston, MA) for N-terminal sequencing.  The primary internal cleavage site 
at Asp-452 of the TAA90K protein was confirmed by C-terminal sequencing and mass 
spectrometry analysis of trypsin- and endopeptidase LysC-digests of the N-terminal 79 
kDa fragment.  To this end, cleaved TAA90K was separated by SDS-PAGE and 
transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore Corporation, 
Bedford, MA).  After staining of the membrane for 1 min in a solution of 0.1% Ponceau 
Red in 1% acetic acid, the 79 kDa band was excised, washed twice in 50% acetonitrile 
and subjected to proteolytic digestion.  The resulting peptides were analyzed by 
microcapillary reverse-phase HPLC nano-electrospray mass spectrometry 
(µLC/MS/MS) on a Thermo LTQ-Orbitrap mass spectrometer. 
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4.11 Detection of TAA90K and MMPs in conditioned medium 
 Cells grown to 70% confluency were cultured in complete F12/DMEM medium.  
In some experiments, TAA90K (1 µg or 5 µg) was added to HT29 cells for 24 h, 48 h or 
72 h. Conditioned medium from colon cancer cell lines, including HT29 cells, grown in 
the presence of absence or TAA90K was collected and centrifuged at 3000 rpm in a 
Sorvall bench top centrifuge to pellet cells.  The medium was concentrated five-fold 
using a Centricon centrifugal filter device (Millipore Corporation, Bedford, MA) and 
subjected to ELISA analysis using the TAA90K-specific monoclonal antibody 1H9, 
mouse anti-proMMP-7 or mouse anti-MMP-7 antibodies (Chemicon, Temecula, CA). 
 
4.12 Metabolic labeling of cells 
 Cells were radiolabeled for 24 h in methionine-free DMEM supplemented with 
one-tenth the normal content of methionine, 10% FCS and 50 µCi/mL of [S35]-
methionine/mL (800 Ci/mmol; NEN, Calgary, Alberta, Canada) as described previously 
(Laferté and Loh, 1992). The medium was collected and centrifuged at 3000 rpm in a 
Sorvall desk top centrifuge to pellet any cells.   
 
4.13 Preparation of tissue lysates 
 Samples from human colon tumors and adjacent normal colon (400-500 mg; 
Asterand, Inc., Detroit, MI) were homogenized using a Polytron homogenizer 
(Brinkmann Instruments, Edmonton, AB) in 8 volumes of 50 mM Tris-HCl, pH 7.4, 
0.15 M NaCl, 1 mM PMSF, 1 mM benzamidine, 10 µg/mL aprotinin, 0.5 µM leupeptin 
and 0.7 µM pepstatin.  The sample was adjusted to 1% Triton X-100, incubated on ice 
for 1 h and centrifuged at 20, 000 g for 30 min.  The resulting supernatant was assayed 
for protein content and analyzed by SDS-PAGE and Western blotting. 
 
4.14 SDS-Polyacrylamide gel electrophoresis 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed as described by Laemmli (1970). Briefly, proteins were separated on a 7.5% 
or 10% polyacrylamide gel for 1-1.5 hrs at 100 volts using a Mini-Protean II 
electrophoresis system (BioRad Laboratories, Mississauga, ON).  Proteins were 
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visualized by staining with 0.088% Coomassie Blue R-250 (BioRad Laboratories, 
Mississauga, ON) in 40% ethanol, 8% acetic acid for 30 minutes followed by destaining 
in a solution containing 10% acetic acid and 20% methanol.  [35 S]-methionine labeled 
proteins were separated by SDS-PAGE and visualized by fluorography after 
enhancement with Entensify (NEN, Perkin Elmer, Boston, MA).    
 
4.15 Dot blot analysis 
 Dot blot analysis was performed as originally described in Sharon et al. (1979).  
Aliquots of 10 µL were spotted directly onto nitrocellulose (Schleicher and Schull, 
Mandel Scientific, Guelph, ON) and allowed to dry at room temperature followed by 
blocking overnight at 4 oC in TBS containing 4% BSA. The nitrocellulose was washed 
three times for 5 minutes with TBST (50 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1% 
BSA, 0.025% Tween, 0.02% NaN3), incubated at room temperature for 2 hours with the 
primary antibody diluted in TBST, washed three times with TBST and incubated for 1 
hour with alkaline-phosphatase-conjugated affinity-purified goat anti-mouse or goat 
anti-rabbit Ig (BioRad Laboratories, Mississauga, ON) diluted 1:3000 in TBST.  The 
nitrocellulose was washed three times with TBST, once with TBS (50 mM Tris-HCl, 
pH 8.0, 0.15 M NaCl, 0.02 % NaN3) containing 0.05 % Tween (BioRad Laboratories, 
Mississauga, ON), once with TBS and once with developing buffer (0.1M Tris-HCl, pH 
9.5, 0.1M NaCl, 50 mM MgCl2). Immunoreactivity was detected colourimetrically by 
incubating the nitrocellulose in developing buffer containing 3.67 µM p-nitroblue 
tetrazidium chloride (NBT) (BioRad Laboratories, Mississauga, ON) and 3.46 µM 5-
bromo-4-chloro-3-indolyl-phosphate-toluidine salt (BCIP) (BioRad Laboratories, 
Mississauga, ON) at room temperature. 
 
4.16 Enzyme-linked immunosorbent assay 
 Enzyme-linked immunosorbent assays (ELISA) were performed as described in 
Laferté et al. (1995).   Samples were applied in a final volume of 100 µL to the wells of 
a Nunc-Immuno 96-well plate with a PolySorb surface (VWR International, Edmonton, 
AB) overnight at 4 oC.  After washing with TBS pH 8.0, wells were blocked with 200 
µL TBS containing 4% BSA for 1h at room temperature.  Wells were washed three 
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times with TBST followed by incubation for 2 hours at room temperature with 100 µL 
primary antibody diluted in TBST. After washing the wells with TBST, plates were 
incubated for 1 hour at room temperature with 100 µL alkaline phosphatase-conjugated 
goat anti-mouse or anti-rabbit Ig (BioRad Laboratories, Mississauga, ON) diluted 
1:3000 in TBST.  Wells were washed three times with TBST, once with TBS containing 
0.05% Tween-20 and once with TBS pH 8.0.  Immunoreactivity was detected 
colorimetrically at 405 nm following addition of 100 µL p-nitrophenyl phosphate 
substrate per well (0.5 mg/mL in 10 mM diethanolamine buffer) (BioRad EIA kit, 
BioRad Laboratories, Mississauga, ON).  
 
4.17 Indirect immunofluorescence analysis 
 Indirect immunofluorescence analysis of live cells was performed as described 
in Laferté and Loh (1992) with the following modifications.  Briefly, 2 x 105 HT29 cells 
in 3% FCS/PBS were pre-incubated with either 10 µg BSA or 10 µg galectin-3 for 1 h 
on ice, prior to incubation with either 10 µg TAA90K or 10 µg BSA for 1 h on ice.  
Following washes, cells were incubated with either normal mouse IgG or MAb 1H9 
(1:200) for 1 h.  After washing, cells were incubated for 30 min with fluorescein 
isothiocyanate (FITC)-labeled goat anti-mouse Ig (1:50) (Dimension Laboratories, 
Mississauga, Ontario, Canada).  Cells were dropped onto glass slides and mounted in 
PBS/glycerol  (1:1 v/v).  
 For analysis of fixed and permeabilized cells, cells were harvested, washed in 
PBS and applied to toxoplasmosis slides (Bellco Glass, Inc., Vineland, NJ, USA).  After 
drying, slides were submerged in -20oC methanol for 4 minutes followed by submersion 
in -20oC acetone for two minutes.  After drying, slides were washed in PBS and 
incubated with primary antibody diluted 1:250 in 3% BSA/PBS for 1 h.  After washing, 
slides were incubated for 30 min with FITC goat-anti mouse Ig (1:50) and washed. 
Coverslips were applied using PBS/glycerol (1:1 v/v).  Fluorescence of both fixed and 
live cells was visualized employing a Nikon epifluorescence microscope.  
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4.18 Western blotting analysis  
 Proteins separated by SDS-PAGE were transferred electrophoretically onto 
nitrocellulose membranes  (Schleicher and Schüll, Mandel Scientific, Guelph, ON) for 2 
hours at 100 volts (Tobwin et al., 1979).  Nitrocellulose blots were blocked overnight at 
4 oC in TBS (pH 8.0)/4% BSA.  Following three 5-min washes in TBST buffer (TBS 
pH 8.0, 0.1% BSA, 0.025% Tween-20), blots were incubated for 2 hours with primary 
antibody.  Following three 5-minute washes in TBST, blots were incubated for 1 hour 
with alkaline phosphatase-labeled, affinity purified goat anti-rabbit Ig or anti-mouse Ig 
(Bio-Rad Laboratories, Mississauga, ON). The substrates 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) and nitro blue tetrazolium (NBT) were used for color development. 
 
4.19 Immunoprecipitation analysis 
 Crude cell lysates (prepared as described in section 4.13) or media collected 
from cells grown in culture were incubated with primary antibodies overnight at 4 oC.  
Protein A-Sepharose CL-4B (Amersham Biosciences, Baie D’Urfé, QC) was 
resuspended in TBS pH 8.0, 1% Nonidet P-40 (BDH), 1% deoxycholate, 1 mM 
benzamidine, 0.02 % NaN3(IP buffer) to a final concentration of 80 mg/mL.  Samples 
were incubated with 100 µL of Protein A suspension on a nutator (Becton, Dickinson 
and Company, Sparks, MD) for 1 hour at 40C. After centrifugation, Protein A-
Sepharose beads were washed once with IP buffer, once with IP buffer containing 0.5 
M sodium chloride (VWR International, Edmonton, AB), once with IP buffer 
containing 0.1% SDS (BioRad Laboratories) followed by a final wash in IP buffer.  
Protein A Sepharose beads were boiled in SDS-PAGE sample buffer (12.5 mM Tris-
HCl pH 6.8, 2 % 2-mercaptoethanol, 2% SDS, 10 % glycerol and bromophenol blue 
(BioRad Laboratories, Mississauga, ON) and the supernatants resolved on SDS-PAGE 
gels.   
 
4.20 Immunohistochemical staining of normal and neoplastic tissues 
 Sections of human colon tumors from 47 archived paraffin specimens collected 
at Royal University Hospital (Saskatoon, SK) as well as normal colon from five 
individuals who died of causes unrelated to cancer (Asterand, Inc., Detroit, MI) were 
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stained with TAA90K-specific monoclonal antibody 4D1 (Laferté et al., 2000).  Five 
micron-thick tumor sections were deparaffinized in xylene and prepared for 
immunohistochemical staining with the EnvisionTM plus system mouse staining kit 
(Dako, Mississauga, ON), according to manufacturer’s instructions with the following 
modifications.  Tumor sections immersed in PBS were heated in a microwave oven for 
20 minutes (4 x 5 min), cooled and washed in EDTA buffer at pH 9.0 prior to blocking 
of endogenous peroxidase. After washing in PBS, sections were incubated for 2 h with 
either normal mouse IgG (Sigma, Oakville, ON) or 4D1 IgG (5 µg/mL in 1% bovine 
serum albumin). After chromogen treatment and washing, sections were dehydrated and 
mounted in Entellan (VWR, Edmonton, AB). A section of human colon tumor 
previously shown to stain strongly with MAb 4D1 was included in each experiment as 
an internal control. To confirm the specificity of MAb 4D1, blocking studies were 
carried out by pre-incubating tissue sections overnight with 70 µg/mL purified 
TAA90K-His. Stained sections were assessed independently by two pathologists using 
a Nikon Eclipse 80i microscope equipped with a digital imaging system and scored as 
positive if at least 10% of the cells within the tumor stained with MAb 4D1 but not with 
normal mouse IgG.  
 
4.21 Determination of protein concentration 
 The concentration of protein in samples was determined using the BioRad DC 
protein assay kit (BioRad Laboratories, Mississauga, ON) following the manufacturer’s 
instructions.  Briefly, dilutions of the sample in a final volume of 50 µL were incubated 
at room temperature for 15 min with 250 µL alkaline copper tartrate solution (reagent 
A) and 2 mL of Folin reagent (reagent B). Reagent A was supplemented with 20 µL 
reagent S per mL of reagent A when detergent was present in the samples. The 
absorbance of the samples was measured at 750 nm and compared to a standard curve 
of gamma-globulin ranging from 0.2 to 1 mg/mL.  
 
4.22 Solid-phase binding assay 
  The ability of TAA90K to bind to galectins, extracellular matrix proteins and 
MMPs was tested using a solid-phase assay. Briefly, 0.5 µg of either galectin-1, galectin 
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-3, collagen I, collagen IV, fibronectin, laminin-1 (Sigma, Oakville, ON), laminin-5, 
laminin -10 (Chemicon, Temecula, CA) or the pro- or active forms of MMPs -1, -2, -7 -
9 (Calbiochem, La Jolla, CA) or BSA (Sigma, Oakville, ON) were added, in triplicate, 
to PolySorb 96-well plates and allowed to adsorb to the plastic surface overnight at       
4 oC. After washing 3 times in PBS (pH 7.0), residual protein-binding sites in the wells 
were blocked with PBS/5% BSA (blocking buffer) for 2 hours at room temperature. 
Following 5 washes with PBS/0.04% Tween (PBST), TAA90K or BSA (2 µg/well) 
diluted in blocking buffer was added to each well and incubated overnight at 4 oC. The 
wells were washed 5 times with PBST and incubated for 2 hours at room temperature 
with TAA90K-specific monoclonal antibody 1H9 (1:1000 dilution in blocking buffer). 
Following 5 washes in PBST, wells were incubated with alkaline phosphatase-labeled, 
affinity-purified goat anti-mouse Ig (1:3000 dilution in blocking buffer) (Bio-Rad 
Laboratories, Mississauga, ON). Bound TAA90K was detected colorimetrically at 405 
nm following addition of the substrate p-nitrophenyl phosphate (BioRad EIA kit, 
BioRad Laboratories, Mississauga, ON). To examine the effect of inhibitors of 
carbohydrate-dependent binding on the TAA90K/galectin-3 interaction, similar 
experiments were carried out except that wells were pre-incubated for 1 hour with 500 
mM lactose or 150 mM lactose containing 2 mg/mL asialofetuin (2X concentration) 
before addition of an equal volume of buffer containing TAA90K (Kopitz et al., 2001). 
 
4.23 Cellular adhesion assay  
 Cell adhesion to TAA90K, galectin-3, extracellular matrix proteins or BSA was 
measured using a colorimetric assay (Takada et al., 1988). Wells of PolySorb 96 well 
plates were coated overnight at 4 oC with serially diluted samples of extracellular matrix 
proteins, TAA90K, galectin-3 or BSA. Prior to use, commercially available galectin-3 
(Calbiochem, La Jolla, CA) was subjected to chromatography on a NAP-5 column 
(Amersham Biosciences, Baie D’Urfé, QC) to remove lactose. Following 3 washes with 
PBS, wells were blocked with PBS/4% BSA for 1 hour at room temperature. After 5 
washes with PBS, wells were incubated with 0.2 mL DMEM supplemented with 32 
µg/mL gentamycin containing 105 cells for 4 hours at 37 oC in a 5% CO2 incubator. 
Non-adherent cells were removed by washing with PBS until cells were no longer 
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detected in the BSA-coated wells. Attached cells were fixed for 30 minutes with 
PBS/4% formaldehyde, washed 3 times with PBS and stained for 15 minutes with 0.05 
mL of a 1% toluidine blue solution. Following 3 washes in PBS, the dye was extracted 
with 200 µL methanol and the optical density was measured at 620 nm. In some 
experiments, HT29 cells were pre-treated for 48 hours with the glycosylation inhibitors 
deoxymannojirimicin (0.3 mM) or swainsonine (5.8 µM).  In other experiments, the 
ability of TAA90K to inhibit galectin-3-mediated cell binding was examined. In this 
case, TAA90K diluted in DMEM supplemented with gentamycin was added to wells 
previously coated with galectin-3 and incubated for 1 hour at 37 oC prior to addition of 
cells. 
 
4.24 Cellular migration assay 
 Migration assays were performed employing transwell chambers containing 
polycarbonate inserts with 8 µm pores (Costar, Corning, Fisher Scientific, Nepean, ON) 
as described (Jasiulious et al., 1996) with the following modifications.  The underside 
of the filter was incubated for 2 h at 37 oC with solutions of extracellular proteins 
including fibronectin, collagen I, laminin-1 (Sigma, Oakville, ON), galectin-3 
(Calbiochem) or TAA90K diluted to 50 µg/mL with DMEM. After washing with PBS, 
filters were blocked with PBS containing 0.5% BSA for 1 hour at 37 oC. Following 
three washes with PBS, filters were placed in a 24-well cluster dish (Costar, Corning, 
Fisher Scientific, Nepean, ON) containing 600 µL complete F12/DMEM media with or 
without 5 µg TAA90K.  One hundred microliters of F12/DMEM media containing 2 x 
105 cells was added to the top of the filter and cells were allowed to migrate to the 
underside of the filter at 37 oC for 48 hours.  In some experiments, 5 µg TAA90K was 
added with the cells to the top of the filter.  In order to assess the extent of cellular 
migration, 20 µL of a 5 mg/mL MTT  (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide: thiazolyl blue, Sigma, Oakville, ON) solution was added 
to the bottom chamber of the transwell plates and incubated for 4 hours at 37oC. Non-
migrating cells that remained in the upper chamber had not migrated and were removed 
with a cotton swab.  Cells that had migrated through the pores and adhered to the 
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underside of the membrane were extracted with DMSO and the optical density was read 
at 540 nm.   
 
4.25 Cellular invasion assay 
 Experiments assessing cellular invasion were performed employing BD BioCoat 
Matrigel Invasion Chambers (Fisher Scientific, Nepean, ON) according to 
manufacturer’s instructions with some modifications.  The invasion chambers consisted 
of 24-well plates containing 12 polycarbonate inserts with 8 µm pores coated with 
reconstituted extracellular matrix (Matrigel).  After the Matrigel was rehydrated in 
warm DMEM for 2 h at 37οC, some wells were pre-incubated with increasing amounts 
of TAA90K and/or galectin-3 for 1h at 37oC before 2.5 x 104 cells were added to the 
inserts.  In some experiments, increasing amounts of TAA90K and/or galectin-3 were 
added with the cells to the inserts. DMEM or DMEM complete medium containing 10% 
FCS was added to the lower chambers of the plate.  Invasion chambers were incubated 
for 24-48 h at 37oC.  After non-invading cells were removed from the upper surface of 
the inserts with a cotton swab, invading cells found on the underside of the filter and in 
the lower chamber were stained with MTT as described in the previous section. 
 
4.26 Statistical analysis  
 In the case of protein binding, ELISA analysis and cellular assays, sample 
means were compared using the two-tailed student's t test. Statistical analysis was 
performed using Microsoft Excel. P values < 0.05 were considered statistically 
significant. 
 
 
 76 
 
 
 
 
5.0 RESULTS: 
5.1 EXPRESSION OF TAA90K IN COLON CANCER 
5.1.1 Immunohistochemical staining of colon tumors and normal colonic mucosa 
 In order to examine the expression pattern of TAA90K in human colon cancer, 
we carried out immunohistochemical analysis of paraffin-embedded colon tumors using 
4D1, a TAA90K-specific monoclonal antibody previously developed in our laboratory  
(Laferté et al., 2000).  We examined 47 colon tumors of varying histopathological grade 
including 10 Duke’s A, 5 Duke’s B, 31 Duke’s C and 1 Duke’s D tumor.  In contrast to 
normal colon which lacked detectable TAA90K expression (Figure 5.1, panel A), 
elevated expression of TAA90K was detected in all colon tumors examined. There were 
a number of staining patterns observed for TAA90K expression in colon tumor sections, 
including diffuse intracellular staining (panel C), granular staining at the apical border 
of colon cancer cells (panel D) and punctate staining consistent with proteins associated 
with secretory vesicles (panel E), staining of luminal secretions (panel F) and in some 
cases, basolateral staining (panel G). Staining of the transitional mucosa at the tumor 
border is shown in panel H. The intensity of stained sections varied from weak to 
intense and the percentage of positively stained cells within the tumor ranged from 10% 
to more than 50%.  Immunohistochemistry carried out in the presence of purified 
TAA90K effectively blocked the complex staining pattern that was previously observed 
(panel B), confirming that the staining pattern was due to TAA90K expression. 
  
5.1.2 Western blotting analysis of colon tumors and normal colonic mucosa 
 In order to confirm the elevated expression of TAA90K in colon tumors 
compared to normal colon, we immunoprecipitated TAA90K from tissue lysates of 
three colon tumors (Duke’s B, C and D) and adjacent normal colon using monoclonal 
antibody 1H9.  Immunoprecipitates were analyzed by Western blotting using a 
polyclonal antibody raised against a bacterially expressed recombinant TAA90K  
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Figure 5.1: Immunohistochemical staining of human colon tumors. Sections of 
human colon tumors were examined by immunohistochemical staining with MAb 4D1 
(5 µg/ml) or normal mouse IgG. Staining patterns obtained with normal IgG are not 
shown since they yielded negative results. (A) Normal colon, 400×, (B) Duke's B2 
tumor (also shown in panel D) incubated with MAb 4D1 pre-absorbed with TAA90K-
His (70 µg/ml), (C) Duke's C2 tumor showing diffuse intracellular staining, 200×, (D) 
Duke's B2 tumor showing granular staining at the apical border of colon cancer cells, 
400×, (E) Duke's C1 tumor showing punctate staining consistent with secretory 
vesicles, 400×, (F) Duke's C2 tumor showing luminal staining, 400×, (G) Duke's A 
tumor showing apical and basolateral staining, 400×, and (H) Duke's C2 tumor showing 
staining of transitional mucosa at the tumor border, 200×. 
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containing an N-terminal poly-His tag (His-TAA90K). As shown in Figure 5.2, colon 
tumors expressed higher amounts of TAA90K than normal colonic mucosa. The 
apparent mobility of TAA90K in the Duke’s B, C and D samples was 106, 101 and 108 
kDa respectively, consistent with variable glycosylation of TAA90K previously 
detected in human colon carcinoma cell lines (Laferté and Loh, 1992). The lower 
molecular mass species of 76-86 kDa detected in each tumor sample likely results from 
proteolytic cleavage of TAA90K previously detected in various cell lines (Laferté and 
Loh, 1992; Koths et al., 1993; Sasaki et al., 1998) These results suggested that 
TAA90K may represent a novel tumor-associated marker for colon cancer. 
 
5.1.3 Secretion of TAA90K by human colon carcinoma cell lines 
 In addition to examining the expression of TAA90K by human colon carcinoma 
tissues, we also examined the secretion of TAA90K by a number of human colon 
cancer cell lines including Caco-2, LoVo, LS123, HT-29, KM20C, SW403 and SW620.  
These cell lines were chosen because they were derived from either primary colon 
tumors of varying grade or from metastases.  
Cell line Source 
Caco-2 Primary colon tumor 
LoVo Metastatic nodule in the 
supraclavicular region 
LS123 Primary colon tumor, 
Duke’s B 
HT-29 Moderately differentiated 
grade II 
KM20C Liver metastasis 
SW403 Grade III adenocarcinoma 
SW620 Lymph node metastasis 
 
Conditioned medium from the cell lines was analyzed for the secretion of TAA90K by 
ELISA employing MAb 1H9 which is specific for TAA90K (Figure 5.3).  Interestingly, 
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Figure 5.2: Analysis of TAA90K expression in human colon tumors and adjacent 
normal colonic mucosa. TAA90K was immunoprecipitated from 0.5 mg of detergent-
solubilized human colon tumors (T1 to T3) or adjacent normal colonic mucosa (N1 to 
N3) using 5 µl of either MAb 1H9 (panel A) or NMS (panel B). Immunoprecipitates 
were analyzed by Western blotting using rabbit anti-TAA90K antiserum (1:2,000 
dilution). The samples designated T1 to T3 and N1 to N3 correspond to Duke's B, 
Duke's C and Duke's D tumors and their adjacent normal colonic mucosa, respectively. 
The size of the molecular weight markers in kilodaltons is shown at the left of the 
figure. The mobility of the immunoglobulin band (IgG) is shown at the right of the 
figure. 
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Figure 5.3 TAA90K secretion by human colon cancer cell lines.  The 
conditioned serum-free medium from colon cancer cell lines was concentrated  
5-fold and coated (100µL) in triplicate in a 96 well plate.  Wells were washed, 
blocked with TBS containing 4% BSA, washed and incubated with MAb 1H9 or 
NMS control (1:1000) for 2 h at room temperature.  After washing, wells were 
incubated with alkaline phosphatase-conjugated goat anti-mouse Ig (1:3000) for 1h 
followed by washing and addition of colorimetric substrates.  The absorbance was 
read at 405 nm.  The mean and standard deviation of triplicate samples are shown. 
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the cell lines that express the highest levels of TAA90K are LoVo, SW620 and KM20C, 
which were all isolated from metastases.  
 
5.2 OPTIMIZATION OF TAA90K ISOLATION FROM HUMAN COLON 
CANCER CELL LINES 
 Immunohistochemical analysis revealed increased extracellular accumulation of 
TAA90K in colon tumors compared to normal colon suggesting that TAA90K may  
play a role in colon cancer progression by affecting cell-cell or cell-extracellular matrix 
(ECM) interactions. Analysis of the conditioned medium of a panel of human colon 
cancer cell lines indicated that secretion of TAA90K is maintained in these established 
cell lines, providing a model system to study TAA90K function and a source of mature, 
fully glycosylated TAA90K. Thus, in order to identify the possible mechanism(s) of 
TAA90K function in colon cancer, we purified TAA90K from the conditioned medium 
of human colon carcinoma cell line HT-29 in sufficient quantity to carry out functional 
studies. The HT-29 cell line was selected as a source of TAA90K because it was 
established from a primary colon tumor, it maintains a typical epithelial morphology, it 
grows to high density and secretes moderate levels of TAA90K.  
 
5.2.1 Purification of TAA90K from human cell lines 
 Initially, attempts were made to purify TAA90K directly from HT-29 
conditioned medium.  Ammonium sulfate precipitation of the conditioned medium 
followed by dialysis was used as a means to concentrate the TAA90K sample and 
remove unwanted proteins.  This approach was not pursued further because of reduced 
solubility of the TAA90K preparation following dialysis (data not shown).  As an 
alternative, the conditioned medium was subjected to lectin affinity chromatography on 
WGA-agarose, a useful method for purifying glycoproteins modified by N-
acetylglucosamine and/or sialic acid (Peters et al., 1979).  Although this approach was 
successful in enriching for TAA90K, an additional gel exclusion chromatography step 
on Superose 6, followed by sample concentration using an Amicon centrifugation 
device, were required to remove contaminating proteins (data not shown).  Because of 
the relatively low yields of TAA90K obtained using this approach (30-50 µg/L media) 
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and significant TAA90K loss in the centrifugation devices, an alternate approach was 
explored to increase TAA90K yields.  
 
5.2.2 Purification of TAA90K-His from HT-29 cells infected with recombinant 
vaccinia virus 
 In order to increase the expression of TAA90K in HT-29 cells and facilitate 
protein purification, we constructed a recombinant vaccinia virus expressing TAA90K-
His containing a C-terminal poly-histidine tag suitable for purification by metal 
chelation affinity chromatography. The use of a recombinant vaccinia virus was 
desirable because it has the capability of infecting a wide range of mammalian cell lines 
and it results in the expression of recombinant protein in every infected cell with the 
proper post-translational modifications (Moss, 1996).  
 
5.2.2.1 Generation of recombinant vaccinia virus 
The first step in the preparation of recombinant vaccinia virus consisted of 
constructing a cDNA encoding TAA90K with an in-frame insertion of a C-terminal 
poly-histidine tag to create pCDTAA90-His. To examine the effect of the C-terminal 
histidine tag on TAA90K conformation, COS-1 cells were transfected with either 
pCD90, which contains the cDNA encoding wild-type TAA90K or pCDTAA90-His. 
Twenty-four hours later, transfected cells were radiolabeled overnight with [35S]-
methionine and the conditioned medium was immunoprecipitated using a panel of 12 
TAA90K-specific monoclonal antibodies (Laferté et al., 2000). Both TAA90K-His and 
wild-type TAA90K were immunoprecipitated equally well with all of the antibodies 
(data not shown), suggesting that the conformation of TAA90K-His, relative to wild-
type TAA90K, was not grossly altered by the presence of the histidine tag. Thus, we 
proceeded with the construction of a recombinant vaccinia virus encoding TAA90K-
His.  This was achieved by disrupting the thymidine kinase (TK) gene in wild-type 
vaccinia virus with the TAA90K-His coding sequence via homologous recombination. 
Rat-2 cells infected with individual recombinant vaccinia clones were tested for the 
expression of TAA90K-His by indirect immunofluorescence using TAA90K or His-tag 
specific monoclonal antibodies.  Figure 5.4 shows an example of Rat-2 cells expressing 
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                 vvTAA90K-His 
               Wild-type vv 
1G3 α-His 
Figure 5.4:  Indirect immunofluorescence of Rat-2 cells infected with wild-
type vaccinia virus or recombinant vaccinia virus expressing TAA90K-His.  
Fixed and permeabilized Rat-2 cells infected with either wild-type (vv) or 
recombinant vaccinia virus (vvTAA90K-His) were incubated with a 1:250 
dilution of TAA90K-specific monoclonal antibody 1G3 or mouse anti-His tag 
antibody.  This was followed by incubation with secondary antibody FITC-goat 
anti-mouse IgG (1:50).   
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recombinant TAA90K-His following infection with one of the recombinant vaccinia 
clones isolated.  
 
5.2.2.2 Optimization of purification strategies 
 TAA90K-His was purified initially from the conditioned medium of HT29 cells 
infected with recombinant vaccinia virus encoding TAA90K-His by metal chelation 
affinity chromatography employing His-bind resin. This method of purification proved 
to be inadequate for capturing TAA90K-His since the majority of the glycoprotein was 
found in the flow through fraction of the column.  The lack of binding of TAA90K-His 
to the column could be due to the extensive glycosylation and oligomerization of 
TAA90K monomers that limit accessibility of the histidine tag to the His-bind resin.   
As a result, only a small amount of TAA90K-His (30-50 µg/L medium) was eluted 
from the column. In addition, the eluted fraction contained a number of additional 
proteins, thereby necessitating additional purification steps (Figure 5.5).  
 As a result, alternate chromatographic methods were evaluated for their ability 
to purify TAA90K-His to homogeneity. Chromatographic methods used successfully 
for the isolation of TAA90K-His consisted of lectin-affinity chromatography on wheat 
germ agglutinin (WGA)-agarose followed by cation- and anion-exchange 
chromatography. As expected, affinity chromatography on WGA-agarose was very 
effective at enriching for TAA90K-His. Although the HiTrap SP cation-exchange resin 
used as a second step did not bind TAA90K-His eluted from the previous WGA-
agarose chromatography step, it did remove a number of contaminating proteins from 
the TAA90K-His enriched sample, including fibronectin. Finally, purified TAA90K-
His was eluted from the HiTrap Q anion-exchange column in a single peak at 
approximately 0.6 M sodium chloride (NaCl) following elution with a gradient of 0.2 M 
to 1 M NaCl (Figure 5.6). Using this strategy, TAA90K-His was purified to near 
homogeneity (400-500 µg/L medium), as indicated by the single band migrating in 
SDS-PAGE with an apparent mobility of 105 kDa (Figure 5.7).  Its identity as Mac-2-
binding protein was confirmed by mass spectrometry.  The minor species migrating at 
82 kDa was shown by mass spectrometry to correspond to a proteolytic cleavage 
product of TAA90K-His.  No other bands were detected in the gel.   
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TAA90K-His 
Figure 5.5: Purification of TAA90K-His from HT-29 conditioned medium 
employing metal chelation chromatography. SDS-PAGE analysis of  
TAA90K-His isolated from the conditioned medium from HT-29 cells infected 
with recombinant vaccinia virus encoding TAA90K-His employing metal 
chelation chromatography on His-bind resin. Molecular weight markers are 
indicated in kilodaltons at the left of the figure.  
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 Figure 5.6:  Elution profile of TAA90K from an anion-exchange column.  
 Following lectin-affinity and cation-exchange chromatography, TAA90K or 
 TAA90K-His were eluted from the anion-exchange column HiTrap Q HP with a 
 gradient of 0.2 M to 1.0 M sodium chloride (open squares). The absorbance at 
 280 nm (closed circles) of the eluted fractions is shown.  
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Figure 5.7:  Analysis of purified TAA90K by SDS-PAGE.  Coomassie-
stained gel showing 1 µg of TAA90K-His purified from conditioned media of 
HT-29  cells infected with recombinant vaccinia virus expressing TAA90K-His. 
The size of the molecular weight markers in kilodaltons is shown at the left side 
of the  figure. 
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Initial functional studies described below were carried out with TAA90K-His.  
However, since the presence of the poly-histidine tag did not aid in the purification of 
TAA90K, the majority of the functional studies described in this thesis were carried out 
with TAA90K purified from HT-29 cells infected with recombinant vaccinia virus 
expressing wild-type TAA90K.  In side by side comparisons, TAA90K-His and 
TAA90K behaved identically in functional assays. 
 
5.3 EXAMINATION OF TAA90K FUNCTION 
5.3.1 TAA90K-PROTEIN INTERACTIONS  
The immunohistochemical analysis of colon tumors revealed an elevated 
extracellular accumulation of TAA90K relative to normal mucosa.  These findings, as 
well as the reported role of TAA90K as an adhesive protein mediating both cell-cell and 
cell-extracellular matrix interactions, suggested that TAA90K functions by interacting 
with extracellular proteins (Sasaki et al., 1998).   We employed solid-phase binding 
assays to examine the interaction of TAA90K with extracellular matrix proteins and 
galectins.   
 
5.3.1.1 Binding of TAA90K to ECM proteins  
TAA90K purified from HT-29 cells bound poorly to collagens I and IV (Figure 
5.8, panel A), however significant binding was observed to the extracellular matrix 
proteins laminin-1 (Figure 5.8, panel B) and fibronectin (Figure 5.8, panel B) as was 
shown previously for TAA90K isolated from EBNA-293 cells (Sasaki et al., 1998).  
Previously unidentified interactions between TAA90K and laminins 5 and 10 (Figure 
5.8, panel B) were also detected.  
 
5.3.1.2 Binding of TAA90K to galectins 
TAA90K is a highly glycosylated protein capable of engaging in both protein-
protein or protein-carbohydrate interactions (Sasaki et al., 1998; Koths et al., 1993; 
Müller et al., 1999). In addition to being modified by β1-6 linked oligosaccharides, 
TAA90K is also modified by poly-N-acetyllactosamine structures (repeating Galβ1-
4GlcNAc units) (Laferté and Loh, 1992; Laferté et al., 2000).  These oligosaccharides  
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Figure 5.8: Binding of TAA90K-His to immobilized galectin-3 and 
extracellular matrix proteins and galectins. For experiments shown in panels 
A and B, wells were coated with the following proteins at 0.5 µg/ml except for 
fibronectin, which was used at 1 µg/ml. Panel A: collagen I (closed circle), 
collagen IV (closed square), galectin-1 (open square), galectin-3 (closed triangle); 
Panel B: laminin-1 (closed square), laminin-5 (closed triangle), laminin-10 (closed 
diamond), fibronectin (closed circle), BSA (open square). For the experiment 
shown in panel C, wells were coated overnight with galectin-3 alone (0.2 µg/ml; 
gray bar) or galectin-3 followed by 250 mM lactose (black bar) or 75 mM lactose 
containing 1 mg/ml asialofetuin (white bar). After washing and blocking, all wells 
(panels A-C) were incubated with increasing amounts of TAA90K-His (with or 
without lactose and asialofetuin), followed by MAb 1H9 and alkaline phosphatase-
labeled goat anti-mouse Ig. Specific binding of TAA90K was detected 
spectrophotometrically at 405  nm. The mean and standard deviation of triplicate 
samples are shown. The asterisk indicates statistical significance with a P-value 
less than 0.05. 
 
A. 
B. 
C. 
** ** ** 
 * 
 * 
    * 
* 
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are potential binding sites for galectin-3, a dominant ligand for TAA90K (André et al., 
1999).  
As expected, TAA90K purified from HT-29 cells bound well to galectin-3 
(Figure 5.8, panel A).  In contrast, TAA90K was shown to have a lower affinity for 
galectin-1. The reduced binding of TAA90K to galectin-1 could be due to cell-type-
specific glycan structures found on TAA90K isolated from HT-29 cells.  In 
collaboration with Dr. Hans-Joachim Gabius  (Ludwig-Maximillians University), we 
examined the interaction of TAA90K with galectins -2, -4, -7 and -9, which revealed 
levels of binding of 0.6%, 27.4%, 63.0% and 32.7% relative to galectin-3.  
 In order to assess the contribution of complex-type oligosaccharides to 
TAA90K-galectin-3 binding, we examined TAA90K-galectin-3 binding in the presence 
of carbohydrates that compete for galectin-3 binding.  To this end, either 250 mM 
lactose or 75 mM lactose and 1mg/mL of the glycoprotein asialofetuin, which contains 
di- and triantennary complex-type N-linked glycans containing N-acetyllactosamine 
(Galβ1-4GlcNAc) were added to the solid-phase binding assay.  The data revealed that 
the interaction between TAA90K and galectin-3 was mediated in part by binding of 
galectin-3 to glycan structures on TAA90K, because the addition of either lactose alone 
or lactose in combination with asialofetuin, significantly reduced their interaction 
(Figure 5.8, panel C) (P<0.05). 
 An alternative approach to determine the effect of carbohydrates on TAA90K-
galectin-3 interaction involved the use of a glycosylation inhibitor to generate an 
alternate glycoform of TAA90K.  TAA90K was purified from HT29 cells treated with 
DMJ which blocks Golgi α-mannosidase I, the enzyme which prevents conversion of 
high-mannose type to complex-type N-linked oligosaccharides (Elbein et al., 1984). 
Evidence in support of altered carbohydrates on TAA90K from cells treated with DMJ 
(TAA90K-DMJ) included a smaller size on SDS-PAGE compared to wildtype 
TAA90K (88 kDa vs. 105 kDa) (Figure 5.9), as well as loss of binding to WGA-
Sepharose and retention by cation-exchange resin, possibly facilitated by loss of the 
negatively charged sialic acid residues present on TAA90K (Laferté and Loh, 1992). In 
collaboration with Dr. Hans-Joachim Gabius, we analyzed the binding affinity between 
galectin-3 and TAA90K-DMJ. TAA90K-DMJ bound poorly to galectin-3 compared to  
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Figure 5.9:  Western blot analysis of TAA90K isolated from HT29 cells 
treated with DMJ.  TAA90K purified from HT29 cells untreated (lane 1) 
or treated (lane 2) with DMJ and infected with recombinant vaccinia virus 
expressing TAA90K was resolved on an SDS-PAGE gel.  TAA90K was 
detected by Western blotting analysis using rabbit anti-TAA90K (1:5000), 
followed by alkaline-phosphatase conjugated goat anti-rabbit IgG second 
antibody (1:3000).  The size of the molecular weight markers in kilodaltons 
is shown at the left side of the figure.  
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Figure 5.10: Effect of type of N-linked glycosylation on TAA90K binding to 
galectin-3. The level of carbohydrate-inhibitable binding (×) of biotinylated human 
galectin-3 to surface-immobilized TAA90K (A) and its variant from 1-
deoxymannojirimycin-treated HT-29 cells (B) was determined using a solid-phase assay. 
Binding was detected spectrophotometrically at 490 nm. Total binding (closed circle, 
closed triangle) to the matrix using 100 ng glycoprotein per well for adsorption was 
reduced by the extent of carbohydrate-independent binding (open circle, open triangle) 
determined in the presence of a mixture of 75 mM lactose and 1 mg asialofetuin/ml as 
inhibitor (crosses). 
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wild-type TAA90K, as expected from the carbohydrate specificity of galectin-3 (Figure 
5.10). These results indicated that the carbohydrates present on wild-type TAA90K play 
a role in mediating its interaction with galectin-3.  
 
5.3.2 TAA90K-MATRIX METALLOPROTEINASE INTERACTIONS 
 The extracellular localization of TAA90K and its observed binding to 
extracellular matrix proteins suggested that TAA90K may play a role in restructuring of 
the ECM, which involves rebuilding and degradation of ECM components. In support 
of this hypothesis, Bair et al. (2006) demonstrated that addition of TAA90K to prostate 
cancer cells resulted in increased extracellular expression of promatrilysin (proMMP-7) 
in the culture medium. The enhanced expression of proMMP-7 by prostate cancer cells 
grown in the presence of TAA90K was shown to be mediated in part by IL-6, since 
cells grown in the presence of neutralizing antibodies to IL-6 exhibited reduced 
expression of proMMP-7 (Bair et al., 2006).  In light of these findings, we undertook to 
examine the effect of TAA90K on expression of proMMP-7 in colon cancer cells, as 
well as the interaction of TAA90K with MMPs.  
 
5.3.2.1 Effect of TAA90K on expression of proMMP-7 in HT-29 cells 
  In order to determine if TAA90K has any effect on the expression of active and 
proMMP-7 in the conditioned medium of HT-29 cells, increasing amounts of TAA90K 
were added to cells grown in serum-free medium.  The medium was concentrated 5-fold 
and tested by ELISA with a monoclonal antibody against pro-MMP-7.  The results 
revealed that addition of 1 µg TAA90K to HT-29 cells enhanced expression of 
proMMP-7 in the conditioned medium 24 h (P<0.005) and 48 h (P<0.0005) post-
treatment, compared to untreated cells. Furthermore, the addition of 5 µg TAA90K to 
HT-29 cells significantly increased the expression of proMMP-7 at 24 h (P<0.05), 48 h 
(P<0.005) and 72 h (P<0.005) post-treatment (Figure 5.11). There was no change in the 
extracellular expression of active MMP-7 from HT-29 cells grown in the presence or 
absence of TAA90K (data not shown). 
 In addition to examining the effect of TAA90K on proMMP-7 extracellular 
expression in HT-29 cells, we also examined the expression of pro- and active forms of  
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Figure 5.11:  ELISA of proMMP-7 expression from HT-29 cells grown in the 
presence or absence of TAA90K.  HT-29 cells were incubated in serum-free medium 
containing 0 µg, 1 µg or 5 µg TAA90K for 24h, 48h or 72h. The medium was 
concentrated 5-fold and 100 µL was added in triplicate to the wells of a 96 well plate.  
The amount of proMMP-7 was detected by incubation with mouse anti-proMMP-7 
antibody or NMS (1:1000) as a control, followed by alkaline-phosphatase-conjugated 
goat anti-mouse IgG second antibody (1:3000). Binding was detected 
spectrophotometrically at 405 nm.  The data shown represents the specific binding of 
anti-proMMP-7 antibody. The mean and standard deviation of triplicate experiments 
coated in triplicate (n=9) are shown.  The asterisk (s) indicates statistical significance 
with a P-value less than 0.05 (*), 0.005 (**) or 0.0005 (***).  
** 
* 
*** 
** 
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MMP-7 in the serum-free conditioned medium of a panel of human colon cancer cell 
lines, including Caco-2, HT-29, KM20C, LoVo, LS-123, SW403 and SW620. To this 
end, the medium was concentrated 5-fold and subjected to an ELISA to measure the 
levels of pro- and active MMP-7 expression (Figure 5.12).  The ELISA detected small 
amounts of active MMP-7 expression in all cell lines examined and variable expression 
of proMMP-7, with maximal expression observed in KM20C and HT-29 cell lines.  
    
5.3.2.2 Binding of TAA90K to MMPs and regulators of MMP activity or 
expression 
In an attempt to elucidate the mechanism involved in the enhanced expression of 
proMMP-7 in the conditioned medium of HT-29 cells treated with TAA90K, we 
performed solid phase binding assays to examine whether TAA90K binds directly to 
either the proenzyme or active forms of MMP-7. TAA90K bound well to both the pro- 
and active forms of MMP-7, but poorly to proMMP-1 (Figure 5.13).  This suggested 
that extracellular binding of TAA90K to pro- or active forms of MMP-7 may stabilize 
MMP-7 and/or protect it against proteolytic degradation. This could account for the 
increased level of proMMP-7 detected in the conditioned medium of TAA90K-treated 
HT-29 cells. On the other hand, no detectable binding of TAA90K to the active (data 
not shown) or proenzyme forms of MMP-2 and -9, two MMPs shown to play a 
significant role in colon cancer progression (reviewed in Zucker and Vacirca, 2004) was 
observed. 
Alternatively, TAA90K could block the interaction between MMP-7 and its 
inhibitors, including tissue inhibitors of matrix metalloproteinases (TIMPs) and α2-
macroglobulin (reviewed in Zucker and Vacirca, 2004; Sottrup-Jensen and Birkedal-
Hansen, 1989).  Thus, we examined whether TAA90K binds to inhibitors of MMPs as a 
possible mechanism for increased expression. Our results indicated that TAA90K does 
not bind to either TIMP -1,  -2 or α2macroglobulin (data not shown), suggesting that 
TAA90K does not affect MMP-inhibitor interactions directly.  However, it is possible 
that TAA90K and TIMPS could compete for binding to the same site on the enzyme.  
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Figure 5.12: ELISA analysis of pro- and active MMP-7 secretion by human colon 
cancer cell lines.  Conditioned serum-free medium from human colon cancer cells was 
concentrated 5-fold and coated (100 µL) in triplicate in a 96 well plate. Wells were 
washed, blocked with TBS containing 4% BSA, washed and incubated with monoclonal 
antibodies against proMMP-7, active MMP-7 or normal mouse serum  (1:1000) for 2 h 
at room temperature.  After washing, wells were incubated with alkaline phosphatase-
conjugated goat anti-mouse Ig (1:3000) for 1h followed by washing and addition of 
substrate. Plates were read at 405 nm.  The mean and standard deviation of triplicate 
samples are shown.    
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 Figure 5.13:  Solid-phase binding assay to examine binding of TAA90K to MMPs.  
Substrates including proMMP-1 (square), proMMP-2 (triangle), proMMP-7 (diamond), 
MMP-7 (circle) and proMMP-9 (X) were coated (0.5 µg) overnight in triplicate in the wells 
of a 96 well plate.  After washing, blocking in BSA, and washing again, different 
concentrations of TAA90K were added to the wells and incubated overnight.  Following 
washing and incubation with MAb 1H9 (1:1000), a goat anti-mouse alkaline phosphatase-
conjugated second antibody (1:3000) was added.  After washing and developing, the assays 
were read at 405 nm. Error bars represent standard deviation. 
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Lastly, we examined whether TAA90K binds to proteins implicated in signaling 
events leading to enhanced proMMP-7 expression. Previous studies have shown that the 
secretion of proMMP-7 by prostate cancer cells requires the binding of IL-1β to its cell  
surface receptor.  This results in activation of the transcription factor NFκB and 
subsequent  expression of IL-6.  Enhanced secretion of IL-6 in turn leads to binding to 
its cell surface receptor (IL-6R), initiating signaling events that result in elevated 
expression of proMMP-7 (Maliner-Stratton et al., 2001). In light of these data, we 
examined whether TAA90K can interact directly with IL-6 or IL-1β  as a means to 
modulate receptor-mediated signaling events.  Using solid-phase binding assays, we 
determined that intact TAA90K interacts with both IL-6 and IL-1β in a concentration-
dependent manner (Figure 5.14). Thus, the TAA90K-enhanced extracellular expression 
of proMMP-7 from HT-29 cells may be mediated in part by its interactions with both 
IL-6 and IL-1β.  
 
5.3.2.3 Proteolytic cleavage of TAA90K by MMP-7 
Matrix metalloproteinases cleave a wide range of substrates, which range from 
ECM proteins such as laminins, fibronectin and collagens to non-ECM proteins such as 
growth factors like TGF-β (McCawley and Matrisian, 2001). Recently, Canals et al. 
(2006) identified TAA90K as a potential target for proteolysis by ADAMTS1, a 
metalloproteinase similar to, but not in the same family as MMPs. In light of these data, 
we examined whether TAA90K is a substrate for MMP-7. When MMP-7 and TAA90K 
(1:50, w/w, respectively) were incubated for 24 h at 37 oC, TAA90K was cleaved to 
fragments of 79 kDa and 22 kDa (Figure 5.15, panel A).  Western blotting analysis of 
these digests using rabbit anti-TAA90K confirmed that both fragments originated from 
TAA90K (Figure 5.15, panel B). The minor bands present in the Western blot are likely 
the result of alternate cleavage sites. 
 
5.3.2.3.1 Purification of proteolytic fragments 
To test whether cleavage of TAA90K by MMPs alters its function, we purified 
cleaved TAA90K for use in functional assays and identification of the amino acid 
cleavage site (s). To this end, TAA90K was cleaved with MMP-7 and purified by 
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Figure 5.14: Solid-phase binding assay to examine binding of intact TAA90K and 
MMP-7-cleaved TAA90K to IL-6 and IL-1β . IL-6 (panel A) or IL-1β (panel B) were 
coated (0.5 µg) overnight in triplicate in the wells of a 96 well plate.  Following 
washing and blocking, either intact TAA90K or MMP-7-cleaved TAA90K were 
incubated overnight.  Following washing, incubation with MAb 1H9 (1:1000) and 
alkaline-phosphatase-labeled goat anti-mouse Ig (1:3000), specific binding of TAA90K 
was detected spectrophotometrically at 405 nm. Error bars represent standard deviation 
and the asterisks (*) indicate P<0.05. 
B. 
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anion-exchange chromatography on HiTrap Q HP resin to remove the enzyme from the 
cleaved TAA90K preparation (Figure 5.15, panel A).  Using this approach, the enzyme 
eluted in the run-through fraction, whereas TAA90K eluted in 1M NaCl.  The cleaved 
TAA90K sample was desalted on a NAP-5 column and used for functional studies. 
Western blotting analysis of cleaved TAA90K revealed that the 79 kDa and 22 kDa 
fragments co-eluted from the anion-exchange column, suggesting that the cleaved 
fragments remain associated within the oligomeric complex. 
To identify the proteolytic cleavage site on TAA90K, MMP-7 treated TAA90K 
was separated by SDS-PAGE, transferred to a PVDF membrane, stained with Ponceau 
Red and the excised bands corresponding to the 79 kDa and 22 kDa fragments were 
submitted for protein sequencing analysis (Harvard Microchem Facility, Boston, MA). 
N-terminal sequencing analysis of the 79 kDa fragment by Edman degradation revealed 
a 7- amino acid peptide sequence, VNDGDMRA, identical to the N-terminal sequence 
of intact TAA90K (Koths et al., 1993).  Similar analysis of the 22 kDa fragment 
revealed an N-terminal peptide sequence of YRYYPYQSFQ, consistent with an internal 
cleavage of the TAA90K sequence at Asp452Tyr453.  There was also evidence of minor 
cleavage sites at Pro450Ser 451 and Gln462Thr463.  C-terminal sequencing analysis of the 
79 kDa fragment was also carried out to determine whether the 79 kDa and 22 kDa 
fragments generated by MMP-7 resulted from a single cleavage event.  Mass 
spectrometry analysis of trypsin and endopeptidase LysC digests of the 79 kDa 
fragment identified Asp452 as the C-terminal residue, consistent with cleavage between 
Asp452 and Tyr 453 (Figure 5.16).   
 
5.3.2.4 Cleavage of TAA90K by other MMPs 
In addition to examining the effect of MMP-7 on TAA90K cleavage, we also examined 
whether TAA90K is a substrate for MMP-2 and -9, two other MMPs that have been 
implicated in colon cancer progression (reviewed in Zucker and Vacirca, 2004).   When 
MMP-2, MMP-7 or MMP-9 were each incubated with TAA90K in a ratio of 1:3 (w/w), 
respectively, for 1 h at 37 oC in the presence of zinc ions, this resulted in cleavage of  
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Figure 5.15:  SDS-PAGE analysis of TAA90K cleaved by MMP-7. Panel 
A. TAA90K was incubated with (lane 3) or without (lane 2) MMP-7 at a 
substrate to enzyme ratio of 50:1 (w/w), respectively, for 24 h at 370C.  
Cleaved TAA90K was purified by anion-exchange chromatography.  Four 
micrograms each of full length and cleaved TAA90K were resolved on a 10% 
SDS-PAGE gel and stained with Coomassie blue. Panel B. MMP-7-treated 
TAA90K was resolved on a 10 % SDS-PAGE gel, transferred to 
nitrocellulose and probed with rabbit anti-TAA90K (1:5000).  The size of the 
molecular weight markers are indicated in kilodaltons at the left of the figure. 
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Figure 5.16:  Schematic diagram of the putative domains of TAA90K indicating 
the major MMP-7 cleavage site. Putative domains are represented by boxes flanked 
by their respective amino acid residues.  Potential asparagine-linked glycosylation 
sites are indicated by asterisks (*). Cleavage sites for plasmin and MMP-7 are 
indicated with arrows.  
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TAA90K into two major fragments of 79 kDa and 22 kDa  (Figure 5.17). As expected 
for matrix metalloproteinases, the enzymatic cleavage was inhibited by 50 mM EDTA since it 
chelates the metal ions required for enzyme activity (reviewed in Zucker and Vacirca, 2004). 
Similarly, boiling of the enzyme at 100oC for 4 minutes inactivated the enzyme and inhibited 
proteolytic cleavage. 
 
5.3.2.5 Binding of MMP-7-cleaved TAA90K to extracellular proteins 
Previous work including our own has shown that TAA90K binds to a number of 
proteins including fibronectin, laminin-1, laminin-5, laminin-10, galectin-3, IL-6, proMMP-7 
and active MMP-7 (Sasaki et al., 1998; Ulmer et al., 2006).  In addition, TAA90K is a 
substrate for MMP-7, yielding fragments of 79 kDa and 22 kDa. In order to elucidate the 
biological effect of TAA90K cleavage by MMP-7, we performed solid-phase binding assays to 
compare the binding of cleaved and intact TAA90K to extracellular proteins.  Cleaved 
TAA90K showed similar binding compared to full length TAA90K for pro- and active MMP-7, 
laminin-1, collagen I, collagen IV and galectin-3 (data not shown).  In contrast, binding of 
cleaved TAA90K to fibronectin was reduced significantly compared to intact TAA90K (Figure 
5.18, panel A). These results suggested that the TAA90K domain responsible for interacting 
with fibronectin has been altered directly by cleavage with MMP-7 or indirectly through a 
conformational change resulting from the proteolytic cleavage.  Similarly, binding of cleaved 
TAA90K to laminin-10 was reduced significantly compared to intact TAA90K (Figure 5.18, 
panel B). Lastly, MMP-7 cleavage of TAA90K resulted in significantly reduced binding to IL-
6 and IL-1β compared to intact TAA90K (Figure 5.14). Interestingly, incubation of HT-29 cells 
with 5 µg TAA90K that had been cleaved by MMP-7 for 48 h revealed elevated proMMP-7 
secretion compared to control cells, however, the results were significantly less than when 5 µg 
of intact TAA90K was added to cells (P<0.003) (Figure 5.19). This suggested that TAA90K 
may modulate the expression of proMMP-7 through its interaction with cytokines. 
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Figure 5.17:  Western blotting analysis of TAA90K cleavage by MMP-2, 
-7 and -9.  Active MMP-2 (lanes 2-4) or  -7 (lanes 5-7) or -9 (lanes 8-10) 
were incubated with TAA90K at a ratio of 1:3 (w/w) at 37oC for 1h.  Prior to 
incubation, the enzymes used in lanes 4, 7 and 10 were boiled at 100oC for 4 
minutes. Digests in lanes 3, 6 and 9 were incubated in an inhibitory buffer 
containing 50 mM EDTA.  Lane 1 contained untreated TAA90K (C). Digests 
were resolved on a 10 % gel and transferred to nitrocellulose.  Western 
blotting analysis was performed with rabbit anti-TAA90K polyclonal 
antibody (1:5000).  The size of the molecular weight markers in kilodaltons is 
shown at the left of the figure.  
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Figure 5.18:  Solid-phase binding assay to examine the effect of TAA90K cleavage 
by MMP-7 on binding to extracellular matrix proteins. Fibronectin (panel A) or 
laminin-10 (panel B) were coated (0.5 µg/well) onto the wells of a 96-well plate 
overnight.  Following washing and blocking, increasing amounts of either intact 
TAA90K or MMP-7-cleaved TAA90K were incubated, followed by MAb 1H9 and 
alkaline phosphatase-labeled goat anti-mouse Ig.  Specific binding of TAA90K was 
detected spectrophotometrically at 405 nm. The mean and standard deviation of 
triplicate samples are shown. The asterisks indicate statistical significance with * 
representing a P-value<0.005.  
 * 
   * 
  * 
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Fibronectin 
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Figure 5.19: ELISA of proMMP-7 expression in conditioned medium from HT-29 
cells grown in the presence or absence of intact TAA90K or MMP-7–cleaved 
TAA90K. HT-29 cells were incubated in serum-free media containing 0 µg (control) or 
5 µg of intact or MMP-7-cleaved TAA90K for 48 h.  Medium was concentrated 5-fold 
and 100 µL was added in triplicate to the wells of a 96 well plate.  The amount of 
proMMP-7 was detected by incubation with mouse anti-proMMP-7 antibody or NMS 
(1:1000) as a control, followed by alkaline-phosphatase-conjugated goat anti-mouse 
IgG second antibody (1:3000). Binding was measured spectrophotometrically at 405 
nm.  The data shown represents the specific binding of anti-proMMP-7 antibody. The 
mean and standard deviation of two experiments coated in triplicate are shown (n=6). 
The single asterisk (*) indicates a statistical significance for the effect of intact and 
MMP-7-cleaved TAA90K compared to control samples with P<0.001. The double 
asterisk (**) indicates a statistical significance for the reduced extracellular expression 
of proMMP-7 following treatment of HT-29 cells with MMP-7-cleaved TAA90K 
(P<0.003). 
 
*              * 
   ** 
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5.3.3 EFFECT OF TAA90K ON TUMOR CELL PROPERTIES 
5.3.3.1 Effect of TAA90K on cellular adhesion 
Although the function of TAA90K in normal and neoplastic tissues is unclear, 
previous studies have implicated TAA90K as a multi-adhesive protein within the 
extracellular matrix, mediating binding to both ECM and cell surface receptors (Sasaki 
et al., 1998).  For this reason, the adhesiveness of human colon cancer cell lines to  
TAA90K isolated from HT-29 cells was examined using cellular adhesion assays.  In 
contrast to previous findings where TAA90K purified from EBNA-293 cells was shown 
to mediate the adhesion of HBL-100 breast epithelial cells (Sasaki et al., 1998; 
Hellstern et al., 2002), TAA90K isolated from HT-29 cells did not mediate the adhesion 
of HT29 cells and six other human colon carcinoma cell lines (Caco-2, KM20C, LoVo, 
LS123, SW403 and SW620).  Similarly, the normal rat intestinal cell line IEC-6, Rat-2 
fibroblasts and HBL100 breast epithelial cells were unable to adhere to TAA90K (data 
not shown).  The lack of binding of HT-29 cells was specific to TAA90K since these 
cells adhered to fibronectin, collagen I and galectin-3 (Figure 5.20). The lack of binding 
of TAA90K to HT-29 cells was confirmed by indirect immunofluorescence experiments 
which showed no staining of intact cells with TAA90K-specific monoclonal antibody 
1H9 (Laferté and Loh, 1992) or following incubation of cells with purified TAA90K 
and MAb 1H9 (data not shown). It is possible that the oligosaccharides present on 
TAA90K synthesized by HT-29 inhibit TAA90K-mediated cell adhesion, in contrast to 
TAA90K isolated from other cell types (Sasaki et al., 1998).   
Interestingly, initial cell adhesion experiments carried out with TAA90K 
purified from uninfected HT-29 cells (no recombinant vaccinia virus) did mediate    
HT-29 cell adhesion. However, it was later determined that the cell adhesion resulted 
from fibronectin contamination.  When fibronectin was later removed from the 
TAA90K preparations by cation-exchange chromatography, a step not used by other 
investigators, we no longer observed cell adhesion to our TAA90K preparations. In 
light of these findings, it is possible that TAA90K preparations isolated from other cell 
types (Sasaki et al., 1998; Hellstern et al., 2001) may have been contaminated with 
extracellular proteins, including fibronectin.  
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Figure 5.20:  Adhesion of HT29 to various proteins. Wells were coated with 
extracellular matrix proteins, galectin-3 or BSA. After incubation with HT29 cells for    
4 h, non-adherent cells were removed by washing. Adherent cells were fixed with 
formaldehyde and stained with toluidine blue. Adhesion of HT29 cells was detected 
spectrophotometrically at 620 nm.  The mean and standard deviation of triplicate 
samples are shown.  
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5.3.3.1.1 Effect of altered cell surface and TAA90K glycosylation on cellular 
 adhesion 
 The lack of cell adhesion to TAA90K may result from cell-type-specific 
glycosylation of TAA90K and/or its cellular receptor(s) resulting in an anti-adhesive 
rather than adhesive interaction. In order to assess the contribution of complex 
carbohydrates to TAA90K function, it was necessary to generate different glycoforms  
of TAA90K.  Previous work from this laboratory showed that the molecular mass of 
TAA90K immunoprecipitated from the conditioned medium of different cell lines 
ranges from 90 kDa to 105 kDa (Laferté and Loh, 1992). These differences in molecular 
mass could be attributed to cell-specific glycosylation differences (Laferté and Loh, 
1992). This meant that expression of TAA90K in different cell lines could yield 
different glycoforms of TAA90K. To this end, recombinant vaccinia virus containing 
the cDNA for TAA90K was used to infect rat intestinal IEC-6 cells in addition to the 
human colon cancer cell lines SW620 and SW480.  The amount of TAA90K produced 
by these cells following infection with recombinant vaccinia virus was significantly less 
than that produced by similar treatment of HT-29 cells.  As a result, it was not possible 
to purify sufficient quantities of recombinant TAA90K from these cell lines for 
functional studies.  
 An alternative approach to generating different glycoforms of TAA90K 
involved treating of HT-29 cells with the glycosylation inhibitors swainsonine (Sw) or 
1-deoxymannonirimycin (DMJ) during infection with recombinant vaccinia virus. DMJ 
prevents the conversion of high mannose to complex-type N-linked oligosaccharides 
(Elbein et al., 1984). Swainsonine inhibits Golgi α-mannosidase II, which prevents the 
synthesis of β1-6 branched complex-type N-linked oligosaccharides (Elbein et al., 
1981). This in turn reduces the level of poly-N-acetyllactosamine [(Galβ1-4GlcNAc)n] 
structures (van den Eijnden et al., 1988). A TAA90K glycoform was purified from HT-
29 cells treated with DMJ. Similar to fully glycosylated TAA90K, TAA90K-DMJ 
treated HT-29 cells also failed to mediate the adhesion of HT-29 cells or HT-29 cells 
treated with DMJ (data not shown). TAA90K isolated from vaccinia-infected HT-29 
cells treated with swainsonine (TAA90K-Sw) contained a mixture of glycoforms, 
including fully glycosylated as well as truncated glycoforms.  Similarly to TAA90K- 
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Figure 5.21:  SDS-PAGE analysis of His-TAA90K isolated from recombinant 
bacteria.  Coomassie-stained gel (panel A) and anti-His Western blot (panel B) of 1 µg 
of His-TAA90K purified from recombinant BL21 bacteria expressing His-TAA90K.  
The size of the molecular weight markers in kilodaltons is shown at the left side of the 
figure. 
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DMJ, TAA90K-Sw failed to mediate adhesion of HT-29 cells or HT-29 cells pre-
treated with swainsonine (data not shown).  
  In an attempt to examine the overall contribution of complex carbohydrates to 
TAA90K function in biological assays, TAA90K devoid of glycan chains was purified 
from recombinant bacteria expressing His-TAA90K. The 60 kDa band shown in Figure 
5.21 corresponds to the unglycosylated form of recombinant TAA90K containing an N-
terminal histidine tag (His-TAA90K). As shown in Figure 5.22, the unglycosylated 
form of TAA90K also failed to mediate the adhesion of HT29 cells.  However, 
treatment of HT29 cells with DMJ to alter cell-surface glycosylation resulted in 
enhanced cell binding to bacterially produced His-TAA90K (Figure 5.22). Thus, the 
adhesive interactions between TAA90K and its putative cellular receptor(s) may be 
modulated by substratum- and cell-type-dependent N-linked glycosylation.   
 
5.3.3.2 Effect of TAA90K on cell adhesion to galectin-3 
 Although our data demonstrated that TAA90K does not mediate cell adhesion 
directly, we investigated whether TAA90K can modulate cell adhesion to other 
substrates.    Since TAA90K is a major ligand for galectin-3, which does mediate 
cellular adhesion (Sasaki et al., 1998; Ulmer et al., 2006), we examined the effect of 
TAA90K on galectin-3 mediated cellular adhesion.  As shown in Figure 5.23, HT-29 
cells adhered to galectin-3. However, the adhesion of HT-29 cells to galectin-3 was 
significantly inhibited in the presence of high amounts of TAA90K (5 µg/well) 
(P<0.0001).  Surprisingly, as the amount of TAA90K relative to galectin-3 was 
reduced, galectin-3 mediated cell binding was enhanced with maximal cell adhesion 
detected in the presence of 8 ng TAA90K. This level of cell binding exceeded that seen 
with galectin-3 alone (P<0.0001). Thus, at high concentration, TAA90K exhibited anti-
adhesive properties by interfering with galectin-3-mediated cell binding, however at 
low concentrations, it enhanced cell binding to galectin-3. When we examined the effect 
of TAA90K on cellular adhesion to other ECM proteins including laminin-1, laminin-
10, fibronectin and collagen I, we observed no effect (data not shown).  
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Figure 5.22:  Adhesion assay to examine the effect of DMJ treatment on HT-29 
adhesion to bacterially expressed TAA90K.  HT29 cells (white bar) or HT29 cells 
pre-treated with DMJ (black bar) were incubated in wells coated with recombinant His-
TAA90K purified from recombinant BL21 bacteria. Non-adherent cells were washed 
away and the remaining cells were fixed and stained.  The adhesion of cells was 
detected spectrophotometrically at 620 nm. The mean and standard deviation of 
triplicate samples are shown.  The asterisk indicates statistical significance with a P-
value less than 0.05.  
* 
* 
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Figure 5.23:  The effect of TAA90K on HT-29 cell adhesion to galectin-3.  Wells 
coated with 5 µg galectin-3 were incubated with increasing amounts of TAA90K 
followed by addition of 105 HT-29 cells.  The horizontal line running through the chart 
corresponds to the amount of HT-29 binding to galectin-3 alone.  The mean and 
standard deviation of three separate experiments done in triplicate (n=9) are shown.  
The asterisks indicate statistically significant difference in cell binding compared to that 
observed with 5 µg galectin-3 alone (*P<0.005; **P<0.0001). 
 * ** 
    ** 
** 
  ** 
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5.3.3.3 Effect of TAA90K on cell migration and invasion 
 Loss of cell-cell and cell-ECM interactions are important stages in the 
progression of colorectal cancer, enabling cancer cells to migrate and invade through 
the ECM during the metastatic process (Bracke et al., 1996; Giancotti and Ruoslahti, 
1999). Galectin-3 has been implicated in modulating cell adhesion to ECM proteins as 
well as enhancing motility and invasion of cancer cells. For example, breast cancer cell 
lines that have been transfected with galectin-3 exhibited enhanced adhesion to ECM  
proteins including laminin and collagen IV (Warfield et al., 1997). In addition, cells 
exhibited enhanced invasion through Matrigel in in vitro invasion assays, which was 
associated with an increased expression of α6β1 integrin (Warfield et al., 1997).  
Furthermore, increased expression of galectin-3 in poorly metastatic cell lines resulted 
in enhanced metastatic potential (Raz et al., 1990). We have shown that TAA90K can 
behave as an anti-adhesive protein, inhibiting adhesion of HT-29 cells to galectin-3 
when present at relatively high concentration. This suggested that TAA90K interferes in 
cell-galectin-3 interactions, thereby contributing to altered tumor cell migration and/or 
invasion, two important aspects of the metastatic process. We also observed that 
addition of TAA90K to HT-29 cells resulted in enhanced extracellular expression of 
proMMP-7 which could potentially lead to enhanced invasion of these cells.   
 In an attempt to elucidate the role of TAA90K in cellular migration and 
invasion, we performed cellular migration assays with HT-29 and SW620 cells. Briefly, 
cells were added to the upper chamber and allowed to migrate through pores in the 
polycarbonate filter.  Cells that adhered to the underside of the filter were stained and 
quantitated. As shown in Figure 5.24, HT-29 cells migrated towards collagen I coated 
on the underside of a polycarbonate filter and SW620 cells migrated towards laminin-10 
and fibronectin. However, neither cell line migrated towards TAA90K.  Furthermore, 
addition of TAA90K to the upper chamber or to the bottom chamber had no effect on 
cellular migration towards these extracellular proteins. 
 Cellular invasion assays were employed to examine the effect of TAA90K on 
the invasion of HT-29 cells.  In these experiments, increasing amounts of TAA90K or 
galectin-3 were pre-incubated with the reconstituted extracellular matrix (Matrigel) 
coated on the top of the polycarbonate filter of the inserts.  The pre-incubation of  
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Figure 5.24 Migration assays examining the effect of TAA90K and extracellular 
proteins on cellular migration. Panel A: Migration of HT-29 cells towards no 
protein (C) or 5 µg each of collagen I (CI), collagen IV (CIV), TAA90K (90K), 
galectin-3 (Gal-3) or MMP-7 cleaved TAA90K (MMP-7- 90K) coated on the 
underside of  the inserts.  Panel B Migration of SW620 cells towards no protein (C) 
or 5 µg each of TAA90K (90K), fibronectin (FN) or laminin-10 (L-10) coated on the 
underside of the inserts.  In some experiments where fibronectin and laminin-10 
were coated on the underside of filters, 5 µg of TAA90K was either added with the 
cells to the upper chambers (FN 90K upper or L-10 90K upper) or to the bottom 
chambers (FN 90K lower or L-10 90K lower). Cells that migrated to the underside 
of the filter were stained with MTT and extracted with DMSO.  Absorbances were 
read at 540 nm. The mean of triplicate experiments is shown and the error bars 
represent standard deviation. 
HT-29 cells 
SW620 cells 
        C        90K     CI       CIV    Gal-3   MMP-7- 
      90K 
   C     90K  FN  FN     FN    L10  L10    L10   
                90K  90K           90K   90K 
               upper  lower       upper   lower 
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TAA90K or galectin-3 did not effect the invasion of HT-29 cells through the 
reconstituted ECM layer, nor did adding TAA90K or galectin-3 in combination with 
the cells to the inserts.  When we examined the affect of adding galectin-3 to the upper 
chamber in combination with different concentrations of TAA90K, no effect on the 
invasion of HT-29 cells through the Matrigel was observed (Figure 5.25). 
 
5.3.3.4 The role of cleaved TAA90K in cell adhesion, migration and invasion 
 Although it appeared that intact TAA90K did not have a direct effect on cell 
adhesion, migration or invasion, we examined the effect of MMP-7-cleaved TAA90K 
in these functional assays.  Previous studies have shown that cleavage of Fas-ligand or 
osteopontin by MMP-7 results in an altered function of the cleaved substrate compared 
to the intact proteins (Powell et al., 1999; Agnihotri et al., 2001).  To this end, we 
observed that MMP-7-cleaved TAA90K, similar to intact TAA90K, did not mediate 
adhesion, migration or invasion of HT-29 cells (Figure 5.24 and 5.25). However, 
MMP-7-cleaved TAA90K, like intact TAA90K, still modulated galectin-3 mediated 
cellular adhesion (Figure 5.26). Low concentrations of cleaved TAA90K enhanced 
galectin-3-mediated cell adhesion, as we showed previously for intact TAA90K (Ulmer 
et al., 2006). This is not surprising because cleaved TAA90K bound well to galectin-3 
in solid-phase binding assays (data not shown). 
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Figure 5.25 Invasion assay to examine the effect of TAA90K and galectin-3 on 
invasion of HT-29 cells. HT-29 cells were added to inserts coated with Matrigel 
(C) or Matrigel pre-incubated with 5 µg each of galectin-3 (Gal-3), TAA90K 
(90K), MMP-7-cleaved TAA90K (MMP-7-90K) or 5µg galectin-3 mixed with 
either 5 µg TAA90K (90K+Gal-3) or 8 ng TAA90K (8ng 90K+Gal-3).  In some 
wells, HT-29 cells were added to the inserts in combination with either 5 µg 
galectin-3 (Gal-3+cells) or 5 µg TAA90K (90K+cells). Cells that invaded through 
the layer of Matrigel were stained with MTT and extracted with DMSO.  
Absorbances were read at 540 nm. The mean of experiments performed in 
triplicate is shown and the error bars represent standard deviation. 
     C    Gal-3  Gal-3  90K    90K    90K    8 ng   MMP-7- 
           +cells            +cells           +Gal-3  90K+    90K 
                                           Gal-3 
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Figure 5.26 Adhesion assay to compare the effect of intact TAA90K and MMP-7 
cleaved TAA90K on galectin-3-mediated HT-29 cell adhesion. Wells coated with 5 
µg galectin-3 were incubated with increasing amounts of either intact TAA90K (black) 
or MMP-7-cleaved TAA90K (grey) followed by addition of 105 HT-29 cells.  The 
horizontal line running through the chart corresponds to the amount of HT-29 binding 
to galectin-3 alone.  The mean of an experiment done in triplicate is shown and the error 
bars represent standard deviation. The asterisk indicates a statistical significance for the 
effect of intact or cleaved TAA90K compared to galectin-3 alone with P<0.05. 
     *  *        *  * 
      *  * 
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6.0 DISCUSSION 
 In this study we have undertaken to examine the expression and possible role of 
TAA90K in human colorectal cancer.  Previous studies have identified elevated levels 
of TAA90K expression in numerous types of cancer and shown a correlation between 
TAA90K expression and cancer progression (Marchetti et al., 2002; Ozaki et al., 2002; 
Singhal et al., 2003; Koopman et al., 2004).  In addition, TAA90K was previously 
identified as a carrier of β1-6 branched N-linked oligosaccharides, cancer-associated 
carbohydrates associated with enhanced metastatic potential (Laferté and Loh, 1992; 
Ochwat et al., 2004; Kim et al., 2006).  Thus, the examination of TAA90K expression 
and the contribution of complex carbohydrates to its function may enhance our 
understanding of its potential role in colorectal cancer initiation and progression.  
 
6.1 Expression of TAA90K in colorectal cancer 
 A number of studies have examined the expression of TAA90K in cancer.  For 
example, immunohistochemical analysis of TAA90K expression by non-small cell lung 
carcinoma (NSCLC) tumors revealed elevated levels that correlated with metastasis as 
well as decreased disease-free and overall survival (Marchetti et al., 2002).  Other 
studies identified elevated TAA90K in the serum of patients suffering from breast, 
colon, stomach, ovarian and lung cancer (Linsley et al., 1986; Natoli et al., 1993; 
Ullrich et al., 1994; Jallal et al., 1995; Iacobelli et al., 1986, 1993, 1994).   
 Our immunohistochemical analysis of human colorectal tumors revealed 
elevated levels of intracellular and luminal expression of TAA90K in all of the colon 
tumors analyzed compared to normal colonic mucosa (Ulmer et al., 2006).  These 
findings suggested that TAA90K is a marker of cancer-associated changes within the 
colonic mucosa. This is likely due to enhanced transcriptional activation of the gene for 
TAA90K as a result of genetic alterations that result during carcinogenesis (Vogelstein 
and Kinzler, 2004).  
A number of immunohistochemical staining patterns were observed, revealing 
that TAA90K is localized intracellularly, at the luminal surface of colon cells or in 
 120 
some cases the basolateral surface.  These staining patterns may indicate distinct 
functions of TAA90K in colorectal cancer depending on its sub-cellular localization. 
For example, in some early-stage Duke’s A tumors, TAA90K was localized at the 
basolateral surface of colon cancer cells consistent with its ability to bind to 
extracellular matrix proteins such as laminins and collagens (Sasaki et al., 1998; Ulmer 
et al., 2006). The localization of TAA90K at the basolateral surface of early-stage 
tumors may depict the localization of TAA90K in normal colonic mucosa.  Although 
we were unable to detect TAA90K expression in normal colon, this is likely the result 
of the sensitivity of the immunohistochemical detection as other studies have revealed 
the presence of TAA90K mRNA in normal epithelial cells, including colon, by 
Northern blot analyses (Ullrich et al., 1994).  
Interestingly, increased expression of galectin-3 was also shown to correlate 
with poor prognosis in patients with colorectal cancer (Endo et al., 2006). In fact, 
galectin-3 expression in colon tumors sections was localized to the underlying stroma of 
the colonic mucosa (Greco et al., 2004), suggesting that TAA90K and galectin-3 may 
interact at the basolateral surface of cells to modulate cell-ECM contacts. In addition to 
its interaction with galectin-3, we identified MMP-7 as a ligand for TAA90K binding. 
Previous work implicated elevated MMP-7 expression in enhanced tumorigenesis and 
invasion in a number of cancers, including colorectal cancer (reviewed in McCawley 
and Matrisian, 2001).  Immunohistochemical analysis of human gastric carcinoma 
revealed elevated levels of proMMP-7 expression at the basolateral surface of cancer 
cells (Yamashita et al., 1998). These results would suggest that TAA90K may function 
by interacting with MMP-7 in the ECM, which may result in remodeling of the ECM 
and altered tumor cell-ECM interactions.  
 Elevated levels of granular, intracellular staining of TAA90K were observed in 
most colon tumors analyzed, consistent with its localization to secretory vesicles (Ulmer 
et al., 2006). Enhanced luminal expression of TAA90K was also observed in a number 
of tumor sections and is likely the result of enhanced secretion of TAA90K from the 
cancer cells. The luminal accumulation of TAA90K in colon tumors, a glycoprotein 
modified by β1-6 branched N-linked oligosaccharides (Laferté and Loh, 1992), 
suggested that TAA90K contributes to colon cancer progression and/or metastatic 
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disease. These results are supported by studies by Fernandes et al. (1991) that revealed 
elevated granular staining as well as luminal expression of glycoproteins bearing β1-6 
branched N-linked oligosaccharides in human colon tumors, as detected by L-PHA. 
Significantly, the level of L-PHA staining of colon tumors was correlated with 
metastatic disease.  
 The elevated luminal expression of glycoproteins bearing β1-6 branched N-
linked oligosaccharides, and potentially poly-N-acetyllactosamine repeats, would be 
expected to provide ligands for galectin-3 (van den Eijnden et al., 1988; reviewed in 
Hughes, 2001). In fact, results have shown that in addition to being localized to the 
stroma in colon tumors, galectin-3 expression was also observed in luminal secretions 
(Greco et al., 2004). These findings suggest that TAA90K and galectin-3 may interact 
extracellularly, resulting in altered cell signaling events at the apical surface of colon 
tumor cells.  
In addition to its potential interaction with galectin-3 at the apical surface, 
TAA90K may also interact with MMP-7 in luminal secretions. In support of this, 
immunohistochemical analysis of human gastric carcinoma revealed elevated levels of 
proMMP-7 expression at the apical surface of cancer cells in addition to enhanced 
basolateral expression (Yamashita et al., 1998). MMP-7 expression was also observed 
in the lumen of dysplastic colon tumors isolated from mice (Wilson et al., 1997). In 
addition, the identification of substrates for MMP-7 that are localized to both the apical 
and basolateral surfaces would suggest that MMP-7 may function at both locations 
(McCawley and Matrisian, 2001). We demonstrated that TAA90K is localized at both 
the basolateral and luminal surfaces of colon tumors, in addition to being a substrate for 
MMP-7 activity. Thus, TAA90K and MMP-7 may function at the apical surface of 
tumor cells resulting in altered cellular signaling events.  In support of this, elevated 
apical secretion of MMP-7 by polarized Madin-Darby canine kidney (MDCK) cells was 
implicated in elevated cellular growth and proliferation (Harrell et al., 2005).  
Immunohistochemical analysis of human colon tumors also revealed elevated 
expression of TAA90K compared to normal mucosa.  These results were confirmed by 
Western blotting analysis following immunoprecipitation of detergent lysates of colon 
tumors and their adjacent normal mucosa with a TAA90K-specific monoclonal 
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antibody.  Western blotting analysis revealed differences in the apparent molecular 
mass of TAA90K immunoprecipitated from different colon tumors (Ulmer et al., 2006).  
These results are consistent with previous findings that identified variations in the 
molecular mass of TAA90K isolated from different human colon cancer cell lines.  This 
variability was shown to be the result of cell-specific differences in glycosylation 
(Laferté and Loh, 1992).  These results suggested that human colon cancer cell lines are 
an adequate representation of human colon tumors and thus, are useful for in vitro 
studies. To this end, we examined the secretion of TAA90K into the conditioned 
medium of human colon cancer cell lines.  ELISA analysis employing a TAA90K-
specific monoclonal antibody revealed variable levels of TAA90K secretion by 
different colon cancer cell lines, consistent with the variable levels of TAA90K 
expression detected in different human colon tumours.  Interestingly, the colon cancer 
cell lines that were established from metastases (KM20C and SW620) expressed the 
highest levels of TAA90K, suggesting a role in the development of lymph node and 
distant metastases in patients with colon cancer.    
 
6.2 Purification of TAA90K 
 Although the accumulation of TAA90K in a number of cancers has been 
associated with poor outcome (Marchetti et al., 2002; Ozaki et al., 2002; Singhal et al., 
2003), the mechanisms of TAA90K function have yet to be elucidated. Since TAA90K 
can be localized in the ECM, interact with ECM proteins as well as mediate cell-cell 
interactions, TAA90K may play a role in colon cancer progression (Inohara et al., 1996; 
Sasaki et al., 1998).  In order to elucidate the role of TAA90K in colon cancer, we 
undertook to purify TAA90K from human colon cancer cells for use in functional 
assays. We employed a number of chromatographic methods including lectin-affinity 
chromatography and ion-exchange chromatography to isolate TAA90K or TAA90K-
His from the human colon cancer cell line HT-29 infected with recombinant virus 
expressing TAA90K or TAA90K-His, respectively. The purity and identity of the     
105 kDa protein was confirmed by mass spectrometry (Ulmer et al., 2006).    
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6.3 Functional experiments with TAA90K 
6.3.1 Interaction of TAA90K with ECM proteins 
 We confirmed previous findings that TAA90K binds to ECM proteins such as 
fibronectin, collagen IV, laminin-1 and to a lesser extent collagen I (Sasaki et al., 1998; 
Ulmer et al., 2006).  In addition, we demonstrated TAA90K binding to laminin-5 and -
10.  In an attempt to identify the domains of TAA90K that are required to mediate 
binding to ECM proteins, Hellstern et al. (2002) carried out solid-phase binding assays 
with TAA90K constructs composed of different combinations of putative domains 
(Figure 2.15).  For example, a recombinant TAA90K consisting of putative domains 3 
and 4 exhibited minimal binding to fibronectin, whereas, a construct consisting of 
domains 2, 3 and 4 did bind fibronectin. These results suggested that domain 2 may 
contain a binding site for fibronectin. Alternatively, the absence of domain 2 may result 
in altered TAA90K conformation, rendering the fibronectin binding site inaccessible.  
Interestingly, we demonstrated that cleavage of TAA90K in the linker region (between 
domains 3 and 4) by MMP-7 resulted in reduced binding to fibronectin.  Thus, this 
cleavage may result in altered conformation of TAA90K monomers, limiting access to 
the fibronectin binding domain. These results, in addition to the observed basolateral 
localization of TAA90K in some early stage Duke’s A colon tumors (Ulmer et al., 
2006) and its expression in the ECM of normal tissues (Sasaki et al., 1998), would 
suggest that TAA90K may function in normal tissues and early cancers by being 
deposited in the ECM and by binding to extracellular proteins. 
 
6.3.2 TAA90K and cellular adhesion 
In addition to examining the interaction of TAA90K with ECM proteins, we 
also examined the ability of TAA90K to mediate the adhesion of cells.  Previous work 
revealed that TAA90K isolated from other cell types was able to mediate the adhesion 
of A431 epidermoid carcinoma cells as well as HBL-100 breast epithelial cells in a β1-
integrin-dependent manner (Sasaki et al., 1998). For these studies, recombinant 
TAA90K was purified from EBNA-293 human embryonic kidney cells transfected with 
the cDNA encoding TAA90K. The purification protocol consisted of ammonium sulfate 
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precipitation and gel exclusion chromatography of the conditioned medium and yielded 
TAA90K of 92 kDa (Sasaki et al., 1998).  
In contrast, TAA90K isolated from HT-29 cells was not able to mediate the 
adhesion of seven colon cancer cell lines nor was it able to mediate the adhesion of a 
number of normal cell lines including HBL-100 cells.  These results suggested that      
HT-29-derived TAA90K is modified by cell-type-specific carbohydrates which convert 
it to an anti-adhesive substrate. This is supported by the apparent molecular weight 
difference between the 92 kDa TAA90K isolated from embryonic kidney cells 
compared to the 105 kDa TAA90K isolated from HT-29 cells.  Furthermore, HT-29 
cells treated with 1-deoxymannojirimycin, which inhibits the conversion of high-
mannose type to complex-type N-glycans, adhered better to bacterially expressed 
TAA90K, which lacks carbohydrate modifications, than to fully glycosylated TAA90K. 
Thus, the presence of carbohydrate moieties on both cell surface receptors and their 
glycosylated ligands may be important in mediating TAA90K-cellular interactions. The 
potential anti-adhesive function of TAA90K-derived from human colon cancer cells 
suggested that it may interfere with specific tumor cell-ECM contacts, resulting in 
enhanced tumor cell motility associated with a more invasive phenotype. Although we 
did not observe an effect of TAA90K on cellular migration using in vitro migration 
assays, the effects mediated by TAA90K may not have been adequately measured 
employing this type of functional assay or may require co-stimulatory molecules.  
Another possibility for the observed differences in TAA90K-mediated cellular 
adhesion is the purification strategies employed to isolate TAA90K from different 
cellular sources.  For example, we initially purified TAA90K from HT-29 cells 
employing either ammonium sulfate precipitation or lectin-affinity chromatography 
followed by anion-exchange and gel exclusion chromatography.  Although we did 
observe cellular adhesion to this preparation of TAA90K, this adhesion was due to 
fibronectin contamination (data not shown).  When fibronectin was later removed by 
cation-exchange chromatography, our TAA90K preparations no longer mediated HT-29 
cellular adhesion. In light of these findings, TAA90K preparations isolated from other 
cell types (Sasaki et al., 1998; Hellstern et al., 2001) may have been contaminated with 
fibronectin. Although these studies demonstrated β1-integrin-dependent cellular 
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adhesion to their TAA90K preparations, they did not observe cellular adhesion to 
recombinant TAA90K consisting only of domains 3 and 4. This form of TAA90K 
which contained a histidine tag, was purified from the medium of transfected EBNA-
293 cells by gel-exclusion and metal chelation affinity chromatography (Hellstern et al., 
2002). This form of TAA90K also failed to bind to fibronectin, suggesting a 
conformational change from wild-type TAA90K resulting in reduced accessibility to 
cellular receptors and fibronectin binding domains. Alternatively, recombinant 
TAA90K containing domains 3 and 4 was isolated employing different 
chromatographic techniques compared to initial experiments with wild-type TAA90K, 
which removed contaminating proteins such as fibronectin capable of mediating cell 
adhesion. 
 
6.3.3 TAA90K and galectins 
 Elevated levels of galectin-1, galectin-3 and TAA90K have been associated with 
malignant cell transformation and cancer progression (reviewed in Grassadonia et al., 
2004).  For example, increased expression of galectin-1 and/or galectin-3 has been 
correlated with the malignant potential of a number of cancers including colorectal 
(Schoeppner et al., 1995; Sanjuan et al., 1997), glioma (Camby et al., 2001) and gastric 
carcinoma (Lotan et al., 1994).  As previously mentioned, elevated serum levels of 
TAA90K correlate with progression and poor prognosis in a number of cancers 
including breast, colon, stomach, ovary and lung (Marchetti et al., 2002; Ozaki et al., 
2002; Singhal et al., 2003; Koopman et al., 2004). In light of these findings, we 
examined the interaction between TAA90K isolated from a human colon cancer cell 
line and galectins-1 and -3, in an attempt to elucidate their roles in colon cancer 
progression.  
 Our studies revealed that TAA90K binds to galectin-3 in a carbohydrate 
dependent manner, as expected for glycoproteins modified with poly-N-
acetyllactosamine structures (Laferté and Loh, 1992; reviewed in Hughes, 2001).  
However, in contrast to TAA90K isolated from fibroblasts (Tinara et al., 2001) 
TAA90K purified from HT-29 cells bound poorly to galectin-1 (Ulmer et al., 2006).  
The difference in binding to galectin-1 was likely due to cell-specific differences in 
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glycosylation and the selectivity of galectin binding for specific carbohydrate structures 
(Ahmad et al., 2002).  In this regard, HT-29 cells were derived from a patient with 
histo-blood group A status consistent with previous work in our laboratory showing that 
TAA90K isolated from these cells binds to a monoclonal antibody specific for type 2 
chain blood group A antigens (data not shown; Prokophishyn et al., 1999). Galectin-3 
binds well to blood group A carbohydrate antigens which are present on HT-29-derived 
TAA90K, however, galectin-1 binding was shown to be reduced in the presence of 
these carbohydrate structures (Sparrow et al., 1987; Ahmad et al., 2002).  Differences in 
binding of galectin-1 and galectin-3 to TAA90K were previously identified by Tinari et 
al. (2001) who determined that these galectins bind to different carbohydrate structures 
on TAA90K, as they do not compete with each other for binding.  In summary, 
TAA90K isolated from HT-29 cells contains carbohydrate structures that are binding 
sites for galectin-3, but not galectin-1, suggesting that TAA90K may mediate its 
function in colon cancer in part by interacting with galectin-3.   
Since we were unable to observe TAA90K-mediated cellular adhesion, we 
examined the effect of TAA90K binding to galectin-3-mediated cellular adhesion. 
Previous studies have shown that galectin-3 mediates adhesion of a number of types of 
cells (André et al., 1999). Our studies demonstrated that galectin-3 can mediate 
adhesion of HT-29 cells (Ulmer et al., 2006). Studies examining cellular aggregation 
determined that the addition of TAA90K to melanoma cells expressing galectin-3 on the 
cell surface resulted in enhanced homotypic interactions, suggesting that TAA90K and 
galectin-3 interact on the cell surface to promote cell-cell adhesions (Inohara et al., 
1996). These interactions may be involved in enhancing the metastatic process by 
forming stable tumor emboli, which are more likely to survive in the vasculature upon 
metastasis. In support of a role for TAA90K and galectin-3 in mediating homotypic 
interactions during embolization, recent studies have shown that elevated plasma levels 
of TAA90K in patients with colorectal cancer correlated with cancer cell surface 
expression of galectin-3 (Greco et al., 2004).  
We demonstrated that TAA90K modulates galectin-3-mediated adhesion of  
HT-29 cells (Ulmer et al., 2006).  At high concentration, TAA90K inhibited cellular 
adhesion to galectin-3, but at lower concentrations it enhanced cell binding.  Other 
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studies have examined cell-mediated effects of galectin-3 to find that sub-micromolar 
amounts of galectin-3 inhibit cellular adhesion and high concentrations promote 
adhesion (Inohara et al., 1996).  These observations may be the result of enhanced 
galectin-3 oligomerization at high concentrations, which may promote cellular adhesion 
through the ability to form cross-links between cells and ECM proteins (Ahmad et al., 
2004).  Our results suggested that high levels of TAA90K bind galectin-3 preventing it 
from accessing cell surface receptors. Alternatively, reduced levels of TAA90K may  
lead to enhanced galectin-3 mediated cellular adhesion possibly through the 
enhancement of galectin-3 oligomerization. Thus, the ratio of TAA90K and galectin-3 
secreted by colon cancer cells may play a role in colon cancer progression and 
metastasis by modulating tumor cell adhesion. Results demonstrating that both 
TAA90K and galectin-3 are localized to the stroma in some colorectal tumors, supports 
their roles in the modulation of tumor cell adhesion to the ECM (Greco et al., 2004; 
Ulmer et al., 2006).  
 In addition to their localization to the stroma of colon tumors, enhanced luminal 
expression of  both galectin-3 and TAA90K has also been observed (Greco et al., 2004; 
Ulmer et al., 2006). The extracellular accumulation of TAA90K and galectin-3 at the 
apical surface of colon cancer cells suggests a role in cellular signaling events. Since 
both TAA90K and galectin-3 have been implicated in immunomodulation, including 
stimulation of pro-inflammatory responses and modulation of T cell responses (Powell 
et al., 1995;Trahey and Weissman, 1999; Rabinovich et al., 2002; Nakahara et al., 
2005), their potential luminal interaction may be involved in modulating host immune 
responses to promote colorectal cancer progression.  
 
6.3.4 TAA90K and MMPs  
Previous studies have revealed that MMPs are the main proteinases involved in 
the invasion of colorectal carcinomas. Specific MMPs that have been implicated in 
colorectal cancer include MMP-1, -2, -3, -7, -9, -12, -13 and MT1-MMP (reviewed in 
Zucker and Vacirca, 2004). Although MMPs play a role in colorectal cancer, MMP-7 
appears to have the most significant effect not only on colorectal tumorigenesis, but also 
in invasion and metastasis (reviewed in Wagenaar-Miller et al., 2004). The expression 
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of MMP-7 is observed at early stages of tumor progression and has been implicated in 
enhancing cellular proliferation as well as the progression from adenoma to invasive 
carcinoma (reviewed in Wagenaar-Miller et al., 2004; Harrell et al., 2005). MMP-7 
expression was observed to be localized in the lumen of dysplastic colon tumors 
isolated from mice (Wilson et al., 1997). Other studies have revealed that MMP-7 is 
expressed by 90% of colonic adenocarcinomas and its expression is correlated with the 
presence of lymph node as well as distant metastases (Newell et al., 1994).  
We examined the expression of proMMP-7 and active MMP-7 in a number of 
human colon cancer cell lines.  We observed variable levels of proMMP-7 expression 
with the various cell lines, with HT-29 and KM20C cells expressing the highest levels 
of proMMP-7. We observed minimal amounts of active MMP-7 expression in any of 
the cell lines tested, but these results are likely due to the low sensitivity of the ELISA 
assay used. Our results are consistent with previous studies, which failed to detect 
active MMP-7 in the conditioned medium of HCA-7 and Caco-2 human colon cancer 
cells or from MMP-7 transfected Madine-Darby canine kidney (MDCK) cells. 
However, in a recent study, a more sensitive fluorometric assay was successful in 
detecting MMP-7 enzyme activity in the conditioned medium of cells (Harrell et al., 
2005).  
In addition to enhancing the invasion of cancer cells, MMPs have also been 
implicated in the recruitment of leukocytes to a site of injury during inflammation 
(reviewed in Coussens and Werb, 2002). Inflammation is a tightly regulated process 
controlled by both anti-inflammatory and pro-inflammatory responses (reviewed in 
Coussens and Werb, 2002).  Inflammation commonly results in response to wound 
healing or infection and is associated with the secretion of pro-inflammatory cytokines.  
After loss of anti-inflammatory signals, chronic inflammation can result and is 
characterized by elevated expression of pro-inflammatory cytokines, which enhance 
tissue remodeling by stimulating DNA replication and cellular proliferation.  These 
events have been associated with the initiation of cancer (reviewed in Coussens and 
Werb, 2002).  For example, inflammatory bowel diseases such as ulcerative colitis and 
Crohn’s disease are associated with elevated levels of pro-inflammatory cytokines 
including TNF-α, IL-1β, IL-6 and IL-8 from mononuclear cells (Neurath et al., 1998).  
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The expression of these cytokines is mediated by NFκB, which enhances the 
transcription of the genes for these cytokines (Neurath et al., 1998). In addition, patients 
with inflammatory bowel disease exhibit increased levels of MMP-1, -3, -7 and -14 
(Newell et al. 1994). Thus, individuals with inflammatory bowel diseases are at 
elevated risk for colon cancer due to chronic inflammation (Campbell et al., 2001).   
 Interestingly, the expression of proMMP-7 in prostate cancer cells was shown to 
be regulated by the NFκB-dependent expression of cytokines including IL-1β and IL-6, 
leading to STAT3 activation (Maliner-Stratton et al., 2001). Furthermore, studies by 
Bair et al. (2006) revealed that the addition of purified TAA90K to prostate cancer cells 
resulted in the enhanced extracellular expression of proMMP-7 in an IL-6-dependent 
manner. Consistent with these findings, we showed that the addition of purified 
TAA90K to HT-29 cells was able to elevate the extracellular expression of proMMP-7. 
Thus, TAA90K may result in enhanced extracellular expression of proMMP-7 through 
a number of possible mechanisms.  For example, TAA90K may interact with proMMP-
7 extracellularly and prevent access by activating proteases, effectively increasing the 
half-life of proMMP-7 in the medium.  TAA90K does not appear to increase the 
extracellular expression of proMMP-7 by binding to inhibitors of MMP activity, since 
TAA90K did not bind to TIMP-1, TIMP-2 or a2-macroglobulin. Alternatively, TAA90K 
may enhance the extracellular expression of proMMP-7 by stimulating the secretion of 
IL-6.  Previous studies have shown that TAA90K is capable of stimulating the release 
of cytokines, including IL-6 (Ullrich et al., 1994; Powell et al., 1995).  In addition to 
being able to stimulate the release of IL-6, we demonstrated in solid-phase binding 
assays that TAA90K is also able to interact directly with both IL-6 and IL-1β. These 
results suggested that TAA90K may stimulate pro-inflammatory responses by binding 
to cytokines as well as stimulating their release. The binding of TAA90K to cytokines 
extracellularly may result in enhanced presentation of the cytokines to their cell surface 
receptors. In support of the role of TAA90K in cytokine-mediated cellular signaling 
events, addition of MMP-7-cleaved TAA90K, which exhibited reduced binding to both 
IL-6 and IL-1β, resulted in reduced extracellular expression of proMMP-7 from HT-29 
cells. Thus, TAA90K may enhance extracellular expression of proMMP-7 by 
modulating pro-inflammatory responses, which have been previously implicated in the 
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initiation of colon cancer (reviewed in Coussens and Werb, 2002; Campbell et al., 
2001).  
 Although we observed enhanced extracellular expression of proMMP-7 from 
HT-29 cells grown in the presence of TAA90K, we did not observe an effect of 
TAA90K on the migration or invasion of these cells. TAA90K may function by 
preventing activation of proMMP-7, resulting in elevated extracellular accumulation of 
proMMP-7 and either no effect on cellular invasion or decreased cellular invasion. 
Alternatively, these results suggest that TAA90K and MMP-7 may function during 
early stages of colon carcinogenesis and may not be directly involved in the invasive 
process.  In support of this, MMP-7 has been shown to play an important role in 
invasion of colon carcinogenesis, however, it has also been implicated in earlier 
processes involving enhanced cellular proliferation and tumorigenesis (reviewed in 
Wagenaar-Miller et al., 2004; Harrell et al., 2005).  In this regard, elevated apical 
expression of active MMP-7 resulted in enhanced growth and cellular proliferation of 
MDCK cells expressing human MMP-7 (Harrell et al., 2005). Furthermore, TAA90K-
enhanced extracellular expression of proMMP-7 by prostate cells was shown to be 
dependent on IL-6 resulting in the activation of STAT3 (Maliner-Stratton et al., 2001; 
Bair et al., 2006). Activation of signal transducer and activator of transcription 3 
(STAT3) has recently been implicated in enhanced cell proliferation and tumor growth 
in colon cancer (Corvinus et al., 2005). Thus, TAA90K-enhanced proMMP-7 
expression may not play a role in invasion, but rather, be involved in enhancing earlier 
stages of colon carcinogenesis including cellular proliferation and tumorigenesis.  
It has been well established that MMPs function extracellularly by cleaving a 
number of ECM and non-ECM proteins such as galectin-3, FasL and osteopontin 
(Ochieng et al., 1994; Powell et al., 1999; Agnihotri et al., 2001). Cleavage of specific 
substrates by MMPs can generate cleavage products with altered function compared to 
the intact protein.  For example, cleavage of galectin-3 by MMP-2 and -9 resulted in 
altered binding to glycoconjugate ligands (Ochieng et al., 1994).  In addition, the 
cleavage of osteopontin by MMP-7 resulted in the generation of cleavage products 
capable of enhancing cellular migration (Agnihotri et al., 2001). Previous studies have 
revealed that TAA90K is susceptible to proteolysis by plasmin and trypsin (Hellstern et 
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al., 2002) suggesting that TAA90K may be a substrate for proteolytic cleavage by other 
proteases including MMPs. In support of this, recent work by Canals et al. (2006) 
identified TAA90K as a putative substrate for the metalloproteinase ADAMTS1. In 
addition, our studies revealed that TAA90K interacts directly with proMMP-7 as well 
as active MMP-7. On the other hand, little or no interactions were observed with other 
MMPs including MMP-1, proMMP-2, active MMP-2, proMMP-9 or active MMP-9.  
In addition to binding to MMP-7, our data revealed that TAA90K was cleaved 
by MMP-2, -7 and -9, MMPs which have been implicated in poor prognosis for patients 
with colorectal cancer (reviewed in Zucker and Vacirca, 2004). N- and/or C-terminal 
sequence analysis of the 79 and 22 kDa TAA90K fragments produced by MMP-7 
cleavage revealed a major proteolytic cleavage site between amino acid residues Asp 452 
and Tyr 453at the junction between the linker region and putative domain 4 and near the 
plasmin and trypsin cleavage sites (Hellstern et al., 2002). These data suggested that 
this region of TAA90K is a protease-sensitive region exposed on the surface of 
TAA90K oligomers. 
Cleavage of TAA90K by proteinases may result in the generation of TAA90K 
fragments with altered activity compared to the intact protein. In support of this, MMP-
7 cleavage of TAA90K resulted in reduced affinity for fibronectin and laminin-10. 
Thus, cleavage by MMP-7 may prevent interactions between TAA90K cleavage 
products and fibronectin or laminin-10 in the ECM, allowing these proteins to be more 
accessible to their cell surface receptors.  The reduced binding of MMP-7-cleaved 
TAA90K to fibronectin may also affect signaling events initiated by fibronectin binding 
to its α5β1 integrin receptor. In this regard, studies examining the expression of MMP-
13 in fibroblasts isolated from wild-type or CyCAP-null mice revealed that induction of 
MMP-13 expression by fibronectin fragments or IL-1β is reduced in CyCAP-null cells 
(Kong et al., 2004). These results suggested that CyCAP is involved in the regulation of 
fibronectin fragment-induced MMP-13 expression. Thus, intact TAA90K may interact 
with fibronectin and have a similar effect in the regulation of MMP expression in 
human cells.  The altered affinity of MMP-7-cleaved TAA90K for fibronectin may be a 
regulatory mechanism involved in this pathway and may be modulated by altered 
binding of MMP-7-cleaved TAA90K to IL-6 and IL-1β, two cytokines implicated in 
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enhanced extracellular expression of proMMP-7 (Maliner-Stratton et al., 2001). Since 
cleavage of TAA90K by MMP-7 results in reduced extracellular expression of 
proMMP-7, this may function as a negative feedback loop in the regulatory pathway 
that controls MMP-7 expression.  
 Collectively, these results suggest that TAA90K is a multi-adhesive protein that 
may function in the extracellular matrix or be involved in cellular signaling events at the 
apical surface of cells.  TAA90K has been found localized at the basolateral membrane 
and was capable of interacting with extracellular proteins including laminins, collagens, 
fibronectin, MMPs and galectin-3, suggesting a structural role in the maintenance of the 
ECM.  TAA90K was not able to mediate cellular adhesion directly, but it does modulate 
cellular adhesion mediated by galectin-3.  The fact that TAA90K stimulates the 
extracellular expression of proMMP-7 by colon cancer cells suggests a potential role for 
TAA90K in the remodeling of the ECM during wound healing or invasion by 
carcinoma cells. The induction of proMMP-7 expression appears to be regulated by 
MMP-7-cleavage of TAA90K, which results in reduced interaction with cytokines and 
reduced extracellular expression of proMMP-7 by HT-29 cells.  
 In the colon tumors that we analyzed, the majority of TAA90K was localized in 
the lumen of the tissues, suggesting a role in cell signaling events. In support of this, 
previous studies have demonstrated luminal expression of galectin-3 and MMP-7 in 
colon tumors, suggesting extracellular co-localization with TAA90K and potential 
modulation of signaling events including inflammatory responses. The cleavage of 
TAA90K by MMPs such as MMP-7 may be involved the regulation of inflammatory 
responses in the colon. Thus, TAA90K, galectin-3 and MMP-7 may contribute to 
cancer progression by enhancing pro-inflammatory responses, which have been 
implicated in the development of cancer.  
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7.0 CONCLUSIONS 
 In addition to being a glycoprotein that is modified by cancer-associated 
carbohydrates, elevated TAA90K expression has been correlated with poor prognosis in 
a number of cancers.  The results of this thesis have demonstrated elevated expression 
of TAA90K in human colon tumors, suggesting a role as a marker for neoplastic 
changes in the colon. TAA90K is a multi-functional protein capable of interacting with 
proteins in the ECM with the potential to modulate tumor cell adhesion and ECM 
remodeling.  Furthermore, TAA90K may stimulate inflammatory responses in the colon 
resulting in elevated levels of IL-6 and MMP-7 secretion, which are risk factors for 
colon cancer.   
 Further analysis of the role of TAA90K in colon cancer progression will be 
required to elucidate the mechanisms involved in TAA90K-mediated enhanced 
extracellular expression of proMMP-7.  In addition, examination of the effect of 
TAA90K and MMP-7 on tumorigenesis will be required.  
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